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Chapter 1 General introduction  
Chapter 2 Antibiotic-nanomedicines: facing the challenge of effective 
treatment of antibiotic-resistant respiratory tract infections 
Chapter 3 Aims and outline 
 
Chapter 1 is a general introduction which covers the discovery and characteristics of Gram-
negative bacteria and their ability to cause pneumonia; the current state of multidrug 
resistance in Gram-negative bacteria; the healthcare threat posed by multidrug-resistant 
Gram-negative pneumonia, and the urgency of developing novel therapeutic approaches 
(focused on antimicrobial peptides and direct drug delivery) to treat multidrug-resistant 
Gram-negative pneumonia. 
Chapter 2 is a review of the current state of antibiotic-nanomedicines research aimed at 
the treatment of antibiotic-resistant respiratory tract infections, including multidrug-
resistant Gram-negative pneumonia. It provides an overview of the current state of research, 
the development of different nanocarriers, and the potential value and clinical status of 
inhalable antibiotic-nanomedicines. 
Chapter 3 is a brief outline of the research presented in the current thesis and the research 
questions it aims to answer.  
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 Gram-negative pneumonia 
Pneumonia is an inflammatory condition of the lungs, usually caused by infection with 
microorganisms such as bacteria. The first observation of bacteria in the airways of 
patients who had died from pneumonia was made by Edwin Klebs in 18751. However, 
the significance of bacteria as the etiological cause of pneumonia was not recognized 
until Carl Friedländer reported their presence in nearly all cases of pneumonia he had 
examined in 18832. This observation of bacteria in infected lung tissue was aided by the 
use of a new staining technique developed by Hans Christian Gram, which facilitated 
the visibility of bacteria in histological sections and hence their association with clinical 
disease3. Gram’s staining technique was refined over the following decades, and after 
more than one hundred years, still remains one of the basic techniques utilized in the 
microbial diagnostic laboratory4,5. It serves as the basis for one of the major 
classifications of bacteria: the differentiation between Gram-negative bacteria and 
Gram-positive bacteria by the composition and characteristics of their cell envelope6. 
Gram-positive bacteria (staining blue-purple) possess a thick peptidoglycan cell-wall 
covering their cell membrane, whereas Gram-negative bacteria (staining pink-red) 
possess a thin peptidoglycan cell-wall in between their cell membrane and a highly 
immunogenic outer membrane mainly composed of lipopolysaccharide (LPS) and 
phospholipids (Figure 1)7.  
The structural differences in bacterial cell envelopes have major repercussions for the 
pathophysiology and treatment of infections caused by Gram-negative or Gram-
positive bacteria. First, the outer membrane of Gram-negative bacteria is a major factor 
in disease spread and severity8. As an example, the lipid A portion of LPS is a potent 
endotoxin, and the spread of a Gram-negative infection to the circulatory system of a 
patient may lead to overstimulation of lipid A receptors of the immune system9,10. The 
resulting inflammatory reaction can lead to ‘septic shock’, a life-threatening medical 
condition that requires immediate medical intervention11. 
12
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Figure 1. Diagram of the cell envelope structure of Gram-negative bacteria and Gram-positive 
bacteria.  
 
Further, the outer membrane of Gram-negative bacteria provides intrinsic protection 
from various antibiotics, detergents, and innate immune components, and is involved 
in many mechanisms of antibiotic resistance12. This is aided by many differing outer 
membrane proteins with a variety of functions (Figure 2)13, including so-called porins 
(which allow the influx of most nutrients while restricting the influx of certain 
antibiotics)14 and efflux pumps (which pump waste products and certain antibiotics out 
of the bacterial cell)15.  
Gram-negative bacteria include several major human commensals and (opportunistic) 
pathogens, such as Klebsiella pneumoniae, the bacillus first discovered by Carl Friedländer 
when he first demonstrated a link between bacteria and pneumonia2,4. Even today, 
diseases caused by Gram-negative bacteria continue to be a major global healthcare 
burden more than a century after their first discovery. These bacteria are the primary 
causative pathogens in ~30% of healthcare-associated infections, rising to ~70% in 
cases of healthcare-associated pneumonia16,17. Pneumonia is associated with high 
mortality rates and lengthy hospital stays18 and over 230,000 deaths and €10 billion in  
1
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Figure 2. Diagram of the function of porins and efflux pumps in the outer membrane of the 
Gram-negative bacterial cell envelope and the role they play in antibiotic resistance. Antibiotic 
A is a representation of antibiotics which cannot pass through porins in the outer membrane. 
Antibiotic B is a representation of antibiotics which pass through porins in the outer membrane, 
but are transported out of the bacterial cell by efflux pumps. Antibiotic C is a representation of 
antibiotics which pass through porins in the outer membrane and are not transported by efflux 
pumps, thereby able to enact their antibiotic activity. Nutrients are capable of passing through 
porins in the outer membrane, and once metabolized, the resulting metabolic waste products 
are transported out of the bacterial cell by efflux pumps. 
14
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 economic costs across the European Union (EU) every year19,20. The healthcare burden 
of pneumonia is projected to further increase in the coming decades due to aging 
populations as well as the emergence and spread of multidrug resistance in Gram-
negative bacteria, which is currently rendering many existing antibiotic therapies 
ineffective21.  
 
Antimicrobial resistance 
Gram-negative bacteria continue to demonstrate their ability to adapt to many different 
types of antibiotics. Already, ~50% of invasive Gram-negative bacterial isolates 
cultured in Europe are resistant to at least one antibiotic (Figure 3)22. The spread of 
multidrug resistance has rendered a growing list of antibiotics ineffective in the 
treatment of Gram-negative infections23, raising concerns about an oncoming post-
antibiotic era in which pan-resistant bacterial infections will be common and there are 
little to no treatment options available for clinicians24. 
 
 
Figure 3. Antibiotic resistance and multidrug resistance among Gram-negative 
Enterobacteriaceae in the EU/EEA in 2017. Shown are the proportions of antibiotic-resistant 
(resistant to ≥1 antibiotic families) and multidrug-resistant (resistant to ≥3 antibiotic families) 
isolates of K. pneumoniae and E. coli found in each individual country in 2017. The data from 
EARS-Net were kindly supplied by the European Centre for Disease Control (ECDC)25. 
1
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Antibiotic resistance can arise via three different mechanisms (Figure 4)26. First, bacteria 
can be intrinsically resistant to antibiotics due to natural characteristics which make 
them resistant to the activity of specific antibiotics27. In this respect, Gram-negative 
bacteria are intrinsically resistant to many antibiotics due to the impermeability of their 
outer membrane28 and the presence of active efflux pumps29. For instance, the outer 
membrane of Gram-negative bacteria is impermeable to large glycopeptide antibiotics 
like vancomycin (a potent antibiotic for Gram-positive bacteria) due to their molecular 
size12. Second, bacteria can become antibiotic-resistant through adaptive mutations 
after exposure to antibiotics30. For example, exposure to fluoroquinolone antibiotics 
such as ciprofloxacin can select for bacteria with mutations in the quinolone resistance 
determining region (QRDR) of the bacterial deoxyribonucleic acid (DNA) gyrase 
gene31. Third, bacteria can acquire antibiotic resistance from other bacteria via the 
horizontal gene transfer of antibiotic resistance genes present on mobile genetic 
elements (MGEs)32. The most common MGEs involved in antibiotic resistance are 
plasmids: extra-chromosomal, circular pieces of DNA that can exist in large numbers 
inside a single bacterial cell33. Plasmid-mediated antibiotic resistance by the Gram-
negative bacterial family Enterobacteriaceae is particularly problematic, as it allows 
emerging forms of antibiotic resistance to rapidly spread through bacterial populations 
with the potential to cause disease – a process that can occur on a global level in the 
modern world34,35. 
Of all current forms of antibiotic resistance, the carriage and expression of extended-
spectrum β-lactamases (ESBLs) are among the most important acquired antibiotic 
resistance determinants worldwide and are especially prevalent in Escherichia coli and  
K. pneumoniae, both of which belong to the Gram-negative Enterobacteriaceae36. ESBLs 
confer resistance to widely used broad-spectrum β-lactam antibiotics, but 
ESBLproducing isolates are often found to be also resistant to several different types 
of antibiotics – making such isolates multidrug-resistant37. In the treatment of such 
cases, carbapenem antibiotics are the drug of choice, but recent years have seen a 
growing prevalence of Gram-negative bacteria producing carbapenem inactivating 
enzymes (carbapenemases), including the K. pneumoniae carbapenemase (KPC)38 and  
16
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Figure 4. Diagram with different examples of mechanisms of resistance. Intrinsic resistance is 
represented by an antibiotic which is able to permeate the Gram-positive membrane but not 
the Gram-negative membrane. Adaptive mutation is represented by the upregulation of an 
intrinsic efflux pump which allows Gram-negative bacteria to keep specific antibiotics out of the 
cell. Horizontal gene transfer is represented by a plasmid-mediated enzyme which degrades 
specific antibiotics.  
 
New Delhi metallo-β-lactamase (NDM)35. The continuing spread of such multidrug-
resistant bacteria has forced clinicians to use ‘drugs of last resort’ such as colistin and 
tigecycline39. Inevitably, the increasing use of these last resort antibiotics has already led 
to the emergence of bacteria resistant to colistin40 or tigecycline41. 
A particularly worrying concurrent development is that fewer new antibiotics are 
reaching clinical development, which has resulted in a lack of antibiotics that are 
effective against multidrug-resistant Gram-negative bacteria42,43. In fact, most currently 
available antibiotic compounds were discovered in the 1960’s and 1970’s by screening 
microorganisms (usually fungi) for naturally produced antibiotic compounds e.g. 
1
17
General introduction
145136 van der Weide BNW.indd   17 07-08-20   14:00
penicillins, macrolides, tetracyclines and aminoglycosides44,45. In later decades, synthetic 
chemistry approaches have been employed to generate new types of antibiotics, for 
example the carbapenems, though both of these approaches have failed to generate any 
new classes of antibiotics in recent decades43. Indeed, as of March 2019, no novel classes 
of antibiotics have entered clinical development for the treatment of Gram-negative 
pneumonia46.  
There are several reasons why the current research and development (R&D) portfolios 
of large pharmaceutical corporations do not include the development of new 
antibiotics, but it is mainly due to the fact that antibiotic discovery is not sufficiently 
profitable when compared to the development of drugs for other disease areas, most 
notably drugs for the long-term treatment of chronic conditions47. The consequence of 
this R&D policy is that relatively few new candidate antibiotics are being developed for 
clinical application44,48. Global authorities such as the EU and the United Nations (UN) 
as well as the World Health Organization (WHO) are aware of this problem and are 
trying to solve the worldwide endemic of antibiotic resistance by focusing on several 
key 'One Health' action areas49-51. These key areas include increased epidemiological 
reporting of antibiotic resistance, the implementation of guidelines for effective 
infection prevention policies, reducing the use of antibiotics as growth promoters in 
food animals, the development of novel rapid diagnostics, and the development of new 
antibiotics which are active against multidrug-resistant bacteria. 
In addition to the activities of these global authorities, small companies and academic 
scientists have recently focused on the development of novel methods for antibiotic 
discovery52, as well as the improvement and development of previously discovered 
classes of antibiotics that have seen little clinical application for the treatment of 
multidrug-resistant Gram-negative infections. One example of a previously discovered, 
yet underutilized, class of antibiotics are the antimicrobial peptides (AMPs)53,54. It is the 
discovery of new classes of antibiotics and/or the development of underutilized classes 
of antibiotics (like AMPs) which are most likely to be successful in the worldwide fight 
against antibiotic-resistant bacteria.  
18
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 Antimicrobial peptides 
AMPs are a diverse family of naturally occurring antimicrobial oligopeptides with 
varying numbers of amino acids55. AMPs are produced by living organisms as a 
defensive mechanism towards micro-organisms and are therefore also referred to as 
host defense peptides56. AMPs were discovered in 1939 by René Dubos when he 
isolated an antimicrobial agent from Bacillus brevis, which was found to be composed of 
two AMPs: gramicidin and tyrocidine57. Since that initial discovery, over 3000 different 
AMPs have been described58. Although AMPs have been known since the 1940’s, this 
family of antibiotics has seen only limited use for the treatment of Gram-negative 
pneumonia, largely due to a number of hurdles that have limited their clinical use, 
including toxic side-effects59, short biological half-life due to degradation by 
proteases59,60, and limited efficacy against Gram-negative bacteria61. In fact, only a 
limited number of AMPs have seen ‘real-world’ application, the most clinically relevant 
being colistin61. 
Colistin is one of the polymyxins, a class of cationic polypeptide antibiotics used for the 
treatment of Gram-negative bacterial infections. The precise mechanism by which 
polymyxins exert their antibiotic activity remains contentious. The main model of ‘self-
promoted uptake’ postulates that the cationic polymyxin molecules first bind and inhibit 
LPS on the outer membrane, which is then followed by an insertion of the polymyxin 
molecule into the cell envelope which results in outer membrane permeabilization and 
disruption of the cytoplasmic membrane, leading to bacterial cell death (Figure 5)62. 
Additional mechanisms also contribute to the antibiotic activity of polymyxins, such as 
the inhibition of the bacterial respiratory chain63. Colistin has been available for clinical 
use since 1959, but was largely discontinued due to reports of potential toxic side effects 
in the 1980’s. The global increase of multidrug-resistant infections and diminishing 
supply of effective antibiotics available has caused a resurgence of colistin as a drug of 
last resort for the treatment of multidrug-resistant Gram-negative infections64, which 
inevitably has also led to the concurrent emergence and spread of colistin resistance65. 
Acquired colistin resistance utilizes various molecular mechanisms, including LPS 
modifications or expression of outer membrane proteins and efflux pumps66. The first 
1
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report of a plasmid conferring mobilized colistin resistance (MCR) was published in 
201540. Since then, different variants of plasmidal colistin resistance have been 
identified and isolated from patients across the world, rendering this drug of last resort 
potentially ineffective67. 
Other AMPs may remain a viable alternative in the treatment of colistin-resistant Gram-
negative infections depending on the absence of colistin cross-resistance – a 
phenomenon which occurs when resistance to one antibiotic results in additional 
 
 
 
Figure 5. Diagram of the ‘self-promoted uptake’ mechanism of antibiotic action employed by 
colistin and cationic antimicrobial peptides. In the first step, the cationic antibiotic binds to the 
LPS on the outer membrane of Gram-negative bacteria. In the second step, the cationic 
antibiotic inserts itself within the membranes of the cell envelope. In the third step, the cationic 
antibiotic causes permeabilization and disruption of the cell envelope. 
20
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 resistance to related antibiotics. Studies have shown that AMPs differ in their potential 
for cross-resistance with colistin, which is most likely due to differences between the 
mechanisms of antimicrobial activity of different AMPs68-70. Like colistin, most AMPs 
are cationic and share the same ‘self-promoted uptake’ mechanism of bacterial killing 
(Figure 5)71. However, while most cationic AMPs have this membrane-disrupting 
mechanism of action in common, many have different additional mechanisms of 
antimicrobial activity including membrane protein targeting, intracellular activity, and 
immunomodulation72-74. As mentioned above, biological hurdles exist to the 
implementation of AMPs into clinical practice, even those AMPs potentially useful for 
the treatment of multidrug-resistant Gram-negative bacterial infections (including 
colistin-resistant infections). To ameliorate those issues, novel therapeutic approaches 
need to be considered in the development of AMPs as effective antibiotic treatments. 
 
Novel therapeutic approaches 
The regular approach to the treatment of bacterial pneumonia in primary care occurs 
via the prescription of a course of oral antibiotics, whereas in secondary and tertiary 
care, more powerful antibiotics are usually prescribed and administered via the 
intravenous route75,76. However, although the parenteral (intravenous) application of 
antibiotics allows for high systemic bioavailability, this route of administration may not 
always achieve the minimum inhibitory concentration (MIC) of antibiotic necessary to 
inhibit or kill bacteria at the actual site of infection. Furthermore, the systemic (whole 
body) application of antibiotics to patients can cause unwanted toxic side-effects due 
to the antibiotic reaching tissues that are not infected77-80 and/or patients becoming 
allergic to the prescribed antibiotic81. Another serious side-effect of systemic antibiotics 
is the enhanced selection of antibiotic-resistant subpopulations of bacteria from the 
patient’s own endogenous microbiota (all of the microorganisms that live in and on our 
bodies), so-called collateral damage82. Such resistant subpopulations, selected from the 
endogenous microbiota, may cause multidrug-resistant invasive infections which prove 
 
1
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very hard to treat in critically ill patients. Therefore, there is room for therapeutic 
improvement beyond the traditional intravenous administration of antibiotics83. 
Along with the development of new antibiotic agents (such as AMPs), current research 
is also focused on the development of novel and improved antibiotic therapeutic 
approaches. Such novel therapeutic approaches may allow for an amelioration of the 
disadvantages associated with treatment strategies involving current antibiotics, 
potentially allowing all kinds of antibiotics to be used more effectively to combat 
multidrug-resistant infections. They may also help reduce or overcome the 
development of antibiotic-resistant subpopulations as a consequence of antibiotic 
therapy. The combination of developing or improving antibiotic agents, in parallel with 
the development of such novel therapeutic approaches, has the potential to be a major 
development in the fight against multidrug-resistant bacterial infections84.  
One such promising novel therapeutic approach is the use of nanotechnology for 
coupling antibiotics with nanocarriers85. Nanocarriers are nanomaterials used as a mode 
of transporting another substance86. In this way, nanotechnological products such as 
nanomedicines can be generated, which can transport therapeutic agents to the 
appropriate tissues and cells in the body. Attaching antibiotics to nanocarriers to create 
antibiotic-nanomedicines allows for improved antibiotic treatment without an increase 
in risk to the patient87.  
Another novel therapeutic approach to effectively treat a patient suffering from an 
infection is the improved administration of antibiotics. Indeed, the direct delivery of 
antibiotics to the site of infection would represent a therapeutic improvement88, 
facilitating increased antibiotic concentrations at the site of infection89,90 and helping to 
reduce any toxic side effects and/or collateral damage associated with the systemic 
administration of antibiotics91,92. For pneumonia, the site of infection is the lung and 
over the last decade there has been an increasing interest into developing and exploiting 
inhalable treatments that deliver antibiotics directly to the lungs93. The accurate delivery 
of antibiotics directly to the pulmonary site of infection via inhalation (in patients) and 
endotracheal aerosolization (in experimental animals) allows the antibiotics to reach 
22
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 higher local concentrations. Inhalation of nanomedicines may further result in 
prolonged biological half-life of the antibiotic due to protection from degradation by 
local proteases resulting in improved therapeutic efficacy93,94. 
The combined approach of the direct delivery of inhalable antibiotic-nanomedicines 
will be further outlined in Chapter 295.  
1
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Abstract 
Respiratory tract infections are one of the most frequent infections worldwide, with an 
increasing number being associated with (multiple) antibiotic-resistant pathogens. Improved 
treatment requires the development of new therapeutic strategies, including the possible 
development of antibiotic-nanomedicines. Antibiotic-nanomedicines comprise antibiotic 
molecules coupled to nanocarriers via surface adsorption, surface attachment, entrapment 
or conjugation, and can be administered via aerosolization. The efficacy and tolerability of this 
approach has been shown in clinical studies, with amikacin liposome inhalation suspension being 
the first inhalatory antibiotic-nanomedicine approved by the United States Food and Drug 
Administration (FDA). In this special report, we summarize and discuss the potential value and 
the clinical status of antibiotic-nanomedicines for the treatment of (antibiotic-resistant) 
respiratory tract infections. 
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Respiratory tract infections (RTIs) present a significant burden on global healthcare and 
have been estimated as the underlying cause of 6% of disability-adjusted life years in 
20151. In primary care, many RTIs are often self-limiting viral infections and are usually 
not fatal unless a secondary bacterial infection occurs2,3. However, in secondary and 
tertiary care, bacterial RTIs predominate over viral infections, with bacterial infections 
being much more likely to lead to significant morbidity and/or mortality in affected 
patients4. The effective antimicrobial treatment of bacterial infections is a crucial 
component in reducing the disease burden of RTIs and may be a life-saving action in 
many cases5. However, pathogenic bacteria continue to demonstrate their ability to 
adapt to many different types of antimicrobial compounds. As a result, global antibiotic 
resistance continues to increase, while the pool of effective antimicrobial compounds 
is simultaneously drying up. There are several reasons why the current research and 
development (R&D) portfolios of pharmaceutical companies are insufficient. 
Importantly, antibiotic discovery is not sufficiently successful as compared to 
developing drugs for other disease areas. The consequence is that relatively few new 
candidate antibiotics have reached the market6,7. Global authorities such as the 
European Union (EU) and the United Nations (UN) as well as the World Health 
Organization (WHO) are aware of this problem and invest in trying to solve the 
worldwide endemic of antibiotic resistance by focusing on several key 'One Health' 
action areas8-10. These key areas include increased epidemiological reporting of 
antibiotic resistance, the implementation of guidelines for effective infection prevention 
policies, reducing the use of antibiotics as growth promoters in food animals, the 
development of novel rapid diagnostics, and the development of new antibiotics which 
are active against extensively resistant microorganisms.  
 
Novel antimicrobial compounds 
Most currently available antimicrobial compounds were initially discovered by screening 
microorganisms (usually fungi) for naturally produced antimicrobial compounds e.g. 
penicillins, macrolides, tetracyclines and aminoglycosides7,11. Additionally, synthetic 
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 chemistry approaches have been utilized to generate new types of antibiotics, for 
example the carbapenems. However, both of these approaches have failed to generate 
any new classes of antibiotics in recent years12. As of September 2018, only one novel 
class of antibiotics has entered clinical development, namely gepotidacin for the 
treatment of RTIs13. Further, two known, but undervalued, classes of antibiotics that 
have previously seen little therapeutic application are also being developed for the 
treatment of RTIs; namely antimicrobial peptides and pleuromutilins14,15. It is the 
discovery and development of these new/undervalued classes of antibiotics (rather than 
the continual adaptation of already existing classes of antibiotics) which is most likely 
to be successful in the worldwide fight against antibiotic resistant bacterial pathogens.  
 
New treatment strategies 
The treatment of RTIs in primary care occurs via the prescription of a course of oral 
antibiotics, whereas in secondary and tertiary care, more powerful antibiotics are usually 
prescribed and administered via the intravenous route16,17. However, although the 
parenteral (intravenous) application of antibiotics allows for high systemic 
bioavailability, this route of administration may not always achieve the necessary 
minimum inhibitory antibiotic concentration at the site of infection. Furthermore, the 
systemic application of antibiotics can cause unwanted toxic side-effects due to the 
antibiotic reaching tissues other than the infected18-21. Another serious side-effect of 
systemic antibiotics is the enhanced selection of antibiotic-resistant bacteria residing in 
the endogenous microbiota, so-called collateral damage22. Such resistant 
subpopulations, selected from the endogenous microbiota, may cause invasive 
infections which prove very hard to treat in critically ill patients Therefore, in addition 
to the development of novel antibiotics, new treatment strategies are also being 
investigated including the administration of β-lactams combined with β-lactamase 
inhibitors, bacteriophage-based treatment, and the synthesis of hybrid antibiotics23-26. 
Another promising approach is the use of antibiotic-nanomedicines, as outlined in this 
Special Report. 
2
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Role of aerosolized antibiotics 
To effectively treat a patient suffering from an infection, it is important to deliver 
antibiotic molecules to the actual site of the infection such that the minimum inhibitory 
concentration (MIC) is achieved while causing minimal side-effects and collateral 
damage to the patient’s own microbiota. For RTIs, the site of infection is the lung and 
over the last decade there has been an increasing interest to exploit pulmonary delivery 
of antibiotics27. The accurate delivery of antibiotics directly to the pulmonary site of 
infection would allow the antibiotics to reach higher local concentrations, thereby 
increasing their effective antimicrobial activity27,28. This local delivery approach also 
avoids ‘first-pass’ metabolism and may help reduce any toxic side-effects associated 
with systemic administration29,30. However, although antibiotics have been non-
invasively administered to patients via aerosols — in solid or liquid particles ranging in 
size from 0.01–100 microns in diameter — the majority of aerosolized antibiotics often 
show suboptimal therapeutic efficacy due to their short lung half-life and low 
therapeutic availability at the intrapulmonary site of infection31. The short half-life and 
too limited therapeutic activity of aerosolized antibiotics is primarily due to mucociliary-
related pulmonary clearance mechanisms present in the host32. Exogenous particles and 
chemicals are typically trapped within the mucus layer in the lungs with cilia facilitating 
coordinated movement of these particles to the pharynx, where these are coughed out 
or swallowed. Deposited particles are also susceptible to alveolar macrophage clearance, 
as alveolar macrophages engulf, transport and thereby clear particles from the alveolar 
epithelium. The large surface area, epithelial permeability and high vascularization of 
the lung also facilitate the rapid absorption of antibiotics into the bloodstream (away 
from the lung) via passive diffusion or passage through tight junctions32. Additionally, 
many antibiotics possess hydrolytically susceptible chemical bonds (e.g., esters and 
amides), causing degradation (and subsequent loss of biological activity) via enzymes 
secreted by the lung. 
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 Nanocarrier formulations  
The protection of antibiotics from clearance, enzymatic/chemical degradation and 
rapid adsorption, as well as the reliable deposition and residence of aerosolized drug 
doses at predetermined locations in the lung, can prove challenging33-35. Incorporation 
of antibiotics in so-called ‘nanocarriers’ can potentially overcome these hurdles. In this 
respect, many different nanocarrier formulations have been developed for antibiotic 
encapsulation or coupling. 
Nanocarriers are particles ranging in size from 10–1000 nm36 and are used in a wide 
variety of medicines, where the active pharmaceutical ingredient is either adsorbed, 
covalently attached to the surface, entrapped or conjugated into the matrix of the 
nanocarrier (Figure 1)37. Nanocarriers may in general be classified based on the type of 
material from which the matrix is made i.e., organic nanocarriers or inorganic 
nanocarriers.  
 
 
Figure 1. Pictorial representation of different types of nanoparticles and their size in 
comparison to various biological and physical objects. Nanocarriers can be classified into two 
essential groups: Organic nanoparticles (e.g. lipid micelles, liposomes, dendrimers, polymeric 
nanoparticles) and inorganic nanoparticles (e.g. gold and mesoporous silica nanoparticles as 
examples). 
2
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Organic nanocarriers, especially liposomes’, are the most widely studied nanoparticulate 
delivery systems38. Liposomes are self-assembling spherical nanostructures consisting 
of one or more lipid bilayers, formed via the intrinsic interfacial properties imparted by 
the constituent phospholipids. Other widely studied organic drug delivery systems 
include polymeric nanocarriers, which can be highly stable due to their high structural 
integrity afforded by the rigidity of the polymer matrix. Poly(lactic-co-glycolic acid) 
(PLGA), chitosan, dextran, alginates, polyvinyl alcohol (PVA), and polyethylene glycol 
(PEG) are examples of components of polymeric nanocarriers that are currently being 
extensively studied as drug delivery systems, owing to their minimal toxicity, 
biodegradability and biocompatibility39. In recent years, other nanocarrier-based drug 
delivery systems have also been described, including polymeric or lipid micelles, solid-
lipid nanoparticles, dendrimers, polymersomes, nanogels, et cetera40.  
Focusing on RTIs and nanomedicine delivery to the lung, a wide variety of nanocarriers 
could potentially be utilized41. The aerodynamic diameter, shape and surface properties 
of the aerosol are the primary factors, with the architecture of the respiratory tract and 
biological clearance mechanisms as key determinants of lung deposition pattern and 
retention of aerosols. For instance, when targeting the lower airways, aerosols with an 
aerodynamic diameter of 1–5 μm are believed to deposit there most efficiently42. In 
practice, this means that micron-sized powder of agglomerated particles or liquid 
dispersions are currently mainly used for the pulmonary delivery of nanomedicines43,44. 
 
Advantages of pulmonary administration of antibiotic-
nanomedicines 
For RTI, aerogenic administration of antibiotic-nanomedicines possess several 
advantages over free inhaled antibiotics32,45-48. 
Increased target localization and efficacy at lower drug dose 
To improve lung bioavailability, Pandey et al. administered poly(DL-lactide-co-glycolide) 
(PLG) nanoparticles containing rifampicin, isoniazid and pyrazinamide via the 
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 pulmonary route to Mycobacterium tuberculosis-infected guinea pigs49. The inhaled 
nanomedicines (as an aerosol) exhibited increased lung retention at therapeutic levels 
and improved dosage schedule (i.e. reduced dosing frequency as an aerosol) compared 
with the free drug given via oral or intravenous route. After a single nebulization of 
drug-loaded PLG nanoparticles, all three antibiotics were detected at therapeutic drug 
levels up to 11 days in lung homogenates, while oral or aerosol-administered free 
antibiotic at the same dose were not detectable after 24 hours. Complete killing of  
M. tuberculosis in the lungs of infected guinea pigs was realized after nebulization of 5 
doses of drug-loaded PLG nanoparticles at 10-day intervals, whereas 46 similar daily 
doses of orally administered drugs were required in order to provide similar therapeutic 
efficacy49.  
Protection against enzymatic/chemical degradation or unwanted 
interactions with other molecules 
Nanocarriers can physically protect sensitive molecules from rapid degradation and 
reduce unwanted interactions with non-relevant host biomolecules. For example, nano-
sized drug delivery systems can be coated with PEG resulting in decreased uptake and 
degradation by cells of the mononuclear phagocyte system — a strategy to increase the 
blood circulation time after intravenous administration50-52.  
Nacucchio et al. showed that encapsulation of the β-lactam antibiotic piperacillin by 
phosphatidylcholine-cholesterol (PC:Chol) liposomes protected the drug from 
hydrolysis by Staphylococcal β-lactamase. This resulted in enhanced antibacterial 
activity of liposomal piperacillin against Staphylococcal growth in biofilms in the 
presence of exogenous β-lactamase53. Meers et al. showed that encapsulation of 
amikacin in dipalmitoylphosphatidylcholine-cholesterol (DPPC:Chol) liposomes is 
beneficial in the treatment of chronic Pseudomonas aeruginosa biofilm infections via 
improvement of biofilm access and/or reducing undesirable interactions with biofilm 
matrix components. Measurement of amikacin release and efficacy in the rat lung, as 
measured by fluorescence polarization immunoassay and viable bacterial count, showed 
that inhaled liposomal amikacin was released in a slow, sustained mode in normal rat 
2
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lungs and was superior in antimicrobial activity compared to inhaled free amikacin in 
infected lungs in a 14 day P. aeruginosa infection model. Further, the use of a filter assay 
and epifluorescence / confocal scanning laser microscopy showed that fluorescently 
labeled DPPC:Chol liposomes could significantly penetrate the P. aeruginosa biofilm54. 
Magabe et al. compared the antibacterial activity of liposomal gentamicin versus free 
gentamicin against gentamicin-resistant strains of P. aeruginosa55. Gentamicin 
encapsulated in DPPC:Chol, 1,2-dimyristoyl-sn-glycero-3-phosphocholine-cholesterol 
(DMPC:Chol), or dipalmitoylphosphatidylcholine-cholesterol (DSPC:Chol) liposomes 
exhibited a higher antimicrobial activity compared to free gentamicin. This effect was 
attributed to either enhanced diffusion of the liposome-encapsulated antibiotic across 
the bacterial cell envelope and/or to protection of the antibiotic from enzymatic 
degradation as a result of liposomal encapsulation.  
Protection from pulmonary clearance mechanisms 
The inclusion of mucoadhesives (e.g. cationic groups) via surface modification of 
nanocarriers has been suggested to improve the pulmonary delivery of drugs via an 
increased lung retention time. In the case of chitosan-modified PLGA nanospheres 
(approximately 650 nm) loaded with elcatonin (an anti-parathyroid agent), the 
elimination rate constant was approximately one-third compared to that of unmodified 
chitosan nanospheres, resulting in enhanced and prolonged pharmacological action 
compared to unmodified chitosan nanospheres56. 
Other studies have suggested that the retention of particles that adhere to airway mucus 
is limited due to mucus clearance mechanisms and that nanocarriers that do not adhere, 
or rapidly penetrate the mucus, allow uniform and long-lasting drug delivery to the 
airways following inhalation. Schneider et al. demonstrated in in vitro experiments that 
particles as large as 200 nm are able to rapidly penetrate the respiratory mucus of 
patients with cystic fibrosis (CF) if the particles are densely coated with PEG. On the 
other hand, mucoadhesive particles were unable to rapidly penetrate respiratory mucus 
regardless of the particle size57. When tested in vivo, the mucoadhesive particles were 
more rapidly eliminated from the lumen of the lung of mice, while the penetrating 
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 nanocarriers were uniformly distributed throughout the mucus layer and exhibited 
improved retention time. This resulted in improved therapeutic efficacy compared to 
both carrier-free drug or a drug delivered via a mucoadhesive nanocarrier system. 
Enhanced internalization by target cells 
In the context of the treatment of intracellular infections, one major challenge is the 
difficulty of antibiotic access to the protective environment within cells. For example, 
Mycobacteria spp. latently reside in the phagocytic intracellular compartments of 
macrophages. Kisich et al. investigated the effects of moxifloxacin encapsulated in 
poly(butylcyanoacrylate) (PBCA) nanoparticles against M. tuberculosis residing in 
macrophages58. Drug-loaded PBCA nanoparticles showed increased antibacterial 
activity via 10-fold reduction of the MIC. In macrophages exposed to moxifloxacin 
PBCA nanoparticles, the intracellular accumulation of moxifloxacin was increased 
three-fold compared to exposure to free drug. Also, the intracellular retention time of 
moxifloxacin increased from 4 hours to 24 hours.  
Controlled antibiotic release 
The use of different types of antibiotic-nanomedicines can enable the controlled release 
of antibiotics into the lung. For example, antibiotic-nanomedicines may allow the 
triggered release of an antibiotic at low pH conditions, such as is found in the inflamed 
lung environment, or may be positively charged to improve their affinity for negatively 
charged bacterial surfaces and biofilms at the site of infection59,60. Additionally, 
antibiotics with time-dependent activity may benefit from the use of sustained-release 
nanomedicines61, resulting in optimal antimicrobial activity over time, while minimizing 
the chance of unwanted side-effects due to uncontrolled and massive release of 
antibiotic within a short period of time. 
Finally, the inhalation of insoluble non-degradable or slowly-degradable particles may 
lead to serious inflammatory responses and oxidative stress, resulting in irritation, 
cellular injury, edema, phagocytosis impairment, and breakdown by host defense 
mechanisms34,35. However, the toxicity of nanoparticles is mainly determined by the 
materials that they are composed of and their surface characteristics. Therefore, 
2
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extensive in vitro and in vivo testing is performed as part of the development process of 
nanoparticle-based drug-carrier systems. This means that the materials and inhalation 
strategies established for a particular antibiotic nanomedicine formulation are carefully 
selected (e.g. the use of biodegradable or biocompatible materials), in order to minimize 
the possibility of adverse reactions when inhaled by patients.  
 
Clinical status 
The use of nanocarriers and the potential value of direct delivery of aerosolized 
nanocarrier-bound antibiotics to the lung has been shown in patients with inhaled 
liposomal formulations of ciprofloxacin (Lipoquin™) and a mixed formulation of non-
encapsulated and liposomal ciprofloxacin (Pulmaquin™). These formulations have 
been evaluated in Phase III clinical trials in CF patients and non-CF patients with RTIs. 
Initially, two Phase IIA clinical trials of liposomal ciprofloxacin formulations 
demonstrated that two-week and four-week once-daily administration of Lipoquin™ in 
CF patients and non-CF bronchiectasis patients was safe and capable of reducing the  
P. aeruginosa bacterial load in sputum62. Although the results obtained using Lipoquin™ 
were encouraging, extra experiments using Pulmaquin™ were performed in order to 
determine if additional clinical benefit might be gained using a rapid antibiotic release 
(peak concentration) strategy when compared to using free antibiotic. In Phase I 
studies, Pulmaquin™ showed significantly higher maximum plasma concentrations of 
ciprofloxacin when compared to Lipoquin™ due to the presence the non-encapsulated 
antibiotic in the Pulmaquin™ formulation. The ciprofloxacin concentrations in plasma 
over time were more than two-fold lower following administration of Pulmaquin™ or 
Lipoquin™ compared to plasma levels of approved doses of oral or intravenous 
ciprofloxacin. This suggested that after administration of liposomal ciprofloxacin the 
potential risk of systemic side-effects, even upon repeated dosing with such 
ciprofloxacin-nanoparticles, was significantly reduced. In Phase IIb clinical trials, 
named ORBIT-1 and ORBIT-2 (directed against non-CF bronchiectasis patients 
suffering from P. aeruginosa infection), both Lipoquin™ and Pulmaquin™ were 
40
Chapter 22
145136 van der Weide BNW.indd   40 07-08-20   14:00
 investigated for their ability to provide the optimum dose of ciprofloxacin with minimal 
side-effect. Pulmaquin showed superior pulmonary safety profile with rapid and 
persistent reduction of bacterial load in sputum. 
Based on these results, Pulmaquin™ was selected and evaluated by Aradigm 
Corporation in a Phase III clinical trial in non-CF bronchiectasis patients (ARD-3150-
1201), ORBIT-3 (NCT01515007) and ORBIT-4 (NCT02104245), which was followed 
by a 28-day open label extension study63. The Aradigm Corporation announced that 
analyses of combined data from both studies demonstrated a statistically significant 
reduction in P. aeruginosa load in the lungs at the end of the first on-treatment period. 
There was also a statistically significant reduction (27%) in pulmonary exacerbation over 
a 48-week double-blind treatment period between the Pulmaquin™ group and the 
placebo group. The median time to first moderate or severe pulmonary exacerbations 
— those exacerbations that require interventions with antibiotics or hospitalization — 
were statistically improved in the Pulmaquin™ treated group (198 days) versus placebo 
group (302 days). Additionally, Pulmaquin™ was safe and well tolerated in both studies. 
Therefore, in the first quarter of 2018, Aradigm Corporation submitted a marketing 
authorization request to the European Medicines Agency (EMA) for Linhaliq™ 
(formerly Pulmaquin™) as a treatment for non-CF bronchiectasis patients with a 
chronic P. aeruginosa lung infection. 
Another antibiotic-nanomedicine i.e. liposomal amikacin has been studied in Phase II 
clinical trials (NCT00558844, NCT00777296, NCT01315236) comparing inhalatory 
liposomal Amikacin (Arikayce™/Arikace™/ALIS™) to placebo in once-daily and 
multidrug regimens. In CF patients with P. aeruginosa infection, once-daily, Arikayce™ 
was shown to improve lung function and improve patient-reported respiratory clinical 
symptoms over a 28 day period of treatment64. Additionally, a statistically significant 
reduction in P. aeruginosa density in sputum (>1 log) was observed compared to baseline 
measurements. In patients with antibiotic-resistant nontuberculous mycobacteria 
(NTM) infections, negative bacterial cultures were obtained by day 84 in 11/45 patients, 
whereas this was achieved in 3/45 patients receiving standard treatment65. Insmed Inc. 
also completed a European and Canadian registrational Phase III studies of Arikayce™ 
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in CF patients — the CLEAR-108 (NCT01315678) and CLEAR-110 (NCT01316276) 
projects66. Overall, once daily Arikayce™ was non-inferior to inhalation treatment with 
tobramycin solution when taken twice daily in patients with CF and chronic 
bronchopulmonary P. aeruginosa infections. Furthermore, inhaled Arikayce™ was 
generally safe and well tolerated. Insmed Inc. also investigated Amikacin Liposome 
Inhalation Suspension (ALIS™) in a Phase 3 clinical trial (INS-312, NCT02628600), 
which was established to investigate the treatment of adult patients with refractory 
NTM infections caused by Mycobacterium avium complex (MAC)67. The study 
demonstrated that ALIS™ when added to guideline-based therapy, eliminated the 
infection in 29% of patients, compared to 9% of patients treated using guideline-based 
therapy. Based on these results, in the first quarter of 2018, Insmed Inc. announced 
United States Food and Drug Administration (FDA) acceptance for a New Drug 
Application (NDA) for ALIS™ for treating NTM lung infections caused by MAC. The 
FDA granted accelerated approval on the fourth quarter for the amikacin liposomes 
inhalation suspension (Arikayce™/ALIS™) for the treatment of lung disease caused 
by MAC in adult patients, left with a few or no treatment options68.  
The EMA (EU) and FDA (USA) have also granted the orphan drug designation 
fusogenic liposomes loaded with tobramycin (Tobramycin Fluidosomes™, Axentis 
Pharma), for CF patient-associated RTIs69,70. Although the results of clinical trials using 
Fluidosomes™ are not available, in vitro studies have described the antimicrobial activity 
of the Fluidosomes™ versus free tobramycin using biofilm infection models of  
P. aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. These studies showed 
an increased antimicrobial effect (>17-50x) of Fluidosomes™ compared to free 
tobramycin in all biofilm models tested71,72. Also in vivo studies using Fluidosomes™ 
have shown increased bactericidal activity against infections caused by antibiotic-
susceptible or resistant P. aeruginosa strains73,74.  
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Conclusions and future perspectives  
The worrying failure of conventional antibiotics in the treatment of infected patients is 
attributable to the worldwide emergence of antibiotic-resistant bacteria, and therefore 
the development and testing of new or undervalued antibiotics, or new antibiotic 
treatment modalities is urgently needed. Furthermore, toxic side-effects associated with 
prolonged oral and parenteral delivery of high dose antibiotics to patients, and a lack of 
a targeting mechanism to guide antibiotics to the focus of infection, may lead to 
treatment with sub-therapeutic levels of antibiotic and therefore inadequate killing of 
the infectious pathogens. The current lack of novel effective antibiotics, implies that 
the development of efficient delivery modalities, such as the use of inhaled, customized 
antibiotic-nanomedicines containing existing and/or novel antibiotics, could result in 
improved treatment of pulmonary infections. In this respect, the sheer variety and 
versatility of nanocarriers available provide many opportunities for the development of 
antibiotic-nanomedicines, including the possibility of targeting the antibiotics to both 
extracellular and intracellular pathogens in infected tissues, or to pathogens embedded 
within protective niches of the lung, within sputum or within pulmonary biofilms. That 
said, only one antibiotic-nanomedicine has entered the market as of this time, mainly 
due to several hurdles limiting their implementation. Some of these hurdles include 
factors relating to manufacturing processes (scaling-up production, good 
manufacturing practice etc.), the unique environment of the lung (e.g. overcoming host 
defense mechanisms) and the different delivery needs in case of treatment of acute 
versus chronic infections (creation of rapid versus slow antibiotic release profiles, 
respectively). At a time when existing antibiotics are becoming ineffective and few new 
antibiotics are in the developmental pipeline, the potential advantages (i.e. reduction of 
patient morbidity and mortality) that could be gained by using antibiotic-nanomedicine 
therapies should be seriously valued. 
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Executive Summary 
Respiratory tract infections (RTIs) and antibiotic treatment  
 Increasing worldwide antibiotic resistance means that the successful treatment of 
RTIs is often challenging. 
 One major critical factor involved in promoting the spread of antibiotic resistance 
is sub-optimal antibiotic dosing and inferior pharmacokinetic profiles (associated 
with antibiotic administration via oral and parenteral routes). 
 Antibiotic therapy may also be associated with host tissue toxicity and damage to 
the host’s protective microbiota. 
New strategies to provide effective treatment against bacterial RTIs 
 Novel antimicrobial compounds could be utilized to treat antibiotic-resistant RTIs, 
but there is currently a lack of novel antibiotics available for clinical use. 
 The effective administration of antibiotics to the site of infection in patients with 
RTIs could be facilitated by the local delivery of (existing and/or novel) antibiotics 
via antibiotics incorporated in nanocarriers (antibiotic-nanomedicines). 
 Antibiotic-nanomedicines could be optimized for targeted deposition of (mixtures 
of) antibiotics at the infection focus in RTIs, thereby increasing the efficacy of 
antibiotic therapy. 
Increased efficacy associated with the use of antibiotic-nanomedicines 
for bacterial RTIs 
 Antibiotic-nanomedicines can increase the antibiotic concentration at the site of 
infection and therefore can help to reduce the emergence of antibiotic resistance. 
 Toxic side-effects and collateral damage by antibiotics to the host’s bacterial flora 
can also be minimized. 
 Custom antibiotic-nanomedicines for tailored antibiotic release kinetics can be 
developed. 
 Protection of the antibiotic from host-related pulmonary clearance mechanisms, 
enzymatic/chemical degradation or detrimental interactions with host biomolecules. 
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 The potential value of direct delivery of aerosolized antibiotic-
nanomedicines to the lung has been shown in patients 
 Inhaled liposomal formulations of ciprofloxacin (Lipoquin™ and 
Pulmaquin™/Linhaliq™) and amikacin (Arikayce™/Arikace/Alis™) have been 
evaluated for their effectiveness and safety in Phase III clinical trials. 
 The FDA granted accelerated approval for the amikacin liposomes inhalation 
suspension (Arikayce™) for the treatment of lung disease caused by Mycobacterium 
avium complex in adult patients, left with a few or no treatment options.  
Conclusions 
 The development and testing of antibiotic-nanomedicines for the targeted delivery 
of antibiotics has the potential to be a powerful tool for the treatment of (antibiotic-
resistant) bacterial RTIs. 
 Antibiotic-nanomedicines can address critical challenges associated with 
conventional antibacterial therapies and administration routes. 
 A better mechanistic understanding of the complex delivery pathways of inhaled 
antibiotic-nanomedicines is required in order to be able to further improve lung 
deposition and maximize therapeutic efficacy. 
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The main focus of the research presented in this thesis was to develop novel 
nanomedicines based on new antimicrobial peptides (AMPs), and to investigate their 
bacterial killing activity against multidrug-resistant Gram-negative bacteria in vitro and  
in vivo. In vivo experiments included the measurement of therapeutic efficacy when the 
nanomedicines were administered directly to the lungs of rats in a rat model of 
multidrug-resistant Gram-negative pneumonia-septicemia. The research described in 
this thesis was part of the collaborative research project “Nanotherapeutics to treat 
bacterial infectious diseases” (PneumoNP) which was financially supported by the 
European Union’s Seventh Programme for Research, Technological Development and 
Demonstration under grant agreement No. 604434 PneumoNP.  
The aim of the PneumoNP project was to develop a theragnostic system for the 
treatment of multidrug-resistant Gram-negative bacterial infections of the lung, with a 
focus on Klebsiella pneumoniae as a causative organism. Alongside the development of a 
new diagnostic kit, PneumoNP partners were involved in the pre-clinical development 
of novel inhalable antibiotic-nanomedicines based on two new AMPs (AA139 and  
SET-M33). These two new AMPs were entrapped in several different nanocarriers 
(polymeric nanoparticles, liposomes, or lipid-core micelles), with an extensive pre-
clinical development pipeline being established in order to prepare the various 
nanomedicine formulations and to select the most effective nanomedicines (Figure 1). 
Other research performed by PneumoNP partners, which is not described in the 
present thesis, included chemical stability measurements and reproducibility testing of 
the nanocarriers, as well as cytotoxicity and genotoxicity assays using nanomedicines, 
and finally, the development of a novel aerosol delivery system.  
The chapters in Section II cover the in vitro investigations of the antimicrobial activity 
of the novel AMPs tested against different clinically relevant multidrug-resistant Gram-
negative bacterial isolates. The data was used as a starting point in the development and 
testing of PneumoNP AMP-nanomedicines. In Chapter 4 we tested the antimicrobial 
activity of two novel AMPs, SET-M33 and AA139, against a collection of genotypically 
diverse K. pneumoniae isolates recovered from individual patients and a variety of 
different clinical samples. 
54
Chapter 33
145136 van der Weide BNW.indd   54 07-08-20   14:01
  
Figure 1. Diagram of the research in the PneumoNP pre-clinical development pipeline to 
develop novel AMP-nanomedicine candidates which is included in this thesis. 
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The collection of isolates showed differing antibiotic resistance profiles, including 
colistin-resistant isolates, and was examined for susceptibility to SET-M33 and AA139 
(and colistin as comparator drug) in different assays. These assays included: 
bacteriostatic activity after 18 hours antibiotic exposure (minimum inhibitory 
concentration, MIC); concentration- and time-dependent bactericidal activity (time-kill 
kinetics, TKK); and susceptibility (determined by MIC) before and after 24 hours 
exposure to SET-M33 or AA139. Chapter 5 describes a more in-depth investigation 
into the precise bactericidal mode of action of SET-M33 against isogenic colistin-
susceptible and colistin-resistant K. pneumoniae and Pseudomonas aeruginosa strains using a 
TKK assay, electron microscopy, nuclear magnetic resonance (NMR) structure analysis, 
and a hemolytic activity assay. 
The chapters in Section III detail the in vivo investigations of our selected AMP-
nanomedicines administered via endotracheal aerosolization. The testing of novel 
treatment modalities in animal experiments is an essential and prerequisite link between 
pre-clinical in vitro studies and clinical trials in patients. In Chapter 6, we first set out to 
establish and characterize a new rat model of acute lobar pneumonia leading to fatal 
septicemia caused by multidrug-resistant (ESBL-producing or KPC-producing)  
K. pneumoniae which could be used to investigate our nanomedicines in vivo. We validated 
this rat model using a high-dose treatment regimen of the ‘drug of last resort’ 
tigecycline, with the carbapenem antibiotic meropenem as comparator drug.  
Chapter 7 and Chapter 8 cover the in vivo investigation of the SET-M33-
nanomedicines and AA139-nanomedicines compared to free SET-M33 and free 
AA139, respectively. In all our in vivo experiments, the nanomedicines were 
administered to rats via endotracheal aerosolization (as a means of direct delivery to the 
lungs). We used single-dose administration of the nanomedicines to determine the 
limiting dose as either maximum tolerated dose (MTD) or maximum feasible dose 
(MFD) in uninfected rats and to screen for the early bacterial killing activity in the lungs 
of infected rats. Based on the results of these studies, the most promising AA139-
nanomedicines were selected for continued investigations. Chapter 8 further elaborates 
on these studies using AA139-nanomedicines via extensive biodistribution studies in 
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 uninfected rats using single-dose administration of radioactively labelled AA139-
nanomedicines. Finally, therapeutic efficacy studies were performed in infected rats 
using once-daily administration of AA139-nanomedicines over a period of 10 days. 
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Chapter 4 Antimicrobial activity of two novel antimicrobial peptides AA139 
and SET-M33 against clinically and genotypically diverse Klebsiella 
pneumoniae isolates with differing antibiotic resistance profiles  
Chapter 5 Investigations into the killing activity of an antimicrobial peptide 
active against extensively antibiotic-resistant Klebsiella pneumoniae 
and Pseudomonas aeruginosa 
 
The chapters in Section II cover the in vitro investigations of the antimicrobial activity of 
novel AMPs against different clinically relevant multidrug-resistant Gram-negative isolates 
as a starting point of the development pipeline towards effective AMP-nanomedicines.  
Chapter 4 describes the antimicrobial activity of two novel AMPs, AA139 and SET-M33, 
against a collection of genotypically diverse Klebsiella pneumoniae isolates recovered from a 
variety of different clinical samples of individual patients. The isolates showed differing 
antibiotic resistance profiles, including colistin resistance, and was examined by determination 
of bacteriostatic activity (minimum inhibitory concentration, MIC); concentration- and time-
dependent bactericidal activity (time-kill kinetics, TKK); and susceptibility (determined by MIC) 
before and after exposure to AMPs. 
Chapter 5 describes a more in-depth investigation into the precise bactericidal mode of action 
of SET-M33 against isogenic colistin-susceptible and colistin-resistant  
K. pneumoniae and Pseudomonas aeruginosa strains using TKK assays, electron microscopy, 
nuclear magnetic resonance (NMR) structure analysis, and hemolytic activity assay. 
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Abstract 
Colistin is an antimicrobial peptide (AMP) used as a drug of last resort, although plasmidal 
resistance (MCR) has been reported. AA139 and SET-M33 are novel AMPs currently in 
development for the treatment of multidrug-resistant Gram-negative infections. As many 
AMPs have a similar mode of action as colistin, which can potentially lead to cross-resistance, 
the antimicrobial activity of AA139 and SET-M33 was investigated against a collection of 50 
clinically and genotypically diverse Klebsiella pneumoniae isolates with differing antibiotic 
resistance profiles, including colistin-resistant strains. The collection was genotypically 
characterized and susceptibility to clinically relevant antibiotics was determined. Susceptibility 
to AA139 and SET-M33 did not deviate among the collection, despite differences in underlying 
mechanisms of resistance or susceptibility to colistin. For 3 colistin-susceptible and 3 colistin-
resistant strains with distinct multidrug-resistant profiles, and an additional MCR-producing 
strain, the bactericidal activity of AA139, SET-M33, and colistin during 24 hours exposure was 
examined. After the 24 hours exposure to AA139, SET-M33, or colistin, the 7 strains were 
tested for changes in susceptibility towards the respective AMPs. AA139 and SET-M33 showed 
a concentration-dependent bactericidal effect irrespective of the susceptibility of the bacteria 
to colistin. Exposure to low concentrations of colistin resulted in the development of colistin 
resistance in colistin-susceptible strains, whereas susceptibility to AA139 and SET-M33 after 
exposure to the respective AMPs was maintained. The two novel AMPs remained effective 
against colistin-resistant strains and may be promising novel drugs for the treatment of 
clinically and genotypically diverse multidrug-resistant K. pneumoniae infections, including 
infections associated with colistin-resistant bacteria. 
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Introduction 
The spread of multidrug-resistance has rendered a growing list of antibiotics ineffective 
in the treatment of antibiotic-resistant bacterial infections, while the past decades have 
seen a dearth in the discovery and development of new antibiotics1. This has caused 
concerns about an oncoming post-antibiotic era, in which pan-resistant bacterial 
infections will be common in the clinical setting and there are little to no treatment 
options left available to clinicians2. Already, this post-antibiotic era is being heralded by 
clinical reports of pan-resistant bacterial infections3.  
Due to the increase of antibiotic-resistant infections, colistin has resurfaced as a drug 
of last resort in the clinic for the treatment of multidrug-resistant infections4. This 
polypeptide antibiotic has been available for clinical use since 1959, but was largely 
abandoned due to issues with potential toxic side effects. The diminishing supply of 
effective antibiotics available for the treatment of multidrug-resistant infections has 
caused a renewal in investigations on the potential of colistin in the clinical setting5.  
Unfortunately, the renewed use of colistin has led to the emergence and spread of 
colistin resistance6. The first report of a plasmid conferring mobilized colistin resistance 
(MCR) was published in 20157. Since then, different variants of plasmidal colistin 
resistance have been identified and isolated from patients across the world, rendering 
even this drug of last resort potentially ineffective8. 
Antimicrobial peptides (AMPs) are a family of naturally occurring antimicrobial 
compounds that were discovered in the first half of the 20th century, of which colistin 
is the most well-known example in the clinical setting9. In nature, AMPs are produced 
by all living organisms as a defensive mechanism towards micro-organisms, and thus 
far over 3000 different AMPs have been described in the Antimicrobial Peptide 
Database (http://aps.unmc.edu/AP/main.php)10,11.  
Most AMPs, including colistin, are cationic and share a broad-spectrum mechanism of 
antimicrobial killing which is non-specific but highly efficient12. This cationic 
mechanism works through disruption of the bacterial cytoplasmic membrane by 
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 interaction of the cationic peptide with anionic bacterial membrane lipids, which leads 
to the arrest of bacterial growth and cell death. While most cationic AMPs have this 
membrane-disrupting mechanism of action in common, many have additional 
mechanisms of antimicrobial activity including membrane protein targeting, 
intracellular activity, and immunomodulation13-15. Studies have shown that AMPs differ 
in their potential for cross-resistance with colistin, which may be the result of 
differences between their additional mechanisms of antimicrobial activity16-18. 
Importantly, AMPs that do not share cross-resistance with colistin may remain a viable 
alternative in the treatment of colistin-resistant infections.  
In the present study, the antimicrobial activity of two novel cationic AMPs AA139 and 
SET-M33 was investigated using a collection of 50 clinically and genotypically diverse 
Klebsiella pneumoniae isolates with differing antibiotic resistance profiles. AA139 
originates from Arenicin-3, an AMP isolated from the marine lugworm Arenicola marina 
with a 21-residue amphipathic β-hairpin structure, and was developed from Arenicin-3 
based on decreases in plasma protein binding properties, cytotoxicity, and hemolytic 
activity19,20. AA139 has shown potent in vitro antimicrobial activity against multidrug-
resistant Gram-negative bacteria and has shown promising in vivo results in a number 
of animal models of infectious disease20,21. Studies into its mode of action have 
suggested a dual mode of action through direct binding of AA139 to membrane 
phospholipids followed by interruption of phospholipid transportation pathways, 
resulting in membrane dysregulation resulting in bacterial cell death19,22.  
SET-M33 is a synthetic tetrabranched peptide linked by a lysine core, providing high 
resistance to proteolytic degradation23. SET-M33 has likewise shown potent 
antimicrobial activity against Gram-negative bacteria and promising in vivo results in a 
number of animal models of infectious disease24. Investigations into its mode of action 
have suggested that SET-M33 directly binds the bacterial lipopolysaccharide (LPS) and 
adopts an α-helix conformation in the membrane phospholipid bilayer, leading to 
membrane disruption resulting in bacterial cell death25,26. Further studies have indicated 
additional mechanisms which may contribute to the use of SET-M33 in treating  
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infectious diseases, namely through immunomodulatory and anti-inflammatory 
activity27, synergistic activity with other antibiotic families28, and anti-biofilm activity25.  
In this manuscript, the authors investigate the potential usefulness of AA139 and  
SET-M33 against clinically and genotypically diverse K. pneumoniae isolates with differing 
antibiotic resistance profiles, including colistin-resistant isolates.  
 
Materials and methods 
Bacterial isolates 
A collection of 50 K. pneumoniae isolates was utilized in this study. The isolates were 
cultured from various clinical specimens: blood, wound, mouth, throat, tracheal 
aspirate, rectum, catheter, urine, and perineum. The collection contains isolates 
representing five different antibiotic resistance profiles, consisting of 10 isolates per 
profile: Wildtype, extended-spectrum β-lactamase (ESBL)-producing, K. pneumoniae 
carbapenemase (KPC)-producing, oxacillinase β-lactamase (OXA)-48-like-producing, 
and New Delhi metallo-β-lactamase (NDM)-producing. Among the ESBL-producing 
isolates was one isolate positive for mobilized colistin resistance (MCR). The majority 
of the clinical samples had been collected between 2008 and 2015 from patients 
admitted at the Erasmus University Medical Center Rotterdam (Erasmus MC), the 
Netherlands. A KPC-producing isolate was obtained from a clinical sample from 
Greece, and 6 NDM-producing isolates were obtained from clinical samples from 
Bangladesh. 
Genotypic characterization 
Polymerase chain reaction (PCR) assays were used to verify the presence of the 
following resistance genes in the K. pneumoniae collection: cefotaxime-M β-lactamase 
(CTX-M) groups 1, 2, 8, 9, 2529; temoniera β-lactamase (TEM)30; sulfhydryl reagent 
variable β-lactamase (SHV)31; OXA-1-like32; OXA-48-like33; KPC34; NDM-135; and 
MCR-17. Multilocus sequence typing (MLST) was used to investigate genetic 
relatedness: partial deoxyribonucleic acid (DNA) sequences of housekeeping genes 
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 were generated using a published high-throughput MLST (HiMLST) strategy that had 
been adapted for K. pneumoniae isolates36. The results were compared to the publicly 
available K. pneumoniae MLST profiles at https://bigsdb.pasteur.fr. Pulsed-field gel 
electrophoresis (PFGE) was performed to further assess the genetic relation between 
the isolates37. 
Antimicrobial agents 
Ceftazidime hydrate, cefotaxime sodium salt, meropenem trihydrate, tigecycline, and 
colistin sulfate salt were purchased from Sigma-Aldrich Chemie BV (Zwijndrecht, the 
Netherlands). AA139 in Ringer’s acetate solution was obtained from Adenium Biotech 
ApS (Copenhagen, Denmark). Dry-frozen L-isomeric SET-M33-acetate38 was obtained 
from Setlance srl (Siena, Italy).  
Antimicrobial susceptibility 
The minimum inhibitory concentrations (MICs) of the K. pneumoniae collection to 
clinically relevant antibiotics were determined using the broth microdilution method 
following European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
guidelines39. Two-fold antibiotic concentration ranges were used; ceftazidime (0.0625–
512 mg/L), cefotaxime (0.0625–512 mg/L), meropenem (0.0156–128 mg/L), 
tigecycline (0.0625–64 mg/L), AA139 (0.0625–64 mg/L), SET-M33 (0.0625– 
64 mg/L), colistin (0.0625–64 mg/L). Antimicrobial susceptibility of the collection was 
also determined using the VITEK®2 system and AST-N344 Gram-Negative 
Susceptibility Cards (bioMérieux Benelux BV, Zaltbommel, The Netherlands). 
Selection of multidrug-resistant isolates 
A panel of 6 K. pneumoniae isolates was selected from the collection for the investigation 
of concentration- and time-dependent bactericidal activity and potential changes in 
susceptibility to AA139, SET-M33 and colistin. This panel of 6 isolates comprised one 
colistin-susceptible and one colistin-resistant strain from each of the three most 
extensively antibiotic-resistant profiles (KPC-producing, OXA-48-like-producing, 
NDM-producing). Selection of isolates was based on genotypic diversity and divergent 
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susceptibilities to clinically relevant antibiotics, representing distinct groups of clinically 
relevant multidrug-resistance. The MCR-producing isolate was investigated using the 
same methods as the selected panel. 
Concentration- and time-dependent bactericidal activity of AMPs 
Time-kill kinetics (TKK) assays were performed as described previously40 in triplicate 
for each of the 7 K. pneumoniae isolates. Four-fold increasing concentrations were used 
from 0.25–64 mg/L for all AMPs. At sampling time-points, suspensions were 
centrifuged at 12,500 × g for 5 minutes to avoid antibiotic carry-over, serially 10-fold 
diluted, and sub-cultured on Mueller Hinton II (MH-II) agar plates. The plates were 
incubated at 37 °C during 20 hours for colony-forming units (CFU) counting. 
Change in susceptibility towards AMPs after exposure 
The 7 K. pneumoniae isolates exposed to AMPs for 24 hours during the TKK assays were 
tested for changes in their susceptibility towards the respective AMPs by MIC 
determination39. For colistin-resistant isolates, a concentration range of 0.5–512 mg/L 
colistin was used to be able to detect further increases in MIC.  
 
Results 
Characterization of K. pneumoniae collection 
The clinical origins of the 50 isolates in the K. pneumoniae collection are shown in 
Supplementary Table S1. A variety of genetic lineages was observed within the 
collection when HiMLST data was compared to global K. pneumoniae MLST genotypes, 
although some isolates clustered together more than others (Figure 1). PFGE data 
showed little overlap between the genetic profiles of the 50 isolates, with 40 clusters 
and singletons at 95% similarity (Supplementary Figure S1).  
PCR data showed that all 50 isolates were positive for the SHV resistance gene as 
expected for K. pneumoniae (Supplementary Table S2). Wildtype isolates did not contain 
additional β-lactamase genes, except for one TEM-positive isolate. ESBL-producing 
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Figure 1. Minimum spanning tree with logarithmic scaling of MLST data of the collection of 50 
K. pneumoniae isolates shown in comparison to a global K. pneumoniae collection of the Pasteur 
Institute, Paris, France. Red; Erasmus MC collection. White; Pasteur Institute collection 
available at http://bigsdb.pasteur.fr accessed at 20 June 2018. 
 
isolates were all positive for CTX-M groups 1 or 9, and many were also positive for 
TEM (70%) or OXA-1 (40%). The MCR resistance gene was detected in one ESBL- 
producing isolate. KPC, OXA-48-like, and NDM resistance genes were restricted to 
their respective antibiotic resistance profiles, i.e. KPC-producing, OXA-48-like-
producing, and NDM-producing isolates. The other plasmid-mediated resistance genes 
were spread between these 3 multidrug-resistance profiles in no obvious pattern.  
Antimicrobial susceptibility of K. pneumoniae collection 
The antimicrobial susceptibility of the K. pneumoniae collection against clinically relevant 
antibiotics (ceftazidime, cefotaxime, meropenem, tigecycline, colistin) as well as against 
two novel AMPs (AA139, SET-M33) was compared based on antibiotic resistance 
profiles (Table 1). 
Wildtype isolates were found to be phenotypically susceptible to all antibiotics tested, 
including the TEM-positive isolate. ESBL-producing and KPC-producing isolates were  
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Table 1. MIC values (mg/L) of K. pneumoniae groups differing in antibiotic resistance profile 
Antibiotic 
resistance 
profile 
Wildtype ESBL KPC OXA-48-like NDM 
Number of 
isolates 
10 10 10 10 10 
 
Ceftazidime 
 
0.5 
0.25 – 1 
64 
2 – 128 
512 
128 – >512 
256 
0.5 – 512 
>512 
>512 – >512 
 
Cefotaxime 
 
0.09 
<0.06 – 1 
512 
128 – >512 
512 
128 – >512 
512 
2 – >512 
>512 
512 – >512 
 
Meropenem 
 
0.06 
0.03 – 0.5 
0.06 
0.03 – 0.13 
32 
16 – 128 
2 
1 – >128 
96 
16 – >128 
 
Tigecycline 
 
2 
1 – 2 
2 
1 – 16 
4 
2 – 8 
2 
1 – 8 
8 
2 – 16 
 
AA139 
 
4 
4 – 4 
4 
4 – 4 
4 
2 – 16 
4 
4 – 8 
4 
2 – 8 
 
SET-M33 
 
8 
8 – 16 
8 
4 – 16 
16 
4 – 16 
16 
8 – 32 
8 
8 – 16 
 
Colistin 
 
1 
0.5 – 2 
0.5 
0.5 – 16 
1.5 
0.5 – 64 
1 
0.5 – >64 
3 
0.5 – 32 
MIC assays were performed in triplicate for each isolate, shown are the median values and 
range. MIC values are interpreted as susceptible, intermediate (italic), or resistant (bold) 
according to EUCAST guidelines. Interpretation has not been performed for the novel 
antimicrobial peptides AA139 and SET-M33.  
 
all resistant to ceftazidime and cefotaxime. ESBL-producing isolates remained 
susceptible to meropenem, while KPC-producing isolates were resistant to meropenem. 
OXA-48-like-producing isolates showed considerable variation in susceptibility 
towards ceftazidime, cefotaxime, and meropenem, with no obvious pattern. 80% of 
NDM-producing isolates were resistant to all antibiotics tested. Tigecycline-resistant 
and colistin-resistant isolates were found among all antibiotic resistance profiles, except 
among Wildtype isolates. Antimicrobial susceptibility towards AA139 and SET-M33 
never exceeded a two-fold change, irrespective of the antibiotic resistance profile. 
The K. pneumoniae collection was then divided into colistin-susceptible and colistin- 
resistant isolates based on colistin MIC values, and the antimicrobial susceptibility of 
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 Table 2. MIC values (mg/L) of K. pneumoniae groups differing in colistin susceptibility 
Antibiotic 
resistance 
profile 
Colistin-
susceptible 
Colistin-
resistant 
 
Number of 
isolates 
37 13 
 
 
Ceftazidime 
 
128 
0.25 – >512 
>512 
1 – >512 
 
 
Cefotaxime 
 
512 
<0.06 – >512 
512 
2 – >512 
 
 
Meropenem 
 
0.5 
0.03 – 128 
64 
0.13 – 
>128 
 
 
Tigecycline 
 
2 
1 – 16 
4 
2 – 16 
 
 
AA139 
 
4 
2 – 8 
4 
2 – 16 
 
 
SET-M33 
 
8 
4 – 16 
16 
8 – 32 
 
 
Colistin 
 
0.5 
0.5 – 2 
32  
4 – >64 
 
MIC assays were performed in triplicate for each isolate, shown are the median values and 
range. MIC values are interpreted as susceptible, intermediate (italic), or resistant (bold) 
according to the EUCAST guidelines. Interpretation has not been performed for the novel 
antimicrobial peptides AA139 and SET-M33. 
 
these two groupings was reanalyzed (Table 2). The groupings showed differences in 
susceptibility to meropenem, colistin, and tigecycline, with the colistin-susceptible 
isolates being susceptible and the colistin-resistant isolates being resistant to these 
antibiotics. The antimicrobial susceptibility to AA139 and SET-M33 did not exceed a 
two-fold change between the two groups. 
VITEK® MICs for the K. pneumoniae collection based on antibiotic resistance profiles 
are shown in Supplementary Table S3. The VITEK® MICs matched the pattern of 
MICs found using the broth microdilution assay.  
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Concentration- and time-dependent bactericidal activity of AMPs 
The MIC results for the selected panel of 3 colistin-susceptible and 3 colistin-resistant 
K. pneumoniae isolates from the three most extensively antibiotic-resistant profiles (KPC-
producing, OXA-48-like-producing, NDM-producing) against the AMPs tested are  
shown in Table 3. The bactericidal activity of the AMPs was investigated for this panel 
of 6 isolates using TKK assays (Figure 2).  
Regarding colistin-susceptible isolates, more than 99.9% of bacteria were killed after  
2 hours of exposure to ≥4 mg/L AA139, ≥4 mg/L SET-M33, or ≥0.25 mg/L colistin. 
After initial bacterial killing, bacterial re-growth up to the level of non-exposed bacteria 
occurred after 24 hours exposure to ≤1 mg/L AA139, ≤4 mg/L SET-M33, or ≤4 mg/L 
colistin. 
Regarding colistin-resistant isolates, more than 99.9% of bacteria were killed after  
2 hours of exposure to ≥16 mg/L AA139, ≥16 mg/L SET-M33, or ≥64 mg/L colistin. 
After initial bacterial killing, bacterial re-growth up to the level of non-exposed bacteria 
occurred after 24 hours exposure to ≤4 mg/L AA139, ≤4 mg/L SET-M33, or  
≤16 mg/L colistin. 
 
Table 3. MIC values (mg/L) of selection of multidrug-resistant K. pneumoniae isolates 
Selection Isolate name 
Antibiotic 
resistance 
profile 
AA139 SET-M33 Colistin 
Colistin-
susceptible 
K. pneumoniae ESBL 1059 KPC 4 8 0.5 
K. pneumoniae R-DYK 4861 OXA-48-like 4 8 1 
K. pneumoniae B-DYK 9557 NDM 4 16 0.5 
Colistin-
resistant 
K. pneumoniae R-DYK 3427 KPC 8 16 64  
K. pneumoniae R-DYK 7926 OXA-48-like 4 16 32 
K. pneumoniae ESBL 635 NDM 4 8 16 
MRC-
producing 
K. pneumoniae R-DYK 11347 ESBL 4 8 16 
MIC assays were performed in triplicate for each isolate, shown are the median values. MIC 
values for colistin are interpreted as susceptible or resistant (bold) according to EUCAST  
guidelines. Interpretation has not been performed for the novel antimicrobial peptides AA139 
and SET-M33. 
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Figure 2. Concentration- and time-dependent bactericidal activity of AA139, SET-M33 and 
colistin (CST) against 3 colistin-susceptible and 3 colistin-resistant K. pneumoniae KPC, OXA-
48-like and NDM isolates. Shown here are the median and interquartile range for 3 colistin-
susceptible or 3 colistin-resistant K. pneumoniae; experiments were performed in triplicate for 
all 6 isolates. The dashed grey line indicates the lower limit of quantification (Log 0.7 CFU/mL).  
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Change in susceptibility towards AMPs after exposure 
After 24 hours of exposure to AA139, SET-M33 or colistin in TKK assays, the 
susceptibility to the respective antibiotic of exposure was determined for the 3 colistin-
susceptible and 3 colistin-resistant K. pneumoniae isolates (Table 4). 
Regarding colistin-susceptible isolates, susceptibility towards AA139 remained 
unchanged except after exposure to AA139 at its MIC, which led to a 4-fold MIC 
increase. Susceptibility towards SET-M33 showed some minor changes, but never 
exceeded a 2-fold increase in MIC after exposure to SET-M33. Exposure to colistin led 
to the development of colistin resistance, even at low concentrations of colistin. 
Regarding colistin-resistant isolates, susceptibility towards AA139 remained unchanged 
except after exposure to AA139 at its MIC, which led to a 4-fold MIC increase. 
Susceptibility towards SET-M33 remained unchanged except after exposure of  
SET-M33 at its MIC, which led to a 2-fold increase in MIC. Exposure to high 
concentrations of colistin led to a further increase in the MIC values for colistin. 
 
 
Table 4. Change in susceptibility to AMPs of K. pneumoniae isolates 
AMP 
concentration 
(mg/L) 
MIC (mg/L) after 24 hours exposure to AMP 
Colistin-susceptible isolates Colistin-resistant isolates 
AA139 SET-M33 Colistin AA139 SET-M33 Colistin 
0 4 8 1 4 16 64 
0.25 4 8 16 4 16 32 
1 4 8 32 4 16 32 
4 16 16 32 16 16 64 
16 nd Nd nd nd 32 128 
64 nd Nd nd nd nd 256 
MIC assays were performed in triplicate for each isolate. Shown are the median MIC values of 
3 isolates pooled together. MIC values for colistin are interpreted as susceptible or resistant 
(bold) according to EUCAST guidelines. Interpretation has not been performed for the novel 
AMPs AA139 and SET-M33. nd, not determined (no regrowth in the original TKK experiment). 
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 AMP antimicrobial activity towards an MCR-producing isolate 
MIC results of an MCR-producing K. pneumoniae isolate towards AMPs can be found in 
Table 3. The TKK results for the MCR-producing isolate are shown in Figure 3. 
 
 
Figure 3. Concentration- and time-dependent bactericidal activity of AA139, SET-M33 and 
colistin (CST) against a MCR-producing K. pneumoniae ESBL isolate. Shown here are the 
median and range from triplicate experiments. The dashed grey line indicates the lower limit 
of quantification (Log 0.7 CFU/mL). 
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Bacterial killing at ≥99.9% was observed after 2 hours of exposure to ≥4 mg/L AA139, 
≥4 mg/L SET-M33, or ≥64 mg/L colistin. After initial bacterial killing, bacterial re-
growth up to the level of non-exposed bacteria occurred after 24 hours exposure to  
≤1 mg/L AA139, ≤4 mg/L SET-M33, or ≤4 mg/L colistin. 
As shown in Table 5, after 24 hours exposure to AA139, SET-M33 or colistin in the 
TKK assay, the change in MIC of SET-M33 for the MCR-producing isolate never 
exceeded a 2-fold increase, and there was no change in the susceptibility of the isolate 
to colistin or AA139. 
 
Discussion 
AA139 and SET-M33 are two promising novel AMPs currently in development as 
potential antibiotics for the treatment of Gram-negative multidrug-resistant infections. 
To examine the clinical relevance of AA139 and SET-M33, a collection of  
50 K. pneumoniae isolates from clinical samples was established representing 5 distinct 
antibiotic resistance profiles: Wildtype, ESBL- producing, KPC-producing, OXA-48- 
like-producing and NDM-producing. These isolates were clinically diverse and 
 
 
Table 5. Change in susceptibility to AMPs of MCR-producing K. pneumoniae isolate 
AMP 
concentration 
(mg/L) 
MIC (mg/L)  
after 24 hours exposure to AMP 
 
AA139 SET-M33 Colistin  
0 4 8 1  
0.25 4 8 16  
1 4 8 32  
4 16 16 32  
16 nd Nd nd  
64 nd Nd nd  
MIC assays were performed in triplicate, shown are the median values. MIC values for colistin 
are interpreted as susceptible or resistant (bold) according to EUCAST guidelines. 
Interpretation has not been performed for the novel AMPs AA139 and SET-M33. nd, not 
determined (no regrowth in the original TKK experiment). 
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 genotypically distinct at the global (MLST) and individual level (PFGE). The 
antimicrobial susceptibility against clinically relevant antibiotics and the presence of 
plasmid-mediated antibiotic resistance genes was determined for all 50 K. pneumoniae 
isolates. 
The susceptibility to AMPs AA139 and SET-M33 of all 50 isolates remained in the 
same order of magnitude regardless of antibiotic resistance profile or susceptibility of 
the isolates to colistin. This implies that the underlying mechanism(s) of resistance in 
these isolates did not affect the susceptibility of the strains to AA139 and SET-M33. 
Given that the growing emergence and spread of colistin resistance in the past few 
years6,7 has been coupled to the potential of colistin cross-resistance16-18, it is necessary 
to test whether novel AMPs such as AA139 and SET-M33 possess antimicrobial activity 
against colistin-resistant isolates. These results suggest that AA139 and SET-M33 have 
potential in the treatment of multidrug-resistant infections, including those associated 
with colistin-resistant isolates. 
In TKK assays using colistin-susceptible isolates, AA139, SET-M33, and colistin 
showed concentration-dependent bactericidal activity, with colistin showing activity at 
lower concentrations than AA139 or SET-M33 within the first 6 hours of exposure. 
Despite these differences in initial bactericidal activity, regrowth of the colistin-
susceptible bacteria after 24 hours of exposure to levels similar to non-colistin exposed 
bacteria was observed at similar concentrations for AA139, SET-M33, and colistin. The 
activity of colistin was reduced against colistin-resistant isolates when compared to 
colistin-susceptible isolates, with a 99.9% CFU/mL reduction and no regrowth of 
colistin-resistant bacteria only being observed at the highest colistin concentration used 
(64 mg/L). The novel AMPs showed a milder decrease in bactericidal activity compared 
to colistin, with a 99.9% CFU/mL reduction and no re-growth of colistin-resistant 
bacteria observed at concentrations of >16 mg/L for AA139 and SET-M33. This 
reinforces our earlier study on SET-M3326, which found that the antimicrobial activity 
of SET-M33 was similarly mildly diminished in colistin-resistant mutants of  
K. pneumoniae and Pseudomonas aeruginosa when compared to the decrease in antimicrobial  
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activity of colistin. Here we demonstrated that this is the case for a selection of clinically 
and genotypically diverse K. pneumoniae isolates for both AA139 and SET-M33. 
After 24 hours antibiotic exposure in the TKK assays, the isolates were tested for 
changes in susceptibility that could suggest adaptation to a resistant phenotype. 
Colistin-susceptible isolates became colistin-resistant after 24 hours exposure to low 
concentrations of colistin, up to a 64-fold increase in MIC. Conversely, changes in 
susceptibility of colistin-susceptible isolates towards AA139 or SET-M33 after 24 hours 
were only observed after exposure to the respective AMPs at their own MIC, but never 
exceeded a 4-fold increase in MIC. In isolates which were already colistin-resistant, a 
further decrease in susceptibility to colistin up to 4-fold decrease was observed after 
exposure to colistin. Conversely, susceptibility of colistin-resistant isolates to AA139 
remained unchanged except for a 4-fold increase in MIC after exposure to AA139 at its 
own MIC, and susceptibility to SET-M33 never decreased more than 2-fold after 
exposure to SET-M33. This finding matches our earlier study26 where we showed that 
colistin-resistance was easily selected in K. pneumoniae and P. aeruginosa isolates after  
24 hours exposure to colistin, while 24 hours exposure to SET-M33 did not lead to 
significant changes in susceptibility to SET-M33 in these isolates. Another study 
likewise suggested that SET-M33 has a lower propensity for resistance selection 
compared to colistin24.  
Finally, antimicrobial activity and susceptibility changes were also examined for an 
MCR-producing isolate in order to investigate a difference between a plasmid-mediated 
colistin-resistant strain and a chromosomal colistin-resistant strain. The bactericidal 
activity of AA139 and SET-M33 against this strain was similar compared to colistin-
susceptible isolates, and no significant changes in susceptibility were observed after  
24 hours exposure. This suggests that plasmid-mediated colistin-resistance does not 
confer cross-resistance towards AA139 or SET-M33, and that treatment with either of 
these AMPs will not readily select AMP resistant mutants.  
The findings of this study suggest that there is only limited cross-resistance between the 
two novel AMPs and colistin for clinical K. pneumoniae isolates, and that the two novel 
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 AMPs have a lower propensity to select for resistant mutants compared to colistin. 
Future studies will be needed to show that this is the same in other Gram-negative 
bacterial species. In spite of the shared cationic mechanism of action between these 
compounds12, cross-resistance may be limited due to differences between their 
additional mechanisms of antimicrobial activity, which studies have suggested for 
AA13919,22, SET-M3324,26,27,41, and colistin15. These different additional mechanisms of 
antimicrobial activity may also explain the apparent difference between the two novel 
AMPs and colistin in their propensity to select for resistant mutants. AA139 and  
SET-M33 may be of interest for future studies on the mechanisms of antimicrobial 
activity and resistance for AMPs.  
An interesting point for discussion with respect to AMPs is that the MICs values of 
AA139 and SET-M33 are substantially higher than the MIC values of colistin when 
compared in weight per volume, and that colistin showed bactericidal activity within 
the first 6 hours of exposure at lower concentrations than AA139 or SET-M33 when 
compared in weight per volume. However, it should be noted that the molecular 
weights of AA139 and SET-M33 are substantially higher compared to colistin, and 
when the MIC values are calculated based on their respective molarities, the MIC values 
for AA139 and SET-M33 are very similar to those of colistin23. Ultimately, the 
usefulness of any given antibiotic for the clinic depends on its therapeutic window of 
effect, and the MIC is only an indicator of the minimum effective dose. Other pre-
clinical investigations which provide further insight into the therapeutic window of 
effect have been performed for both of the novel AMPs.  
The in vivo efficacy of AA139 has been investigated in mice disease models of a 
peritonitis/bacteremia neutropenic Escherichia coli infection, a neutropenic thigh E. coli 
infection, as well as a urinary tract E. coli infection42-44. These studies demonstrated  
in vivo efficacy of AA139 against Gram-negative bacteria at similar concentrations as the 
effective concentrations found in the present study, with low toxicity and safety issues 
reported21. 
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SET-M33 demonstrated in vitro hemolytic activity26 and ex vivo cytotoxic activity38 only 
at concentrations well above the effective concentrations found in the current study. In 
vivo toxicity studies on SET-M33 in mice showed no to mild toxic signs of acute toxicity, 
depending on the route of administration, at the effective concentrations found in the 
present study24,38. The in vivo efficacy of SET-M33 has been tested in various mouse 
models of disease; lethal intraperitoneal infection models caused by E. coli or  
P. aerigunosa23, a lethal sepsis model caused by E. coli38, and three neutropenic models of 
sepsis, lung infection, and skin infection caused by P. aerigunosa24. Notably, when colistin 
was administered at similar concentrations in terms of weight per volume as SET-M33, 
it resulted in far more severe toxic side effects including death whereas no toxic side 
effects were reported for SET-M3324.  
 
Conclusions 
AA139 and SET-M33 are two novel AMPs currently in development for clinical 
application which showed consistent antimicrobial activity towards clinically and 
genotypically diverse K. pneumoniae isolates with differing antibiotic resistance profiles. 
Both AA139 and SET-M33 remained effective against colistin-resistant isolates, 
including an isolate carrying plasmid-mediated colistin resistance. Exposure of  
K. pneumoniae isolates to the two novel AMPs did not lead to significant change in 
susceptibility. These findings suggest that AA139 and SET-M33 are promising novel 
antibiotics for the treatment of multidrug-resistant K. pneumoniae infections, even when 
the bacteria have developed colistin resistance following previous treatment with 
colistin. An important conclusion is that in comparative studies with high molecular 
weight antibiotics and low molecular weight antibiotics, it may be more insightful to 
express antibiotic concentrations in terms of molarity rather than weight per volume. 
  
78
Chapter 44
145136 van der Weide BNW.indd   78 07-08-20   14:01
 Acknowledgements 
HiMLST analysis was performed at the Streeklaboratorium voor de Volksgezondheid 
Kennemerland, Haarlem, the Netherlands. Analysis of blood plasma was performed by 
the Clinical Farmacological and Toxicological Laboratory at the Erasmus University 
Medical Center, Rotterdam, The Netherlands.  
Funding 
This work was financially supported by the European Union’s Seventh Program for 
Research, Technological Development and Demonstration under grant agreement No. 
604434 PneumoNP. 
Competing interests 
This study was performed in collaboration with Adenium Biotech ApS and Setlance srl, 
who are respectively the patent holders of AA139 and SET-M33. 
 
References 
1. O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. The 
Review on Antimicrobial Resistance. 2014;20. 
2. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and 
Therapeutics. 2015;40(4):277. 
3. Bathoorn E, Tsioutis C, da Silva Voorham J, Scoulica E, Ioannidou E, Zhou K, et al. Emergence 
of pan-resistance in KPC-2 carbapenemase-producing Klebsiella pneumoniae in Crete, Greece: a close 
call. Journal of Antimicrobial Chemotherapy. 2016;71(5):1207-12. 
4. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management 
of multidrug-resistant gram-negative bacterial infections. Clinical Infectious Diseases. 
2005;40(9):1333-41. 
5. Nation RL, Li J. Colistin in the 21st century. Current Opinion in Infectious Diseases. 
2009;22(6):535. 
6. Wang R, Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, et al. The global distribution and spread 
of the mobilized colistin resistance gene mcr-1. Nature Communications. 2018;9(1):1179. 
7. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of plasmid-mediated 
colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and 
molecular biological study. The Lancet Infectious Diseases. 2016;16(2):161-8. 
8. Kluytmans J. Plasmid-encoded colistin resistance: mcr-one, two, three and counting. 
Eurosurveillance. 2017;22(31). 
9. Fox JL. Antimicrobial peptides stage a comeback. Nature Publishing Group; 2013. 
10. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective 
therapeutic strategies. Nature Biotechnology. 2006;24(12):1551. 
4
79
Antimicrobial activity of novel antimicrobial peptides AA139 and SET-M33
145136 van der Weide BNW.indd   79 07-08-20   14:01
11. Wang G, Li X, Wang Z. APD3: the antimicrobial peptide database as a tool for research and 
education. Nucleic Acids Research. 2015;44(D1):D1087-D93. 
12. Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial 
peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2006;1758(9):1529-39. 
13. Bechinger B, Gorr S-U. Antimicrobial peptides: Mechanisms of action and resistance. Journal 
of Dental Research. 2017;96(3):254-60. 
14. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in 
immune defense. Trends in Immunology. 2009;30(3):131-41. 
15. Trimble MJ, Mlynárčik P, Kolář M, Hancock RE. Polymyxin: alternative mechanisms of action 
and resistance. Cold Spring Harbor Perspectives in Medicine. 2016;6(10):a025288. 
16. Napier BA, Burd EM, Satola SW, Cagle SM, Ray SM, McGann P, et al. Clinical use of colistin 
induces cross-resistance to host antimicrobials in Acinetobacter baumannii. mBio. 2013;4(3):e00021-
13. 
17. Pränting M, Andersson DI. Mechanisms and physiological effects of protamine resistance in 
Salmonella enterica serovar Typhimurium LT2. Journal of Antimicrobial Chemotherapy. 
2010;65(5):876-87. 
18. Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM, Savage PB. Susceptibility of colistin-
resistant, Gram-negative bacteria to antimicrobial peptides and ceragenins. Antimicrobial Agents and 
Chemotherapy. 2017;61(8):e00292-17. 
19. Huang JX, Neve S, Elliot AG, Cain AK, Boinett CJ, Zuegg J, et al. Novel Arenicin-3 peptide 
antibiotics with broad-spectrum activity against MDR Gram-negative bacterial act via dual mode of 
actions. 54th International Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 
Infectious Diseases Society of America (IDSA) Joint Meeting: 
https://adeniumBiotech.com/publications/; 2014. 
20. Neve S, Lociuro S, Morrissey I, Hawser S, Nordkild P. The arenicin-3 derived clinical candidate 
AA139 shows potent activity against Gram-negative pathogens, Poster F-261.  54th ICAAC Meeting; 5-
9 September 2014; Washington, DC2014. 
21. Lociuro S. Oral presentation: Arenicin antimicrobial peptides (novel AMPs with a novel mode 
of action). 54th International Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 
Infectious Diseases Society of America (IDSA) Joint Meeting: 
https://adeniumBiotech.com/publications/; 2014. 
22. Cain AK, Boinett CJ, Barquist L, Neve S, Huang JX, Elliot AG, et al. Transposon directed insertion-
site sequencing (TraDIS) to elucidate the mode of action of the antimicrobial Arenicin-3 (Arn-3). 54th 
International Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases 
Society of America (IDSA) Joint Meeting: https://adeniumBiotech.com/publications/; 2014. 
23. Pini A, Falciani C, Mantengoli E, Bindi S, Brunetti J, Iozzi S, et al. A novel tetrabranched 
antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. 
The FASEB Journal. 2010;24(4):1015-22. 
24. Brunetti J, Falciani C, Roscia G, Pollini S, Bindi S, Scali S, et al. In vitro and in vivo efficacy, 
toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Scientific 
Reports. 2016;6:26077. 
25. Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, et al. Isomerization of an 
antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLOS 
ONE. 2012;7(10):e46259. 
26. van der Weide H, Brunetti J, Pini A, Bracci L, Ambrosini C, Lupetti P, et al. Investigations into 
the killing activity of an antimicrobial peptide active against extensively antibiotic-resistant K. 
pneumoniae and P. aeruginosa. Biochimica et Biophysica Acta (BBA)-Biomembranes. 
2017;1859(10):1796-804. 
27. Brunetti J, Roscia G, Lampronti I, Gambari R, Quercini L, Falciani C, et al. Immunomodulatory 
and anti-inflammatory activity in vitro and in vivo of a novel antimicrobial candidate. Journal of 
Biological Chemistry. 2016:jbc. M116. 750257. 
80
Chapter 44
145136 van der Weide BNW.indd   80 07-08-20   14:01
 28. Pollini S, Brunetti J, Sennati S, Rossolini GM, Bracci L, Pini A, et al. Synergistic activity profile of 
an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-
negative bacterial pathogens. Journal of Peptide Science. 2017;23(4):329-33. 
29. Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-
M extended-spectrum β-lactamases. Journal of Antimicrobial Chemotherapy. 2005;57(1):154-5. 
30. Mabilat C, Goussard S. PCR detection and identification of genes for extended-spectrum β-
lactamases.  Diagnostic Molecular Microbiology: Principles and Applications: American Society for 
Microbiology; 1993. p. 553-9. 
31. Nüesch-Inderbinen MT, Hächler H, Kayser FH. Detection of genes coding for extended-
spectrum SHV beta-lactamases in clinical isolates by a molecular genetic method, and comparison 
with the E test. European Journal of Clinical Microbiology & Infectious Diseases. 1996;15(5):398-402. 
32. Karisik E, Ellington MJ, Pike R, Warren RE, Livermore DM, Woodford N. Molecular 
characterization of plasmids encoding CTX-M-15 β-lactamases from Escherichia coli strains in the 
United Kingdom. Journal of Antimicrobial Chemotherapy. 2006;58(3):665-8. 
33. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G. Development of a set of multiplex PCR 
assays for the detection of genes encoding important β-lactamases in Enterobacteriaceae. Journal of 
Antimicrobial Chemotherapy. 2010;65(3):490-5. 
34. Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of 
carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and 
inhibitor-resistant TEM-30 β-lactamases in New York City. Clinical Infectious Diseases. 2004;39(1):55-
60. 
35. Islam MA, Talukdar PK, Hoque A, Huq M, Nabi A, Ahmed D, et al. Emergence of multidrug-
resistant NDM-1-producing Gram-negative bacteria in Bangladesh. European Journal of Clinical 
Microbiology & Infectious Diseases. 2012;31(10):2593-600. 
36. Souverein D, Boers SA, Veenendaal D, Euser SM, Kluytmans J, Den Boer JW. Polyclonal Spread 
and Outbreaks with ESBL Positive Gentamicin Resistant Klebsiella spp. in the Region Kennemerland, 
The Netherlands. PLOS ONE. 2014;9(6):e101212. 
37. Gruteke P, Goessens W, Van Gils J, Peerbooms P, Lemmens-den Toom N, van Santen-
Verheuvel M, et al. Patterns of resistance associated with integrons, the extended-spectrum β-
lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial 
outbreak. Journal of Clinical Microbiology. 2003;41(3):1161-6. 
38. Pini A, Lozzi L, Bernini A, Brunetti J, Falciani C, Scali S, et al. Efficacy and toxicity of the 
antimicrobial peptide M33 produced with different counter-ions. Amino Acids. 2012;43(1):467-73. 
39. The European Committee on Antimicrobial Susceptibility. Breakpoint tables for interpretation 
of MICs and zone diameters, Version 4.0. EUCAST; 2014. 
40. de Steenwinkel JEM, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, et al. 
Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic 
activity of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 2010;65(12):2582-9. 
41. Pini A, Giuliani A, Falciani C, Fabbrini M, Pileri S, Lelli B, et al. Characterization of the branched 
antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. Journal of Peptide 
Science. 2007;13(6):393-9. 
42. Lociuro S, Neve S, Lundberg CV, Andersen JM, Nordkild P. Clinical candidate AA139 - Efficacy 
in two neutropenic bacteraemia/peritonitis models caused by E. coli strains with different MIC values. 
54th International Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious 
Diseases Society of America (IDSA) Joint Meeting: https://adeniumBiotech.com/publications/; 2014. 
43. Lociuro S, Neve S, Lundberg CV, Andersen JM, Nordkild P. Clinical candidate AA139 - Efficacy 
in a neutropenic thigh model caused by E. coli AID#172. 54th International Conference of 
Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) 
Joint Meeting: https://adeniumBiotech.com/publications/; 2014. 
 
 
4
81
Antimicrobial activity of novel antimicrobial peptides AA139 and SET-M33
145136 van der Weide BNW.indd   81 07-08-20   14:01
44. Neve S, Lociuro S, Lundberg CV, Nordkild P. Clinical candidate AA139 - Efficacy against ESBL 
producing E. coli in the murine urinary tract infection model. 54th International Conference of 
Antimicrobial Agents and Chemotherapy (ICAAC) and Infectious Diseases Society of America (IDSA) 
Joint Meeting: https://adeniumBiotech.com/publications/; 2014. 
82
Chapter 44
145136 van der Weide BNW.indd   82 07-08-20   14:01
 Supplementary Table S1. Origin of collection of 50 K. pneumoniae isolates 
Antibiotic 
resistance 
profile 
Isolate name Year of isolation 
Country of 
origin Specimen type 
W
il
d
ty
p
e 
B-DYK 12747 2012 The Netherlands Blood 
B-DYK 10317 2012 The Netherlands Blood 
B-DYK 12568 2012 The Netherlands Blood 
B-DYK 16504 2013 The Netherlands Blood 
B-DYK 16341 2013 The Netherlands Blood 
R-DYK 7291 2013 The Netherlands Rectum 
B-DYK 12374 2012 The Netherlands Catheter 
R-DYK 4671 2011 The Netherlands Mouth 
R-DYK 4967 2012 The Netherlands Throat 
B-DYK 10031 2012 The Netherlands Tracheal aspirate 
ES
B
L 
B-DYK 8315 2012 The Netherlands Blood 
ESBL 1218 2013 The Netherlands Blood 
ESBL 1644 2013 The Netherlands Blood 
ESBL 1457 2013 The Netherlands Blood 
ESBL 645 2012 The Netherlands Blood 
ESBL 39 2011 The Netherlands Urine 
ESBL 399 2011 The Netherlands Rectum 
ESBL 175 2011 The Netherlands Perineum 
R-DYK 11347 2015 The Netherlands Rectum 
ESBL 2360 2014 The Netherlands Throat 
K
P
C
 
B-DYK 12459 2012 The Netherlands Blood 
R-DYK 6863 2013 The Netherlands Throat 
R-DYK 6792 2013 The Netherlands Perineum 
R-DYK 6296 2013 The Netherlands Urine 
B-DYK 14517 2013 The Netherlands Rectum 
ESBL 1059 2013 The Netherlands Rectum 
6196 n/a Greece n/a 
R-DYK 3427 2010 The Netherlands Urine 
KPC 3 n/a The Netherlands n/a 
KPC 11 n/a The Netherlands n/a 
O
X
A
-4
8
-l
ik
e 
R-DYK 7328 2013 The Netherlands Rectum 
R-DYK 4441 2011 The Netherlands Rectum 
R-DYK 6152 2012 The Netherlands Throat 
R-DYK 6373 2013 The Netherlands Urine 
R-DYK 4861 2012 The Netherlands Perineum 
R-DYK 7926 2013 The Netherlands Rectum 
B-DYK 6635 2011 The Netherlands Rectum 
B-DYK 5797 2011 The Netherlands Urine 
B-DYK 7193 2011 The Netherlands Rectum 
R-DYK 4208 2011 The Netherlands Rectum 
N
D
M
 
B-DYK 9557 2012 The Netherlands Blood 
ESBL 635 2012 The Netherlands Rectum 
B-DYK 12649 2012 The Netherlands Wound 
R-DYK 5976 2012 The Netherlands Rectum 
BKp002 2010 Bangladesh Urine 
BKp004 2008 Bangladesh Urine 
BKp005 2008 Bangladesh Urine 
BKp006 2008 Bangladesh Tracheal aspirate 
BKp008 2010 Bangladesh Tracheal aspirate 
BKp009 2010 Bangladesh Urine 
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Supplementary Figure S1. PFGE data of 49 isolates from the collection of 50 K. pneumoniae 
isolates. One isolate was untypable and was not included. A phylogenetic tree was constructed 
based on the relatedness of the isolates according to PFGE results. Clusters were based on 
>95% similarity. 
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 Supplementary Table S2. PCR data of the collection of 50 K. pneumoniae isolates 
Antibiotic 
resistance 
profile 
Wildtype ESBL KPC OXA-48-like NDM 
Number of 
isolates 
10 10 10 10 10 
CTX-M 
1 nd 8 1 6 10 
2 nd nd nd nd nd 
8 nd nd nd nd nd 
9 nd 2 1 nd nd 
25 nd nd nd nd nd 
TEM 1 7 10 7 9 
SHV 10 10 10 10 10 
OXA 
1 nd 4 1 6 8 
48 nd nd nd 10 nd 
KPC nd nd 10 nd nd 
NDM-1 nd nd nd nd 10 
MCR-1 nd 1 nd nd nd 
The distribution of plasmid-mediated resistance genes within the collection of 50 K. 
pneumoniae isolates based on their antibiotic resistance profile as determined using PCR 
assays. nd, not detected.  
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Supplementary Table S3. VITEK® 2 MIC data of the collection of 50 K. pneumoniae isolates 
Antibiotic resistance profile Wildtype ESBL KPC OXA-48-like NDM 
Number of isolates 10 10 10 10 10 
Ampicillin 16 ≥32 ≥32 ≥32 ≥32 
Amoxicillin/Clavulanic Acid ≤2 12 ≥32 ≥32 ≥32 
Piperacillin/Tazobactam ≤4 6 ≥128 ≥128 ≥128 
Cefuroxime ≤1 ≥64 ≥64 ≥64 ≥64 
Cefuroxime Axetil ≤1 ≥64 ≥64 ≥64 ≥64 
Cefoxitin ≤4 ≤4 ≥64 8 ≥64 
Cefotaxime ≤1 ≥64 20 ≥64 ≥64 
Ceftazidime ≤1 16 ≥64 ≥64 ≥64 
Cefepime ≤1 2 48 16 ≥64 
Imipenem ≤0.25 ≤0.25 ≥16 2 ≥16 
Meropenem ≤0.25 ≤0.25 ≥16 1 ≥16 
Gentamicin ≤1 ≥16 4 ≥16 ≥16 
Tobramycin ≤1 8 ≥16 ≥16 ≥16 
Ciprofloxacin ≤0.25 0.5 ≥4 ≥4 ≥4 
Norfloxacin ≤0.5 2 ≥16 ≥16 ≥16 
Trimethoprim ≤0.5 ≥16 ≥16 ≥16 ≥16 
Trimethoprim/sulfamethoxazole ≤1 ≥16 ≥16 ≥16 ≥16 
MICs (mg/L) were determined using the automated VITEK® 2 antimicrobial identification 
system for the collection of 50 K. pneumoniae isolates, shown are the median values for each 
antibiotic resistance profile. The collection was grouped based on their antibiotic resistance 
profile. Interpretation of antimicrobial susceptibility was defined by the VITEK® antimicrobial 
identification system as susceptible, intermediate (italic), or resistant (bold) according to 
EUCAST guidelines. Trimethoprim/sulfamethoxazole was expressed as the trimethoprim 
concentration.   
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Abstract 
SET-M33 is a multimeric antimicrobial peptide active against Gram-negative bacteria in vitro 
and in vivo. Insights into its killing mechanism could elucidate correlations with selectivity. SET-
M33 showed concentration-dependent bactericidal activity against colistin-susceptible and 
resistant isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa. Scanning and 
transmission microscopy studies showed that SET-M33 generated cell blisters, blebs, 
membrane stacks and deep craters in K. pneumoniae and P. aeruginosa cells. Nuclear magnetic 
resonance (NMR) analysis and circular dichroism (CD) spectra in the presence of sodium 
dodecyl sulfate (SDS) micelles showed a transition from an unstructured state to a stable 
α-helix, driving the peptide to arrange itself on the surface of micelles. SET-M33 kills Gram-
negative bacteria after an initial interaction with bacterial lipopolysaccharide. The molecule 
becomes then embedded in the outer membrane surface, thereby impairing cell function. This 
activity of SET-M33, in contrast to other similar antimicrobial peptides such as colistin, does 
not generate resistant mutants after 24 hours of exposure, non-specific interactions or 
toxicity against eukaryotic cell membranes, suggesting that SET-M33 is a promising new option 
for the treatment of Gram-negative antibiotic-resistant infections. 
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Introduction 
Extensive use of broad-spectrum antibiotics has led to the development and spread of 
extensively antibiotic-resistant strains of bacteria, making antimicrobial resistance a 
global problem. Antibiotic-resistant bacteria kill 25,000 people in the European Union 
(EU) every year. Infections such as urinary tract infections1, pneumonia2 and 
septicemia3 are increasingly associated with multidrug-resistant Gram-negative bacteria 
in all regions of the world4. These antibiotic-resistant bacteria generally cause infections 
associated with increased risk of poor clinical outcome and mortality compared to non-
resistant strains of the same bacteria5. The World Health Organization (WHO) warns 
that antimicrobial resistance is an increasingly serious threat to global public health and 
calls for action across all government sectors and society6 to avoid a dreaded ‘post-
antibiotic’ era. 
A recent rekindling of antibiotic research has shown that the antimicrobial  
peptide (AMP) class of antibiotics is particularly promising for use against  
infections caused by multidrug-resistant microorganisms7-9. AMPs are an  
important component of the natural defenses of most living organisms, and  
more than 2500 AMPs have been registered in the Antimicrobial Peptide  
Database (https://aps.unmc.edu/AP/main.php)10. However, despite their desirable 
characteristics, antimicrobial peptides have had limited pharmaceutical development 
due to their toxicity, instability and manufacturing costs, and therefore only a few AMPs 
have actually been approved for clinical use11,12. 
The most common mechanism of antimicrobial killing by antimicrobial peptides is 
disruption of the cytoplasmic membrane, for example by pore formation, which is 
rather non-specific but highly efficient13-15. Alternative mechanisms of action include 
peptide translocation into the cytoplasm where the antibiotic interferes with bacterial 
metabolic processes, such as protein synthesis or deoxyribonucleic acid (DNA) 
replication, while other peptides are known to interact directly with specific membrane 
components16-18. In particular, cationic AMPs have been demonstrated to induce 
anionic lipid clustering which appears to arrest bacterial growth or trigger cell death19,20. 
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 SET-M33 is an antimicrobial peptide that 
has been extensively studied in recent 
years21-25. It is a cationic non-natural 
peptide built in a branched form (Figure 
1) that makes it more resistant to 
degradation in biological fluids26.  
SET-M33 has shown efficacy against a 
number of Gram-negative multidrug- and 
extensively drug-resistant clinical 
isolates21,24. It has also shown acceptable toxicity in human cells and in mice22, as well 
as anti-inflammatory activity23. Nevertheless, its mechanism of action has not yet been 
researched in depth. In this study we used different techniques to study the mechanism 
of action of SET-M33 against two Gram-negative bacterial species, Klebsiella pneumoniae 
and Pseudomonas aeruginosa: 1) bacterial killing kinetics over time to see concentration-
dependency and onset of resistance; 2) electron microscopy imaging of treated bacteria 
to visualize membrane disturbance; 3) hemolytic activity to assess eukaryotic cell 
toxicity and 4) nuclear magnetic resonance (NMR) and circular dichroism (CD) to study 
the structure of the peptides in the presence of micelles and their ability to stabilize in 
a facial amphiphilic helix. 
 
Materials and methods 
Peptide synthesis 
All peptides were prepared by solid-phase synthesis through standard Fmoc chemistry 
using a Syro multiple peptide synthesizer (MultiSynTech, Witten, Germany). Side chain 
protecting groups were 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl for R,  
t-butoxycarbonyl for K, and t-butyl for S (Iris Biotech GmbH, Marktredwitz, 
Germany). The final products were cleaved from the solid support, de-protected by 
treatment with trifluoroacetic acid (TFA) containing triisopropylsilane and water 
(95/2.5/2.5), and precipitated with diethyl ether. Final peptide purity and identity was 
NH
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 KKIRVRLSA
KKIRVRLSA
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Figure 1. Structure of SET-M33. 
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confirmed by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry 
(MS) on a Bruker Daltonics Ultraflex III MALDI time-of-flight (MALDI-TOF) mass 
spectrometer and by reverse-phase high-performance liquid chromatography  
(RP-HPLC) on a Phenomenex Jupiter® C18 analytical column (300 Å, 250 × 4.6 mm). 
Q-33 (linear peptide, QKKIRVRLSA) was produced on TentaGel® S RAM resin (Iris 
Biotech GmbH, Marktredwitz, Germany). The crude peptide, released as amide, was 
purified by reverse-phase chromatography on a Phenomenex Jupiter® C18 column  
(300 Å, 250 x 10 mm), in a linear gradient, using 0.1% TFA/water as eluent A and 
acetonitrile as eluent B (from 99% to 50% of eluent A in 30 minutes). The compound 
QKKIRVRLSA–NH2 was characterized: MALDI MS: 1198.97 [M+H]+; RP-HPLC:  
tR = 19.62 minutes, purity >99%. 
SET-M33 (tetrabranched peptide, (KKIRVRLSA)4K2KβA) was synthesized on a 
Fmoc4-Lys2-Lys-β-Ala Wang resin (Iris Biotech GmbH, Marktredwitz, Germany). The 
crude peptide, released as carboxylic acid, was purified by reverse-phase 
chromatography on a Phenomenex Jupiter® C18 analytical column (300 Å, 250 ×  
10 mm) in a linear gradient, using 0.1% TFA/water as eluent A and acetonitrile as eluent 
B (from 82% to 75% of eluent A in 60 minutes). The purified peptide was obtained as 
a trifluoroacetate salt and exchanged to acetate using a quaternary ammonium resin 
(AG1–X8, 100–200 mesh, 1.2 mEq/mL capacity). The resin-to-peptide ratio was 
2000:1, resin and peptide were stirred for 1 hour, the resin was then filtered off, washed 
extensively, and the peptide was recovered and freeze-dried. The compound 
(KKIRVRLSA)4K2KβA–OH was characterized: MALDI MS: 4682.48 [M+H]+;  
RP-HPLC: tR = 21.10 minutes, purity >99%. SET-M33 solubility; water, ≥20 mg/mL; 
saline, ≥20 mg/mL; phosphate-buffered saline (PBS), ≥15 mg/mL. 
Selection of colistin-resistant mutants of K. pneumoniae R-DYK 4861 and 
P. aeruginosa B-162  
K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were both extensively antibiotic-
resistant clinical isolates and colistin-susceptible. Colistin-resistant mutants of both 
strains were obtained by step-wise serial passages of bacterial strains27 in BBL™ Mueller 
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 Hinton II (MH-II) broth (Becton, Dickinson Benelux NV, Erembodegem, Belgium) 
containing colistin concentrations in the range 2–64 mg/L (colistin sulfate, Sigma-
Aldrich Chemie BV, Zwijndrecht, the Netherlands). This involved sub-culturing  
100 µL of overnight culture of the bacteria (grown in MH-II broth) into MH-II broth 
containing 2 mg/L colistin and incubating overnight at 35ºC. In subsequent steps  
100 µL of overnight culture was sub-cultured into MH-II broth containing two-fold 
increases in the concentration of colistin until the highest colistin concentration of  
64 mg/L was achieved. Finally, 100 µL volumes were sub-cultured onto solid MH-II 
medium (Becton, Dickinson Benelux NV, Erembodegem, Belgium). Colistin-resistant 
colonies were then characterized phenotypically using VITEK® 2. 
Phenotypic characterization of bacterial isolates 
Phenotypic characterization of K. pneumoniae B-DYK 4861 and P. aeruginosa B-162 
isolates and their colistin-resistant mutants was performed by determining their 
susceptibility for a panel of 18 different antibiotics from the main classes of antibiotics 
using the VITEK® 2 antimicrobial identification system (BioMérieux Benelux BV, 
Zaltbommel, The Netherlands) and AST-N140 cards (Vitek AMS). Interpretation of 
antimicrobial susceptibility was based on European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) 2014 guidelines (Supplementary Table S1)28. 
Antimicrobial susceptibility of bacterial isolates: minimum inhibitory 
concentration (MIC) 
Antimicrobial susceptibility was assessed by determining the MIC of SET-M33 and 
colistin using the broth microdilution technique according to 2014 EUCAST guidelines. 
The MIC assay measures visible inhibition of bacterial growth after 24 hours exposure 
of bacteria to antibiotic in MH-II broth. The two-fold antibiotic concentration range 
used for SET-M33 and colistin was 0.063–64 mg/L. 
Concentration- and time-dependent bactericidal activity of SET-M33 and 
colistin: time-kill kinetics (TKK) 
The concentration- and time-dependent killing capacity of SET-M33 was determined 
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using TKK assays, as previously described29. Briefly, stationary-phase MH-II broth 
cultures of K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 were diluted in 25 mL 
MH-II broth until a density of approximately 7×105 colony-forming units (CFU)/mL 
was achieved. Bacterial cultures were exposed to antimicrobial antibiotics at 2-fold 
increasing concentrations for 24 hours at 37 °C under shaking conditions at  
96 rpm at 37 ºC. Next, 1 mL samples were taken at 0, 1, 2, 4, 6, and 24 hours of antibiotic 
exposure and centrifuged at 12500 × g for 5 minutes to pellet the cells, which were then 
resuspended in sterile PBS. Agar plates were incubated for 24 hours (K. pneumoniae) or 
48 hours (P. aeruginosa) at 37 °C in order to determine the number of CFU. The lower 
limit of quantification in this assay was 5 CFU/mL (log 0.7). For colistin-susceptible 
bacterial isolates, the two-fold antibiotic concentration range was 0.125–64 mg/L for 
SET-M33 and colistin alike. For colistin-resistant isolates, the two-fold antibiotic 
concentration range was 0.125–64 mg/L for SET-M33 and 1–512 mg/L for colistin. 
Flasks showing re-growth of bacteria after 24 hours antibiotic exposure were examined 
for changes in antibiotic susceptibility using the antibiotic MIC assay described above, 
but with an antibiotic concentration range of 0.5–512 mg/L for the colistin-resistant 
isolates. 
Sample preparation for electron microscopy 
P. aeruginosa PAO1 and K. pneumoniae American Type Culture Collection (ATCC) 13833 
cells in logarithmic phase were resuspended at 2×108 CFU/mL in PBS and incubated 
with 1.5 µM SET-M33 at room temperature for 15, 30, and 60 minutes. The mixture 
was then centrifuged for 5 minutes at 10,000 rpm.  
Scanning electron microscopy (SEM) 
Centrifuged bacteria were resuspended in 500 µL PBS and a drop of liquid cell 
suspension was placed on untreated glass coverslip for five minutes. The coverslip was 
then fixed for immersion in 2.5% glutaraldehyde solution in phosphate buffer 0.1 M  
pH 7.2 (PB) for 2 hours at 4 °C, washed in PB, post-fixed in 1% OsO4 in PB for  
30 minutes at 4 °C, dehydrated in an ascending alcohol series, and dried in a Balzers 
CPD 030 CO2 critical point dryer. The coverslip was then mounted on an aluminum 
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 stub, coated with 20 nm gold in a Balzers MED010 sputtering device, and observed in 
a Philips XL20 scanning electron microscope with an electron accelerating voltage of 
20 kV. 
Transmission electron microscopy (TEM) 
Centrifuged bacteria were fixed in 2.5% glutaraldehyde solution in PB for 2 hours at  
4 °C, washed in PB, post-fixed in 1% OsO4 in PB for 30 minutes at 4 °C, dehydrated 
in an ascending alcohol series, incubated twice in propylene oxide and finally infiltrated 
and embedded in epon/araldite resin that was polymerized at 60 °C for 48 hours. 
Ultrathin sections (60 nm thick) were cut from samples on a Reichert-Jung Ultracut E 
ultramicrotome, mounted on 200-mesh copper grids, stained with uranyl acetate and 
lead citrate and observed in a FEI Technai™ G2 SPIRIT transmission electron 
microscope using an electron accelerating voltage of 100 kV under standard operating 
conditions.  
Nuclear magnetic resonance (NMR) 
All NMR samples were prepared by dissolving lyophilized peptides in 500 µl H2O/D2O 
(95:5) to a final concentration of 1.0 mM, with the exception of SET-M33, which was 
dissolved to a final concentration of 0.25 mM. Since the resonance of N-terminus amide 
would be missed in aqueous media due to chemical exchange, the peptide sequence of 
the Q-33 peptide, bearing a leading glutamine [33-34], was used instead, allowing us to 
gain structural information on the Lys1 residue. Samples with micelles were prepared 
using 100 mM fully deuterated sodium dodecyl sulfate (SDS-d25; Cambridge Isotopes). 
Paramagnetic spectra were recorded with 2.5 mM gadolinium-(III)-
diethylenetriaminepentaacetic acid-bisamide (Gd(III)DTPA-BMA). All spectra were 
acquired on a Bruker DRX Avance™ spectrometer operating at 14.1 Tesla at a 
temperature of 298 K. Two-dimensional spectra were recorded by accumulating  
32 free induction decays (FIDs) for 512 experiments, digitalizing over 2048 points. 
Spectral width was set at 6000 Hz and repetition delay at 3 seconds. The mixing time 
for total correlation spectroscopy (TOCSY) and nuclear Overhauser effect (NOE) 
spectroscopy (NOESY) spectra was set at 45/75 milliseconds and 100/200/300 
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milliseconds, respectively. All spectra were processed to a final size of 2048 by 1024 
points. Peak assignment and integration were carried out with Sparky 3 software30 while 
calibration of NOE peak volumes, distance calculation and restrained torsion angle 
dynamics for structure calculation were performed using Dyana software31. 
Circular dichroism (CD) 
CD spectra were recorded at 25 °C with a Jasco 815 spectropolarimeter using quartz 
cells having a path length of 0.1 cm. SET-M33 (100 µM) or Q-33 (100 µM) were 
dissolved in pure water or 30 mM sodium dodecyl sulfate (SDS). The results were 
processed with the application Spectra Manager II™ Suite. 
Hemolytic activity 
The ability of SET-M33 peptide to induce hemolysis of human red blood cells was 
assessed. Whole blood in ethylenediaminetetraacetic acid (EDTA)-coated tubes was 
centrifuged at 1100 × g for 10 minutes. Red blood cells diluted 1:100 in PBS were 
incubated for 24 hours at 37 °C in PBS with two-fold serial dilution of all peptides from 
4 mg/L to 1.8 g/L. The absorbance of the supernatants was determined in a 96-well 
plate at 490 nm using a microplate reader. Data for 100% hemolysis were obtained by 
adding 0.1% Triton X-100 in water. The negative control was PBS. The hemolysis rate 
of each peptide was calculated with the following equation:  
Hemolysis (%) = Apeptide-APBSAtriton-APBS  × 100%  ;  where A = absorbance. 
Fast protein liquid chromatography (FPLC)-gel filtration 
Lipopolysaccharide (LPS) from P. aeruginosa (ATCC 27316, Sigma Aldrich) and SET-
M33 was gel-filtered on a Superdex® 75 10/300 GL FPLC column using an ÄKTA 
purifier (GE Healthcare) in PBS pH 7.4. 100 µL 2 mg/mL SET-M33 or 13 mg/mL 
LPS or 13 mg/mL LPS + 2 mg/mL SET-M33 was injected on a Superdex® 75 10/300 
GL FPLC column with a flow rate of 0.75 mL/min and absorbance was measured at 
220 and 260 nm. 
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 Results and discussion 
The K. pneumoniae and P. aeruginosa isolates used in the following experiments were 
resistant to a wide range of β-lactam antibiotics (penicillins, cephalosporins and 
carbapenems) including the 4th generation cephalosporin cefepime, aminoglycosides 
(gentamycin and tobramycin) and fluoroquinolones (ciprofloxacin and norfloxacin). 
Interpretation of antimicrobial susceptibility was based on EUCAST 2014 guidelines28. 
Susceptibility of bacterial isolates to SET-M33 and colistin: minimum 
inhibitory concentration (MIC)  
The susceptibility of the colistin-susceptible K. pneumoniae B-DYK 4861 and P. aeruginosa 
B-162 isolates and their colistin-resistant mutants to SET-M33 and colistin in terms of 
MIC are shown in Table 1. Colistin resistance did not affect SET-M33 susceptibility in 
these two strains, confirming our previous data on seven different colistin-resistant  
K. pneumoniae strains21. SET-M33 showed a MIC of 8 mg/L for K. pneumoniae ATCC 
13833 and P. aeruginosa PAO1. 
 
 
Table 1. MICs of SET-M33 and colistin for bacterial isolates in triplicate 
Bacterial isolate 
Colistin-
susceptible  
K. pneumoniae  
R-DYK 4861 
Colistin-
resistant  
K. pneumoniae  
R-DYK 4861 
Colistin-
susceptible  
P. aeruginosa 
B-162 
Colistin-
resistant  
P. aeruginosa 
B-162 
SET-M33 
 
mg/L 
 
16 
16 – 16 
16 
16 – 32 
16 
8 – 16 
16 
8 – 16 
 
μM 
 
2.7 
2.7 – 2.7 
2.7 
2.7 – 5.5 
2.7 
1.4 – 2.7 
2.7 
1.4 – 2.7 
Colistin 
 
mg/L 
 
0.50 
0.25 – 0.50 
>512 
>512 – >512 
2 
2 – 2 
512 
128 – 512 
 
μM 
 
0.22 
0.11 – 0.22 
>222 
>222 – >222 
0.87 
0.87 – 0.87 
222 
55 – 222 
Shown are the median values and range. MIC values for colistin are interpreted as susceptible 
or resistant (bold) according to EUCAST guidelines. Interpretation has not been performed for 
SET-M33. 
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SET-M33 and colistin activity against colistin-susceptible and colistin-
resistant K. pneumoniae B-DYK 4861 and P. aeruginosa B-162: time-kill 
kinetics (TKK) 
The major killing effect of an antibiotic against an organism depends on the exposure 
time or concentration of the drug at the active target site. In the present study we 
investigated extensively drug-resistant K. pneumoniae and P. aeruginosa populations, taking 
the effects of exposure time and concentration into account.  
Colistin-susceptible and colistin-resistant K. pneumoniae isolates were killed by ≥99.9% 
after 2 hours of exposure to ≥4 mg/L and ≥8 mg/L SET-M33, respectively (Figure 2A 
and 2B). This was followed by bacterial re-growth up to the level of non-exposed 
bacteria after 24 hours exposure to ≤4 mg/L and ≤16 mg/L, respectively. Colistin killed 
≥99.9% of the colistin-susceptible K. pneumoniae isolate after 2 hours of exposure to  
≥0.5 mg/L (Figure 2C) and bacterial re-growth after 24 hours exposure was observed 
up to ≤32 mg/L. In the colistin-resistant isolate, colistin concentration-dependent 
killing was observed in the first hour of exposure but ≥99.9% killing was not achieved 
after 2 hours of exposure (Figure 2D). 
For P. aeruginosa, ≥99.9% killing was achieved in colistin-susceptible and colistin-
resistant isolates after 2 hours of exposure to ≥8 mg/L SET-M33 (Figure 2E and 2F). 
Colistin killed ≥99.9% of bacteria in the colistin-susceptible P. aeruginosa isolate after  
2 hours of exposure to a concentration ≥1 mg/L (Figure 2G). In the colistin-resistant  
P. aeruginosa isolate, colistin concentration-dependent killing was observed in the first  
2 hours of exposure, followed by bacterial re-growth up to the level of non-exposed 
bacteria after 24 hours, at all the colistin concentrations tested (Figure 2H).  
We also showed that exposure to SET-M33 sterilized colistin-susceptible K. pneumoniae 
and P. aeruginosa populations already at one-fold (16 mg/L) (Figure 2A) and four-fold 
(64 mg/L) (Figure 2E) the MICs, respectively. In contrast, after exposure to colistin, 
sterilization only occurred at the extremely high concentration of 64 mg/L (Figure 2C 
and 2G), which is 128-fold and 32-fold the MICs of colistin-susceptible K. pneumoniae 
and P. aeruginosa, respectively. Colistin-resistant K. pneumoniae and P. aeruginosa were 
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Figure 2. Concentration- and time-dependent bactericidal activity of SET-M33 and colistin 
against isolates of K. pneumoniae R-DYK 4861 (A-D) and P. aeruginosa B-162 (E-H). Data are 
medians and range of 3 experiments. 
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sterilized with 64 mg/L SET-M33 (Figure 2B and 2F) in both cases (four-fold the MIC) 
but never with colistin (Figure 2D and 2H). 
SET-M33 and colistin showed concentration-dependent bactericidal activity against 
colistin-susceptible and colistin-resistant isolates of K. pneumoniae and P. aeruginosa. This 
result is similar to the action of different widely used antibiotics e.g. aminoglycosides 
and fluoroquinolones, as well as other AMPs32. SET-M33 retains activity against both 
colistin-susceptible and colistin-resistant bacteria. This result indicates that SET-M33 is 
impervious to the mechanisms associated with colistin resistance.  
Selection of resistance 
Selection of resistance was assessed in the same experiments: when re-growth was 
observed after 24 hours of exposure to antibiotic, bacterial susceptibilities were 
determined as MIC. Re-growth of colistin-susceptible strains of K. pneumoniae and  
P. aeruginosa after 24 hours of exposure to SET-M33 was never associated with selection 
of SET-M33 resistance (Table 2): in fact, MIC values did not increase more than  
0.5-2 fold, whereas re-growth of K. pneumoniae after 24 hours of colistin exposure was 
associated with decreased susceptibility and a manifold increase in MIC (Table 2). 
Colistin was more effective against P. aeruginosa, although bacteria regrowing at 1 mg/L 
colistin showed a 6-fold increase in MIC.  
Similar results were obtained with the colistin-resistant strains, although re-growth of 
colistin-resistant K. pneumoniae showed slightly lower susceptibility to SET-M33 with a 
4-fold increase in MIC (Supplementary Table S2). 
Gram-negative bacteria can reduce their susceptibility to AMPs by reducing their net 
negative surface charges, modifying capsule polysaccharides, or reducing outer 
membrane fluidity33. In contrast to colistin, resistance to SET-M33 does not readily 
develop during 24 hours of continuous exposure. This finding provides evidence that 
some of the resistance mechanisms that affect colistin do not affect SET-M33 to the 
same extent. For example, the mutations that lead to colistin resistance may not have 
the same effect on the activity of SET-M33, or alternatively, exposure to SET-M33 may 
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 Table 2. Change in K. pneumoniae R-DYK 4861 and P. aeruginosa B-162 susceptibility to  
SET-M33 and colistin after 24 hours exposure to antibiotic as determined by MIC assay 
Antibiotic 
concentration 
(mg/L) 
SET-M33 (mg/L) Colistin (mg/L) 
Colistin-
susceptible  
K. pneumoniae 
Colistin-
susceptible  
P. aeruginosa 
Colistin-
susceptible  
K. pneumoniae 
Colistin-
susceptible  
P. aeruginosa 
control 16 16 0.5 2 
0.125 16 16 >64 2 
0.25 16 16 >64 2 
0.5 16 16 >64 4 
1 16 16 >64  121 
2 16 16 >64 nd 
4 32 16 >64 nd 
8 nd 16  641 nd 
16 nd  121  >642 nd 
32 nd nd  >641 nd 
64 nd nd nd nd 
Colistin-susceptible bacterial cultures were exposed to two-fold increasing concentrations of 
SET-M33 or colistin for 24 hours at 37 °C under shaking conditions. When bacteria re-grew 
after 24 hours exposure to antibiotic, their MIC susceptibilities (performed in triplicate) were 
also determined and the median value reported. nd, not determined (no regrowth in the original 
TKK experiment); 1, one out of three samples did not show bacterial re-growth; 2, two out of 
three samples did not show bacterial re-growth.  
 
not elicit the type of resistance mutations that are selected or induced by colistin. Ways 
of avoiding resistance will be investigated in further studies. Importantly, the fact that 
resistance to SET-M33 does not appear within the 24 hours exposure period to the 
antibiotic provides evidence that the use of SET-M33 in the clinic may have advantages 
over the use of colistin. For example, colistin is currently used as an antibiotic of last 
resort for multidrug-resistant bacteria34,35, but besides its toxic side effects, it is also 
becoming dangerously more often ineffective due to increasing number of resistant 
strains36-38. 
Electron microscopy 
The effect of SET-M33 treatment at MIC (8 mg/L SET-M33) for 15, 30 and 60 minutes 
on bacterial cell morphology was studied by SEM and TEM. SEM images (Figure 3) 
5
101
Investigations into the killing activity of antimicrobial peptide SET-M33
145136 van der Weide BNW.indd   101 07-08-20   14:01
showed that after 30 minutes of SET-M33 treatment, the surfaces of K. pneumoniae 
ATCC 13833 and P. aeruginosa PAO1 cells lost their smoothness and developed 
superficial blisters. After 60 minutes of SET-M33 treatment, bacterial cells appeared 
larger than control cells and many were empty and showed large holes, mainly at the 
poles. 
TEM images (Figure 4) showed significant signs of alteration in most bacterial cells 
after 30 minutes of SET-M33 treatment: P. aeruginosa and K. pneumoniae cells appeared 
turgid and filamentous material appears on the external side of the outer membrane. In 
the first 30 minutes after incubation with SET-M33, only a few K. pneumoniae and  
P. aeruginosa bacterial cells (rare in the micrograph field) showed cell damage. 
 
 
Figure 3. SEM micrographs of K. pneumoniae ATCC 13833 and P. aeruginosa PAO1. SEM 
micrographs of A) untreated K. pneumoniae; B) K. pneumoniae after 30 minutes incubation 
with SET-M33 at MIC); C) K. pneumoniae after 60 minutes incubation with SET-M33 at MIC; 
D) untreated P. aeruginosa; E) P. aeruginosa after 30 minutes incubation with SET-M33 at MIC; 
F) P. aeruginosa after 60 minutes incubation with SET-M33 at MIC. Scale bar 2 µm. 
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Figure 4. TEM micrographs of K. pneumoniae ATCC 13833 and P. aeruginosa PAO1. TEM 
micrographs of A) untreated K. pneumoniae; B) K. pneumoniae after 60 minutes incubation 
with SET-M33 at MIC; C) untreated P. aeruginosa; D) P. aeruginosa after 60 minutes incubation 
with SET-M33 at MIC. Scale bar 500 nm. 
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Some linear peptides are reported to kill bacteria very quickly16, while others, such as 
magainin-2, kill bacteria after 15-90 minutes. SET-M33 damages bacteria in the latter 
time range: indeed, microscopy only showed initial signs of bacterial membrane 
disturbance in very few cells after 10-15 minutes of exposure. With longer exposure, 
the damage to bacterial membranes increased in frequency and severity.  
Peptide conformation – Nuclear magnetic resonance (NMR) structure 
analysis and circular dichroism (CD) spectra 
The supramolecular structure of peptides is important and has been extensively studied 
in interactions of peptides with bacterial membranes16,39,40. The NMR spectra of free 
SET-M33 showed a chemical shift index typical of a random coiled conformation and 
no significant inter-residue NOEs, indicating that the peptide explores a large 
conformational space. On addition of SDS-d25 micelles, the NMR spectrum of  
SET-M33 undergoes a generalized broadening, caused by the production of slow-
tumbling high-mass species, precluding further analysis. The high-mass species could 
be aggregates of SET-M33-SDS-d25, possibly promoted by the multimericity of SET-
M33. We therefore synthesized an analogue peptide, Q-33, in linear form and capped 
it with an additional amino acid (Q-KKIRVRLSA) at the N-terminus in order to 
generate a model of SET-M33 that could be studied in the presence of SDS-d25. Q-33 
has an extremely lower half life in serum and plasma than SET-M33, 2 hours versus  
24 hours, and consistently it has a lower activity against Gram-negative bacteria41,42. The 
additional Q allowed us to study the structure of all residues, including the first lysine. 
Q-33 did not show any stable conformation in water, but addition of SDS-d25 micelles 
caused a generalized dispersion of proton resonances and the emergence of NOE 
peaks, indicating that a stable conformer was present as a consequence of the peptide 
micelle interaction. In particular, NOE signals of the Hαi-HNi+3, Hαi-Hβi+3 and HNi-
HNi+2 types for residue i=1–6 are diagnostic of α-helix conformation spanning residues 
1-9 (Figure 5A). Peak integration of a total set of 32 NOEs allowed us to calculate the 
relative interproton distances, which were used as constraints for simulation of torsion 
angle dynamics and subsequent peptide structure calculations. The resulting structure 
showed a regular α-helix encompassing the full-length of the peptide. 
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Figure 5. A) NOESY spectrum of Q-33 peptide in the presence of SDS-d25 micelles showing 
the Hα-HN correlation path typical of α-helices. B) Structural model of peptide conformation 
and interaction geometry with micelle surface (dashed line) as derived from NMR data, 
attenuation values A obtained by adding the soluble paramagnetic probe Gd(III)DTPA-BMA to 
the peptide/SDS-d25 sample are reported in the upper part. C) CD spectrum of SET-M33 100 
µM in water and SDS 30 mM. D) CD spectrum of Q-33 100 µM in water and SDS 30 mM. 
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To assess the interaction geometry of the helix with SDS-d25 micelles, a paramagnetic 
solution-NMR experiment was performed. Total correlation spectroscopy (TOCSY) 
spectra of the peptide-micelle system were acquired in the presence and absence of 
increasing concentrations of the paramagnetic probe Gd(III)DTPA-BMA. The soluble 
probe causes nuclear spin relaxation proportional to the local surface accessibility of 
the molecule investigated43-45. Relaxation is measured by calculating the decrease in peak 
volumes on addition of the probe, and is summarized as a bare number, the attenuation 
value A, which ranges from 0 to 2 and can be determined for each known proton peak. 
Protons shielded by contact with the solvent, and therefore not accessible to the probe, 
show low A values, while exposed protons show high A values (Figure 5B, upper part). 
Attenuation analysis was carried out on the Q-33-micelle system and an accurate 
accessibility profile was determined. Residues I3 and L7 showed much lower 
accessibility of the probe to their sidechains, and this can be ascribed to shielding by 
close interaction with the micelle surface. Charged residue pairs K1/R4 and K2/R6, 
situated on the opposite side of the helix, showed a higher A value, while V5 and S8 
showed the highest attenuation due to their high exposure to the solvent. The resulting 
structure was a helix lying on the micelle surface with I3/L7 sidechains inserted into 
the SDS-d25 assembly, and R and K sidechains arranged parallel to the surface, their 
charged tips interacting with the negative sulfate groups (Figure 5B). This facial 
amphiphilic structure has already been reported for other positively charged peptides46, 
such as LL37 fragments47 and CRAMP48.  
Finally, we wanted to assess whether SET-M33 and Q-33 had the same ability to adopt 
a helix conformation in a membrane mimicking environment, using CD. The technique 
proved to be applicable to both the tetrabranched and the linear peptide. SET-M33 and 
Q-33 CD spectra were recorded at room temperature in water and in SDS 30 mM. In 
line with the NMR experiments, SET-M33 showed a non-structured conformation in 
water but the CD spectrum shifted sharply to longer wavelengths in the presence of 
SDS micelles (Figure 5C), and the calculated helix ratio switched from 0% to 30%. A 
similar result was obtained with Q-33 (Figure 5D): the spectra recorded in water had a 
calculated helix ratio of 3.3% compared to 39% in the presence of SDS micelles. The 
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 CD spectra of SET-M33 and Q-33, recorded with or without micelles, were very similar, 
confirming that Q-33 was a reliable model of SET-M33 for the NMR experiments.  
Selectivity / hemolytic activity 
The ability of cationic peptides to stabilize as an α-helix, and particularly as a facial 
amphiphilic structure, is often associated with self-aggregation and undesired peptide 
interactions with blood proteins due to exposed hydrophobic surfaces46. The tendency 
to self-aggregate is correlated to hydrophobicity and provides an indirect estimate of 
the propensity for partitioning into lipid membranes with unselective detergent-like 
characteristics. Antimicrobial peptides need to be selective for prokaryotic membranes; 
a well-established method of verifying their ability to damage eukaryotic cell membranes 
is to measure their hemolytic activity49. Our results showed that red blood cells 
incubated with increasing concentrations of SET-M33 did not show more than 26% 
lysis, even using a concentration of 1.8 mg/mL (320 µM), which is more than 100-fold 
the MIC (Figure 6). 
 
 
Figure 6. Hemolytic activity of SET-M33. Percentage of red blood cell hemolysis after 24 hours 
incubation at 37 °C. The MIC required to inhibit 90% of tested isolates (MIC90) of  
K. pneumoniae and P. aerigunosa is indicated at 2.7 μM SET-M33. 
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In contrast with other cationic peptides50, SET-M33 showed very little hemolytic 
activity against red blood cells, although it shares the ability to form a regular α-helix 
shape. Indeed, SET-M33 also proved not to be cytotoxic to human bronchial epithelial 
cells (16HBE14 and CFBE41)23. Self-aggregation, often associated with amphiphilic 
structures and undesired secondary effects50, was also studied in FPLC experiments 
(Supplementary Figure S1) and showed that no self-aggregation occurred when  
SET-M33 was dissolved in PBS. The presence of LPS promoted the formation of high-
mass hetero-multimers, but not homo-multimers, in line with what we observed and 
described above in relation to SDS.  
 
Conclusions 
Current understanding of the mechanism of action of cationic AMPs includes a first 
step of electrostatic attraction between the cationic peptide and the negatively charged 
bacterial outer membrane. As SET-M33 is a cationic amphiphilic peptide it is attracted 
to the negatively charged bacterial membrane. Once close to the microbial surface, 
AMPs need to cross the polysaccharide cell wall barrier before interacting with the 
cytoplasmic membrane15,51,52. In line with this, in previous studies, SET-M33 was 
shown, by surface plasmon resonance, to bind LPS of K. pneumoniae and P. aeruginosa53 
and the binding prevented tumor necrosis factor α (TNF-α) release, neutralizing 
endotoxin activity in vitro and in vivo22,42. In the present study, NMR investigation of  
Q-33/SDS micelles in solution and in the presence of a paramagnetic probe showed 
that the α-helix arranges itself on the surface of micelles as previously described for 
other antimicrobial peptides54-56. Though direct measurement of the geometry of  
SET-M33/SDS micelle interactions was not possible, we demonstrated with CD that 
the structural transition observed using Q-33/SDS micelles also occurs using the 
original tetrabranched SET-M33 peptide. The α-helix showed to be partially buried in 
the lipid-bilayer. In the course of 15 to 60 minutes, the signs of membrane damages are, 
indeed, evident in electron microscopy. We also knew that SET-M33 is internalized in 
E. coli within 5 minutes, proving that it can cross cell wall and plasma membranes, 
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 causing enhanced membrane permeability, as observed with fluorescent probes42. 
Bacterial death may realistically be caused by impairment of the membrane homeostasis 
and functionality.  
Interestingly, SET-M33 is different from other α-helix antimicrobial peptides in that it 
shows little propensity to self-aggregate and also no hemolytic activity. Homo-
aggregation, which is considered related with undesired toxicity49,50, is never observed. 
This aspect probably contributes in preventing non-specific interactions with eukaryotic 
cells49,50 and indeed correlates with an acceptable tolerability profile obtained in 
toxicology studies in mice21. 
SET-M33 does not show any cross-resistance with colistin in colistin-resistant bacteria 
and, differently from colistin, it appears to generate substantially no resistance within  
24 hours of exposure in extensively resistant isolates of K. pneumoniae and P. aeruginosa. 
These observations suggest that the two peptides have a different mechanism of action. 
SET-M33 is attracted onto the surface of bacteria by the anionic charges of the cell wall. 
Being the core of the branched peptide completely flexible, we speculate that in the 
presence of phospholipid-bilayers, the peptide can assume a star like conformation, 
where hydrophobic residues are buried in the surface and hydrophilic residues point 
outwards. The disturbance of bi-layers integrity, produced by SET-M33’s peculiar way 
to interact with membranes, makes it more difficult for bacteria to trigger resistance 
mechanisms than it is for colistin. 
Finally SET-M33, in contrast to other similar antimicrobial peptides such as colistin, 
does not generate resistant mutants after 24 hours of exposure, and non-specific 
interactions or toxicity against eukaryotic cell membranes, suggesting that SET-M33 is 
a promising new option for the treatment of Gram-negative antibiotic-resistant 
infections.  
5
109
Investigations into the killing activity of antimicrobial peptide SET-M33
145136 van der Weide BNW.indd   109 07-08-20   14:01
Acknowledgements 
We thank Silvia Scali for qualified assistance with peptide synthesis and Giacomo Landi 
for support with FPLC chromatography.  
Funding 
Setlance srl and Erasmus University Medical Center Rotterdam received funding from 
the European Union’s Seventh Programme for Research, Technological Development 
and Demonstration under grant agreement No. 604434 (PneumoNP). A.P. received 
funding from the Italian Foundation for Cystic Fibrosis (Project FFC#17/2016). 
Competing interests 
Chiara Falciani, Alessandro Pini and Luisa Bracci are co-founders of Setlance srl. SET-
M33 is owned by Setlance srl. 
 
References 
1. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from 
uncomplicated urinary tract infections: the ECO· SENS Project. Journal of Antimicrobial Chemotherapy. 
2003;51(1):69-76. 
2. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately 
identify potentially resistant pathogens: a systematic review and meta-analysis. Clinical Infectious 
Diseases. 2013;58(3):330-9. 
3. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative 
pathogens: current and emerging therapeutic approaches. Expert Opinion on Pharmacotherapy. 
2014;15(10):1351-70. 
4. Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspectives in Medicinal 
Chemistry. 2014;6:PMC. S14459. 
5. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial 
resistance. Expert Review of Anti-infective Therapy. 2008;6(5):751-63. 
6. Organization WH. Antimicrobial resistance: global report on surveillance: World Health 
Organization; 2014. 
7. Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective 
therapeutic strategies. Nature Biotechnology. 2006;24(12):1551. 
8. de la Fuente-Nunez C, Silva ON, Lu TK, Franco OL. Antimicrobial peptides: role in human 
disease and potential as immunotherapies. Pharmacology & Therapeutics. 2017;178:132-40. 
9. Haney EF, Mansour SC, Hancock RE. Antimicrobial peptides: An introduction.  Antimicrobial 
Peptides: Springer; 2017. p. 3-22. 
10. Zhang L-j, Gallo RL. Antimicrobial peptides. Current Biology. 2016;26(1):R14-R9. 
11. Roscia G, Falciani C, Bracci L, Pini A. The development of antimicrobial peptides as new 
antibacterial drugs. Current Protein and Peptide Science. 2013;14(8):641-9. 
110
Chapter 55
145136 van der Weide BNW.indd   110 07-08-20   14:01
 12. Brunetti J, Falciani C, Bracci L, Pini A. Models of in-vivo bacterial infections for the development 
of antimicrobial peptide-based drugs. Current Topics in Medicinal Chemistry. 2017;17(5):613-9. 
13. Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. 
Biochimica et Biophysica Acta (BBA)-Biomembranes. 1999;1462(1-2):11-28. 
14. Bechinger B, Lohner K. Detergent-like actions of linear amphipathic cationic antimicrobial 
peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2006;1758(9):1529-39. 
15. Cushnie TT, O’Driscoll NH, Lamb AJ. Morphological and ultrastructural changes in bacterial 
cells as an indicator of antibacterial mechanism of action. Cellular and Molecular Life Sciences. 
2016;73(23):4471-92. 
16. Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature 
Reviews Microbiology. 2005;3(3):238. 
17. Wilmes M, Cammue BP, Sahl H-G, Thevissen K. Antibiotic activities of host defense peptides: 
more to it than lipid bilayer perturbation. Natural Product Reports. 2011;28(8):1350-8. 
18. Bierbaum G, Sahl H-G. Lantibiotics: mode of action, biosynthesis and bioengineering. Current 
Pharmaceutical Biotechnology. 2009;10(1):2-18. 
19. Epand RM, Epand RF. Bacterial membrane lipids in the action of antimicrobial agents. Journal 
of Peptide Science. 2011;17(5):298-305. 
20. Epand RM, Epand RF. Domains in bacterial membranes and the action of antimicrobial agents. 
Molecular BioSystems. 2009;5(6):580-7. 
21. Pollini S, Brunetti J, Sennati S, Rossolini GM, Bracci L, Pini A, et al. Synergistic activity profile of 
an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-
negative bacterial pathogens. Journal of Peptide Science. 2017;23(4):329-33. 
22. Brunetti J, Falciani C, Roscia G, Pollini S, Bindi S, Scali S, et al. In vitro and in vivo efficacy, 
toxicity, bio-distribution and resistance selection of a novel antibacterial drug candidate. Scientific 
Reports. 2016;6:26077. 
23. Brunetti J, Roscia G, Lampronti I, Gambari R, Quercini L, Falciani C, et al. Immunomodulatory 
and anti-inflammatory activity in vitro and in vivo of a novel antimicrobial candidate. Journal of 
Biological Chemistry. 2016;291(49):25742-8. 
24. Pini A, Lozzi L, Bernini A, Brunetti J, Falciani C, Scali S, et al. Efficacy and toxicity of the 
antimicrobial peptide M33 produced with different counter-ions. Amino Acids. 2012;43(1):467-73. 
25. Pini A, Falciani C, Mantengoli E, Bindi S, Brunetti J, Iozzi S, et al. A novel tetrabranched 
antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. 
The FASEB Journal. 2010;24(4):1015-22. 
26. Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, et al. Synthetic peptides in the form of 
dendrimers become resistant to protease activity. Journal of Biological Chemistry. 
2003;278(47):46590-5. 
27. Vila-Farrés X, Ferrer-Navarro M, Callarisa AE, Martí S, Espinal P, Gupta S, et al. Loss of LPS is 
involved in the virulence and resistance to colistin of colistin-resistant Acinetobacter nosocomialis 
mutants selected in vitro. Journal of Antimicrobial Chemotherapy. 2015;70(11):2981-6. 
28. Testing ECoAS, Testing ECoAS. Breakpoint tables for interpretation of MICs and zone 
diameters. Version 7.1, 2017. 2017. 
29. de Steenwinkel JE, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, et al. 
Time–kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic 
activity of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy. 2010;65(12):2582-9. 
30. Goddard T, Kneller D. San Francisco: University of California. SPARKY. 
31. Güntert P, Mumenthaler C, Wüthrich K. Torsion angle dynamics for NMR structure calculation 
with the new program DYANA. Journal of Molecular Biology. 1997;273(1):283-98. 
32. Lampiris H, Maddix D. Clinical use of antimicrobial agents (chapter 51). In: Katzung B, Masters 
S, Trevors A, editors. Basic and Clinical Pharmacology 2012. 
 
 
5
111
Investigations into the killing activity of antimicrobial peptide SET-M33
145136 van der Weide BNW.indd   111 07-08-20   14:01
33. Campos MA, Vargas MA, Regueiro V, Llompart CM, Albertí S, Bengoechea JA. Capsule 
polysaccharide mediates bacterial resistance to antimicrobial peptides. Infection and Immunity. 
2004;72(12):7107-14. 
34. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging 
antibiotic for multidrug-resistant Gram-negative bacterial infections. The Lancet Infectious Diseases. 
2006;6(9):589-601. 
35. Petrosillo N, Giannella M, Antonelli M, Antonini M, Barsic B, Belancic L, et al. Clinical 
experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative 
bacteria. Antimicrobial Agents and Chemotherapy. 2014;58(2):851-8. 
36. Ah Y-M, Kim A-J, Lee J-Y. Colistin resistance in Klebsiella pneumoniae. International Journal of 
Antimicrobial Agents. 2014;44(1):8-15. 
37. Giske CG. Contemporary resistance trends and mechanisms for the old antibiotics colistin, 
temocillin, fosfomycin, mecillinam and nitrofurantoin. Clinical Microbiology and Infection. 
2015;21(10):899-905. 
38. Liu Y-Y, Wang Y, Walsh TR, Yi L-X, Zhang R, Spencer J, et al. Emergence of plasmid-mediated 
colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and 
molecular biological study. The Lancet Infectious Diseases. 2016;16(2):161-8. 
39. Hancock RE, Lehrer R. Cationic peptides: a new source of antibiotics. Trends in Biotechnology. 
1998;16(2):82-8. 
40. Kemayo Koumkoua P, Aisenbrey C, Salnikov E, Rifi O, Bechinger B. On the design of 
supramolecular assemblies made of peptides and lipid bilayers. Journal of Peptide Science. 
2014;20(7):526-36. 
41. Pini A, Giuliani A, Falciani C, Runci Y, Ricci C, Lelli B, et al. Antimicrobial activity of novel 
dendrimeric peptides obtained by phage display selection and rational modification. Antimicrobial 
Agents and Chemotherapy. 2005;49(7):2665-72. 
42. Pini A, Giuliani A, Falciani C, Fabbrini M, Pileri S, Lelli B, et al. Characterization of the branched 
antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity. Journal of Peptide 
Science: an official publication of the European Peptide Society. 2007;13(6):393-9. 
43. Bernini A, Spiga O, Venditti V, Prischi F, Botta M, Croce G, et al. The use of a ditopic Gd (III) 
paramagnetic probe for investigating α-bungarotoxin surface accessibility. Journal of Inorganic 
Biochemistry. 2012;112:25-31. 
44. Bernini A, De Angelis LH, Morandi E, Spiga O, Santucci A, Assfalg M, et al. Searching for protein 
binding sites from molecular dynamics simulations and paramagnetic fragment-based NMR studies. 
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2014;1844(3):561-6. 
45. Bernini A, Venditti V, Spiga O, Ciutti A, Prischi F, Consonni R, et al. NMR studies on the surface 
accessibility of the archaeal protein Sso7d by using TEMPOL and Gd(III)(DTPA-BMA) as paramagnetic 
probes. Biophysical Chemistry. 2008;137(2):71-5. 
46. Xiong M, Lee MW, Mansbach RA, Song Z, Bao Y, Peek RM, et al. Helical antimicrobial 
polypeptides with radial amphiphilicity. Proceedings of the National Academy of Sciences. 
2015;112(43):13155-60. 
47. Li X, Li Y, Han H, Miller DW, Wang G. Solution structures of human LL-37 fragments and NMR-
based identification of a minimal membrane-targeting antimicrobial and anticancer region. Journal of 
the American Chemical Society. 2006;128(17):5776-85. 
48. Yu K, Park K, Kim Y, Kang SW, Shin S, Hahm KS. Solution structure of a cathelicidin-derived 
antimicrobial peptide, CRAMP as determined by NMR spectroscopy. The Journal of Peptide Research. 
2002;60(1):1-9. 
49. Prenner EJ, Kiricsi M, Jelokhani-Niaraki M, Lewis RN, Hodges RS, McElhaney RN. Structure-
Activity Relationships of Diastereomeric Lysine Ring Size Analogs of the Antimicrobial Peptide 
Gramicidin S mechanism of action and discrimination between bacterial and animal cell membranes. 
Journal of Biological Chemistry. 2005;280(3):2002-11. 
 
112
Chapter 55
145136 van der Weide BNW.indd   112 07-08-20   14:01
 50. Jiang Z, Vasil A, Vasil M, Hodges R. “Specificity determinants” improve therapeutic indices of 
two antimicrobial peptides piscidin 1 and dermaseptin S4 against the gram-negative pathogens 
Acinetobacter baumannii and Pseudomonas aeruginosa. Pharmaceuticals. 2014;7(4):366-91. 
51. Datta A, Bhattacharyya D, Singh S, Ghosh A, Schmidtchen A, Malmsten M, et al. Role of 
aromatic amino acids in lipopolysaccharide and membrane interactions of antimicrobial peptides for 
use in plant disease control. Journal of Biological Chemistry. 2016;291(25):13301-17. 
52. Datta A, Ghosh A, Airoldi C, Sperandeo P, Mroue KH, Jiménez-Barbero J, et al. Antimicrobial 
peptides: insights into membrane permeabilization, lipopolysaccharide fragmentation and application 
in plant disease control. Scientific Reports. 2015;5:11951. 
53. Falciani C, Lozzi L, Pollini S, Luca V, Carnicelli V, Brunetti J, et al. Isomerization of an 
antimicrobial peptide broadens antimicrobial spectrum to gram-positive bacterial pathogens. PLOS 
ONE. 2012;7(10):e46259. 
54. Hartmann M, Berditsch M, Hawecker J, Ardakani MF, Gerthsen D, Ulrich AS. Damage of the 
bacterial cell envelope by antimicrobial peptides gramicidin S and PGLa as revealed by transmission 
and scanning electron microscopy. Antimicrobial Agents and Chemotherapy. 2010;54(8):3132-42. 
55. Sato H, Feix JB. Peptide–membrane interactions and mechanisms of membrane destruction 
by amphipathic α-helical antimicrobial peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes. 
2006;1758(9):1245-56. 
56. Bahar A, Ren D. Antimicrobial peptides. Pharmaceuticals. 2013;6(12):1543-75. 
  5
113
Investigations into the killing activity of antimicrobial peptide SET-M33
145136 van der Weide BNW.indd   113 07-08-20   14:01
Supplementary Table S1. Phenotypic characterization of bacterial isolates 
Bacterial isolate 
colistin-
susceptible  
K. pneumoniae 
R-DYK 4861 
colistin-
resistant  
K. pneumoniae 
R-DYK 4861 
colistin-
susceptible  
P. aeruginosa 
B-162 
colistin-
resistant 
P. aeruginosa 
B-162 
Ampicillin ≥32 ≥32   
Amoxicillin/ 
Clavulanic Acid 
≥32 ≥32   
Piperacillin/ 
Tazobactam 
≥128 ≥128 ≥128 ≥128 
Cefuroxime ≥64 ≥64   
Cefuroxime Axetil ≥64 ≥64   
Cefoxitin ≥64 ≥64   
Cefotaxime ≥64 ≥64   
Ceftazidime 16 16 ≥64 32 
Cefepime ≥64 ≥64 ≥64 ≥64 
Imipenem ≥16 ≥16 ≥16 ≥16 
Meropenem ≥16 ≥16 ≥16 ≥16 
Gentamicin ≥16 ≥16 ≥16 ≥16 
Tobramycin ≥16 ≥16 ≥16 ≥16 
Ciprofloxacin ≥4 ≥4 ≥4 ≥4 
Norfloxacin ≥16 ≥16   
Trimethoprim ≥16 ≥16   
Trimethoprim/ 
sulfamethoxazole 
≥320 ≥320   
Colistin ≤0.5 ≥16 ≤0.5 ≥16 
MICs (mg/L) were determined using the automated VITEK® 2 antimicrobial identification 
system and AST-N140 cards. Interpretation of antimicrobial susceptibility was defined by the 
VITEK® antimicrobial identification system as susceptible, intermediate (italic), or resistant 
(bold) based on EUCAST 2017 guidelines.  
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 Supplementary Table S2. Change in colistin-resistant K. pneumoniae R-DYK 4861 and  
P. aeruginosa B-162 susceptibility to M33 and colistin after 24 hours exposure to antibiotic as 
determined by MIC assay 
Antibiotic 
concentration 
(mg/L) 
M33 (mg/L) Colistin (mg/L) 
colistin-resistant 
K. pneumoniae 
colistin-resistant 
P. aeruginosa 
colistin-resistant 
K. pneumoniae  
colistin-resistant 
P. aeruginosa 
control  16 16 >512  512 
0.125  32 16   
0.25  16 16   
0.5  32 16   
1  32 16 >512  256 
2  64 16 >512  256 
4  64 16 >512  256 
8 >64 16 >512  256 
16 >64 16 >512  512 
32  Nd  162 >512  512 
64  Nd nd >512  512 
128   >512  512 
256   >512  5121 
512   >512 >5121 
Colistin-resistant bacterial cultures were exposed to two-fold increasing concentrations of  
SET-M33 or colistin for 24 hours at 37 °C under shaking conditions. When bacteria re-grew 
after 24 hours exposure to antibiotic, their MIC susceptibilities (performed in triplicate) were 
also determined and the median value reported. nd, not determined (no regrowth in the original 
time-kill kinetics experiment); 1, one out of three samples did not show bacterial re-growth;  
2, two out of three samples did not show bacterial re-growth.   
5
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Supplementary Figure S1. Fast protein liquid chromatography (FPLC). A) SET-M33;  
B) Lipopolysaccharide (LPS); C) LPS and SET-M33. Peak at tR = 9 minutes might correspond 
to SET-M33-LPS hetero-multimer. 
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Chapter 6 Successful high-dosage monotherapy of tigecycline in a multidrug-
resistant Klebsiella pneumoniae pneumonia-septicemia model in rats 
Chapter 7 In vitro and in vivo bacterial killing activity of novel antimicrobial 
peptide SET-M33-nanomedicines against multidrug-resistant 
Klebsiella pneumoniae 
Chapter 8 Therapeutic efficacy of novel antimicrobial peptide AA139-
nanomedicines in a multidrug-resistant Klebsiella pneumoniae 
pneumonia-septicemia model in rats 
 
The chapters in Section III cover the in vivo investigation of selected antimicrobial peptide 
(AMP)-nanomedicines in uninfected and infected rats. 
In Chapter 6, we established and characterized a rat model of pneumonia-septicemia caused 
by multidrug-resistant Klebsiella pneumoniae which was validated using a high-dose treatment 
regimen of tigecycline, with meropenem serving as comparator drug.  
Chapter 7 and Chapter 8 cover the investigation of SET-M33-nanomedicines and AA139-
nanomedicines, respectively. Nanomedicines were selected by screening of their in vitro 
antimicrobial activity. The nanomedicines were administered by endotracheal aerosolization at 
a single dose to determine their limiting dose in uninfected rats and to assess the bacterial 
killing activity in the lung of infected rats. Based on these results, the most promising AA139-
nanomedicines were selected for continued investigation in Chapter 8. Biodistribution of 
nanomedicines was investigated in uninfected rats, and therapeutic efficacy studies were 
performed in infected rats using a 10-day treatment. 
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Abstract 
Background: Recent scientific reports on the use of high dose tigecycline monotherapy as a 
‘drug of last resort’ warrant further research into the use of this regimen for the treatment 
of severe multidrug-resistant Gram-negative bacterial infections. In the current study, the 
therapeutic efficacy of tigecycline monotherapy was investigated and compared to 
meropenem monotherapy in a newly developed rat model of fatal lobar pneumonia-septicemia. 
Methods: A Klebsiella pneumoniae producing extended-spectrum β-lactamase (ESBL) and an 
isogenic variant producing K. pneumoniae carbapenemase (KPC) were used in the study. Both 
strains were tested for their in vitro antibiotic susceptibility and used to induce pneumonia-
septicemia in rats, which was characterized using disease progression parameters. Therapy 
with tigecycline or meropenem was initiated at the moment that rats suffered from 
progressive infection and was administered 12-hourly over 10 days. The pharmacokinetics of 
meropenem were determined in infected rats. 
Results: In rats with ESBL pneumonia-septicemia, the minimum dosage of meropenem achieving 
survival of all rats was 25 mg/kg/day. However, in rats with KPC pneumonia-septicemia this 
meropenem dosage was unsuccessful. In contrast, all rats with KPC pneumonia-septicemia 
were successfully cured by administration of high-dose tigecycline monotherapy of 25 
mg/kg/day (i.e., the minimum tigecycline dosage achieving 100% survival of rats with ESBL 
pneumonia-septicemia in a previous study). 
Conclusions: The current study supports recent literature recommending high-dose tigecycline 
as a last resort regimen for the treatment of severe multidrug-resistant bacterial infections. 
The use of ESBL- and KPC-producing K. pneumoniae strains in the current rat model of 
pneumonia-septicemia enables further investigation, helping provide supporting data for follow-
up clinical trials in patients suffering from severe multidrug-resistant bacterial respiratory 
infections. 
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Introduction 
Recent data from the US indicate that Gram-negative bacteria are responsible for more 
than 30% of hospital-acquired infections1. A complicating factor in the treatment of 
infections caused by Gram-negative bacteria is the worldwide increase of antimicrobial 
resistance. In particular, Gram-negative bacteria resistant to carbapenem antibiotics —
due to the presence of plasmid-mediated multidrug-resistance, such as with extended-
spectrum β-lactamase (ESBL) or Klebsiella pneumoniae carbapenemase (KPC) — can no 
longer be effectively treated with β-lactam antibiotics and tend to be susceptible only 
to ‘drugs of last resort’2,3.  
Tigecycline (an antibiotic belonging to the class of glycylcyclines) is one such drug of 
last resort, although resistance to tigecycline has been reported4. Further, although the 
United States Food and Drug Administration (FDA) issued a warning in 2013 relating 
to an apparent increased death rate during antibiotic treatment using tigecycline (loading 
dose of 100 mg followed by 50 mg every 12 hours)5, multiple studies have suggested 
that using a high dose of tigecycline could actually improve outcome in comparison to 
conventional dosing6,7. Additionally, the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) has recently recommended the use of high-dosage 
tigecycline treatment in seriously ill patients infected with multidrug-resistant bacteria8. 
As well as dosing issues, another debate about the role of tigecycline involves its use in 
monotherapy as opposed to combination therapy, particularly in the treatment of 
multidrug-resistant Gram-negative bacterial infections. This issue is complicated by the 
fact that comparative clinical efficacy studies into tigecycline are complex, involving 
differing patient characteristics, various combinations of antibiotics, and differences in 
the nature and severity of infections9,10.  
To investigate this issue further, in rats we developed a model of bilateral pneumonia-
septicemia in which we were able to compare the therapeutic efficacy of individual 
antibiotics at similar conditions of severity, duration of infection, and host defense. This 
novel pneumonia-septicemia model was based on a previously established rat model of 
unilateral pneumonia-septicemia (in which one lung was left uninfected), which was 
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 intended for antimicrobial pharmacokinetic and pharmacodynamic studies11. Further, 
in order to mimic the actual clinical situation, the rat infection model is fatal if left 
untreated, with rat survival (based on rats reaching humane endpoints) as a treatment 
outcome parameter. In the present study, we established and characterized the lobar 
pneumonia leading to fatal septicemia, which was caused by either an ESBL-producing 
K. pneumoniae strain or its isogenic KPC-producing variant. The model was used to 
investigate the therapeutic efficacy of tigecycline as monotherapy as compared to 
meropenem monotherapy, a potent carbapenem antibiotic which serves as the 
conventional treatment for multidrug-resistant Gram-negative bacterial infections12.  
 
Materials and Methods 
Bacterial strains 
K. pneumoniae American Type Culture Collection (ATCC) 43816™ (capsular serotype 2) 
was used as a parent strain to generate the isogenic ESBL-producing variant K. 
pneumoniae ESBL EMC2003 (referred to in this study as K. pneumoniae ESBL) and the 
isogenic KPC-producing variant K. pneumoniae KPC EMC2014 (referred to in this study 
as K. pneumoniae KPC) via bacterial conjugation with an ESBL-producing or KPC-
producing clinical isolate and subsequent selection on antibiotic agar plates. The 
stability of both plasmid-containing strains was assessed through five consecutive 
passages in Mueller-Hinton II (MH-II) broth (Becton Dickinson BV, Vianen, the 
Netherlands). The virulence of the bacterial strains was maintained by rat lung passage 
every 12 months. ATCC Quality Control strains K. pneumoniae ATCC 13883™ (WT),  
K. pneumoniae ATCC 700603™ (ESBL) and K. pneumoniae ATCC BAA1705™ (KPC) 
were used as reference strains. 
Genotypic characterization of bacterial strains 
Due to the complex relationship between antibiotic resistance and virulence factors, it 
is important to report the genotypic data of bacterial strains used in microbiological 
studies13,14. Polymerase chain reaction (PCR) assays were used to verify the presence of 
6
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the following resistance genes: cefotaxime-M β-lactamase (CTX-M) groups 1, 2, 8, 9, 
2515; temoniera β-lactamase (TEM)16; sulfhydryl reagent variable β-lactamase (SHV)17; 
oxacillinase β-lactamase (OXA)-1-like18; OXA-48-like19; KPC20; and New Delhi 
metallo-β-lactamase (NDM)-121. Multilocus sequence typing (MLST) was used to 
investigate genetic relatedness. For this, partial deoxyribonucleic acid (DNA) sequences 
of the seven housekeeping genes gapA, infB, mdh, pgi, phoE, rpoB and tonB were 
generated and compared using a published high-throughput MLST (HiMLST) 
strategy22 that had been adapted for K. pneumoniae isolates23. To further assess the genetic 
relation between the strains, pulsed-field gel electrophoresis (PFGE) was used as 
previously described24. 
Antibiotics and anesthetics 
The antibiotics used were amikacin hydrate, ceftazidime hydrate, ciprofloxacin 
hydrochloride monohydrate, colistin sulfate salt, gentamicin sulfate, meropenem 
trihydrate, norfloxacin, tigecycline, tobramycin sulfate salt, trimethoprim, and 
sulfamethoxazole (Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands). For  
co-trimoxazole, the ratio trimethoprim:sulfamethoxazole was 1:19. Meropenem was 
combined with cilastatin sodium (Bosche Scientific LLC, New Brunswick, NJ, USA) 
(1:1) when used in vivo to inhibit the function of dehydropeptidase enzyme, which is a 
known catalyst of meropenem in rats25.  
The anesthetics used were medetomidine hydrochloride (Eurovet Animal Health BV, 
Bladel, the Netherlands), fentanyl citrate (Hameln Pharma Plus GmbH, Hameln, 
Germany) and midazolam hydrochloride (Actavis Group PTC ehf, Hafnarfjörður, 
Iceland), which were administered together intraperitoneally at 0.5 mg/kg, 50 μg/kg 
and 5 mg/kg, respectively. Antagonists were atipamezole hydrochloride (Vetoquinol 
BV, ‘s Hertogenbosch, the Netherlands), naloxone hydrochloride dihydrate (Hameln 
Pharma Plus GmbH) and flumazenil (Fresenius Kabi Nederland BV, Zeist, the 
Netherlands), which were administered together intraperitoneally at 1.5 mg/kg,  
0.7 mg/kg, and 0.3 mg/kg, respectively. 
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 Antimicrobial susceptibility of K. pneumoniae strains 
The antimicrobial susceptibility of bacterial strains was assessed by minimum inhibitory 
concentration (MIC) determination using the broth microdilution method following 
EUCAST guidelines26, which represents the lowest antibiotic concentration needed to 
inhibit bacterial growth under standardized and predefined laboratory conditions. 
Phenotypic characterization of bacterial strains was based on antimicrobial 
susceptibility as determined using the VITEK®2 system and AST-N344 Gram-
Negative Susceptibility Cards (bioMérieux Benelux BV, Zaltbommel, the Netherlands). 
Concentration- and time-dependent bactericidal activity of antibiotics in 
vitro 
The bacterial killing capacity of meropenem and tigecycline was investigated using the 
time-kill kinetics (TKK) assay as previously described27. Two-fold increasing antibiotic 
concentrations were used representing ⅟16-fold up to 32-fold the epidemiological cut-
off value (ECOFF) of the two antibiotics as reported by EUCAST28. The ECOFF of  
K. pneumoniae for meropenem is 0.125 mg/L and for tigecycline was 1 mg/L, but has 
recently been increased to 2 mg/L. Samples were centrifuged at 12,500 × g for 5 min 
to avoid drug carry-over, serially 10-fold diluted and subcultured on MH-II agar plates 
(Becton Dickinson BV, Vianen, the Netherlands) for colony-forming units (CFU) 
counts after 24 hours at 37 °C. At 24 hours, changes in antibiotic susceptibility were 
determined via MIC assay using subsamples of 1 mL to prepare bacterial inocula. 
Animals 
Specified pathogen-free (SPF) male strain RP/AEur/RijHsd albino rats bred at the 
Laboratory Animals Center of Erasmus University Medical Center Rotterdam (Erasmus 
MC) were used. Rats (age, 10-18 weeks; body weight, 250-350 g) were housed 
individually in ventilated cages and were given food and water ad libitum. Rats were 
randomly allocated to experimental groups once they reached the appropriate age and 
body weight. Group sizes were based on estimates of the hazard ratio. Euthanasia was 
applied by CO2 exposure when humane endpoints were reached or at termination of 
experiments.  
6
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Ethics 
Animals were maintained and handled in accordance with the Guidelines for 
Accommodation and Care of Animals (European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other Scientific Purposes). All animal 
procedures were performed in accordance with the Dutch Animal Experimentation Act 
(BWBR0003081) which meets the requirements of the European Union Animal 
Directive (2010/63/EU). Experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the Erasmus MC. The current study was designed 
to abide by the three Rs principles of animal research (replace, reduce, refine) wherever 
possible29 and was written to conform to the animal research: reporting of in vivo 
experiments (ARRIVE) guidelines for reporting animal research30. 
Rat model of pneumonia-septicemia 
Acute bilateral pneumonia-septicemia in rats (referred to in this study as ESBL 
pneumonia-septicemia or KPC pneumonia-septicemia) was established in groups of  
11 rats using suspensions of washed bacteria in the logarithmic phase of growth. After 
intubation and cannulation of the trachea under anesthesia, rats were held in a vertical 
position and the lungs were inoculated with 60 µL PBS containing the respective 
absolute lethal dose (LD100) inocula: 2×106 K. pneumoniae ESBL or 6×107 K. pneumoniae 
KPC. An implantable programmable temperature transponder (IPTT)-300 (Plexx BV, 
Elst, the Netherlands) was implanted subcutaneously. Infected rats were monitored  
12-hourly for 11 days to assess the disease progression as well as pre-defined humane 
endpoints by changes in body temperature and body weight, and by external symptoms 
of disease including ungroomed appearance, pallor, nose bleeding, lack of reactivity, 
inactivity, instability, or abnormal breathing of rats. Rat survival was based on rats 
reaching humane endpoints, at which point euthanasia was applied by CO2 exposure. 
After dissection, bacteria isolated from lung and blood were identified by matrix-
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer 
(Bruker Daltonics, Bremen, Germany) to rule out co-infection – a pre-established 
exclusion criterium.  
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 Characterization of pneumonia-septicemia model 
The early phase of infection was characterized at 24 hours and 48 hours after initiation 
of infection by viable counts of K. pneumoniae in lungs and blood taken from 6 rats per 
time point. Blood obtained by cardiac puncture was collected from euthanized rats in 
lithium-heparin tubes (Sarstedt BV, Etten-Leur, the Netherlands). The five lung lobes 
were collected separately, each in 2 mL PBS and homogenized using the gentleMACS™ 
Octo Dissociator (Milteny Biotec BV, Leiden, the Netherlands). Blood and lung 
homogenates undiluted and in 10-fold dilutions were subcultured on MH-II agar plates 
(Sigma-Aldrich Chemie BV, Zwijndrecht, the Netherlands) for CFU counts after  
24 hours at 37 °C. In blood plasma samples the alanine aminotransferase (ALAT) and 
aspartate aminotransferase (ASAT) levels were assessed for hepatic function, and the 
creatinine and blood urea nitrogen (BUN) levels for renal function at the Department 
of Clinical Chemistry, Erasmus MC. Histopathological examination of the infected 
lungs at 24 hours after infection was performed in 2 rats with ESBL pneumonia-
septicemia and 2 rats with KPC pneumonia-septicemia. In sacrificed rats, in situ lungs 
were fixated with 10% formalin under constant pressure to re-expand the lungs. 
Segments of the left lung were dehydrated in ethanol and toluol, and finally embedded 
in paraffin. Paraffin-embedded tissues were cut into 4 µm sections from which one in 
every 15 cuts was used for hematoxylin-eosin (HE) staining and one for Gram-staining. 
Antimicrobial treatment of pneumonia-septicemia 
The therapeutic response to meropenem was determined in rats with ESBL 
pneumonia-septicemia and rats with KPC pneumonia-septicemia. The response to 
tigecycline was only investigated in rats with KPC pneumonia-septicemia, as this had 
already been investigated in a previous unilateral pneumonia-septicemia rat model 
caused by the identical K. pneumoniae ESBL strain11. Treatment groups consisted of  
11 rats. Antibiotics were always administered intraperitoneally in a volume of 2.5 mL/kg 
12-hourly for 10 days, started at 24 hours after initiation of infection. Meropenem in 
doses ranging from 6.25 to 25 mg/kg/day were administered by 2-fold increases until 
a minimum effective dose (MED) of meropenem was reached at which all rats survived. 
6
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Tigecycline was administered at 25 mg/kg/day i.e. the MED necessary for survival of 
all rats with ESBL pneumonia-septicemia from a previous study11. Disease progression 
was monitored 12-hourly. Rats reaching humane endpoints were euthanized and 
dissected to rule out co-infection. 
Pharmacokinetics of meropenem 
Meropenem plasma concentrations were determined in 3 rats with ESBL pneumonia-
septicemia. Rats received 3 doses of 25 mg/kg/day meropenem 12-hourly, starting at 
24 hours after initiation of infection. Blood obtained by tail vein puncture was collected 
in ethylenediaminetetraacetic acid (EDTA)-coated tubes (Sigma-Aldrich Chemie BV, 
Zwijndrecht, the Netherlands). Meropenem concentrations were determined by high-
performance liquid chromatography-mass spectrometry (HPLC-MS)31. The lower limit 
of quantification of meropenem was 0.20 mg/L. The calibration line was linear from 
0.20 to 40.0 mg/L with a determination coefficient of at least 0.995. Rat samples were 
prepared together with calibration standards and quality control samples at three levels. 
The values of the volume of distribution (V), the clearance (CL) and the concentration 
half-life time (t1/2) of the meropenem elimination process were calculated using a 
PKSolver 2.0 one-compartment model of extravascular administration with time delay 
to account for absorption32. V and CL were presented as a fraction of the absorbed 
dose (bioavailability, F). The protein binding of meropenem in rats has been reported 
as 22.4%33. As only the unbound fraction of the drug is responsible for its antimicrobial 
effect, the values of: 1) the cumulative percentage of a 12-hour period that the unbound 
fraction of drug exceeded the MIC (ƒT>MIC) and 2) the highest unbound drug 
concentration reached in blood plasma (ƒCmax), were calculated based on unbound 
meropenem concentrations. 
Statistical analysis 
Kaplan-Meier rat survival curves were generated, and statistical differences in rat 
survival rates were calculated using the log rank test using Prism 5.01 (Graphpad Inc., 
San Diego, CA, USA). 
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 Results 
Bacterial strains 
The results from HiMLST (Supplementary Table S1) and PFGE (data not shown) 
assays confirmed the isogenicity of the K. pneumoniae ESBL and K. pneumoniae KPC 
strains. ESBL and KPC resistance genes were detected via PCR as expected in the 
respective strains (Supplementary Table S1). 
Antimicrobial susceptibility of K. pneumoniae strains 
The antimicrobial susceptibility of K. pneumoniae ESBL and K. pneumoniae KPC for 
clinically relevant antibiotics was assessed by MIC determination and compared with 
the MIC values of 3 ATCC Quality Control reference strains. The K. pneumoniae ESBL 
strain was resistant to ceftazidime and tobramycin, and susceptible to meropenem based 
on MIC values (Table 1). The isogenic K. pneumoniae KPC strain was resistant to 
ceftazidime, tobramycin and meropenem. According to the EUCAST 2020 guidelines, 
 
  
Table 1. MIC values of clinically relevant antibiotics for K. pneumoniae strains 
Strain 
ATCC 
43816 
EMC 
2003 
EMC 
2014 
ATCC 
13883 
ATCC 
700603 
ATCC 
BAA1705 
Phenotype WT Parent ESBL KPC WT ESBL KPC 
M
IC
 (
m
g
/
L)
 
CAZ 0.5 256 256 0.5 64 128 
MEM 0.063 0.063 16 0.063 0.063 32 
AMK 2 2 2 1 1 32 
TOB 0.5 >64 >64 0.5 8 32 
CIP 0.031 0.125 0.063 0.125 0.5 >32 
NOR 0.125 0.25 0.25 0.25 2 512 
SXT 0.5 1 2 0.5 4 >64 
CST 0.5 1 0.5 2 1 0.5 
TGC 1 1 2 1 16 4 
MIC assays were performed in triplicate, median values are displayed. MIC values are 
interpreted as susceptible, intermediate (italic), or resistant (bold) according to EUCAST 2019 
guidelines. CAZ, ceftazidime; MEM, meropenem; AMK, amikacin; TOB, tobramycin; CIP, 
ciprofloxacin; NOR, norfloxacin; SXT, trimethoprim/sulfamethoxazole expressed as the 
trimethoprim concentration; CST, colistin; TGC, tigecycline; WT, wildtype. 
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both K. pneumoniae isolates are resistant to tigecycline, as are all the reference strains used 
in this study26. However, both K. pneumoniae isolates still fell within the antimicrobial 
wild-type distribution of K. pneumoniae based on the ECOFF value of tigecycline for  
K. pneumoniae (2 mg/L), and can be considered representative of the tigecycline 
susceptibility of wild-type K. pneumoniae populations — albeit on the high-end of the 
wild-type distribution28.  
VITEK®2 data (Supplementary Table S2) showed that K. pneumoniae ESBL and  
K. pneumoniae KPC were both resistant to a wide range of β-lactam antibiotics and 
aminoglycoside antibiotics. 
Concentration- and time-dependent bactericidal activity of antibiotics in 
vitro 
The in vitro killing capacity of meropenem and tigecycline against K. pneumoniae ESBL or 
K. pneumoniae KPC during 24 hours was determined using TKK assays. In the absence 
of antibiotics, the bacterial populations rapidly increased within 24 hours of incubation 
(Figure 1). Meropenem showed time-dependent killing against K. pneumoniae ESBL. A 
concentration of ≥0.125 mg/L meropenem resulted in a 100-fold reduction in bacterial 
numbers after 2 hours and complete bacterial elimination after 24 hours. At 0.03 mg/L 
meropenem, bacteria were initially killed, although after 24 hours, bacterial re-growth 
occurred up to the level of non-exposed bacterial growth after 24 hours. However, this 
finding was not associated with changes in susceptibility to meropenem. Concentrations 
of ≤0.015 mg/L meropenem had no effect on in vitro bacterial growth. For K. pneumoniae 
KPC, initial killing by meropenem was observed at concentrations ≥0.5 mg/L during 
the first 2 hours exposure, but bacterial re-growth was observed at all concentrations 
up to the level of non-exposed bacteria after 24 hours.  
The mode of action of tigecycline was observed to be bacteriostatic and the antibiotic 
was equally effective against K. pneumoniae ESBL and K. pneumoniae KPC, indicating that 
the 2-fold difference in MIC values to tigecycline for the two strains represents essential 
agreement in susceptibility to this antibiotic. Inhibition of bacterial growth after  
24 hours of exposure was only observed above 2 mg/L tigecycline. Concentrations 
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Figure 1. Concentration- and time-dependent bactericidal activity of meropenem (MEM) and 
tigecycline (TGC) against K. pneumoniae strains. Bacterial cultures of K. pneumoniae ESBL or 
K. pneumoniae KPC were exposed to two-fold increasing concentrations of antibiotic for  
24 hours. Shown are the median ± range of in triplo experiments. The dashed grey line 
indicates the lower limit of quantification of log 0.7 
 
below 2 mg/L resulted in growth inhibition during 4 hours of exposure, but bacterial 
re-growth occurred after 24 hours, which was never associated with changes in bacterial 
susceptibility to tigecycline. Concentrations ≤0.25 mg/L had no effect. 
Characterization of pneumonia-septicemia model 
Rats were inoculated with K. pneumoniae ESBL or K. pneumoniae KPC and developed 
acute bilateral pneumonia with septicemia. Bacterial numbers increased rapidly in all 
lung lobes, with the relatively large lobes containing the most bacteria (Figure 2). As a 
consequence of a higher inoculum used to induce KPC pneumonia-septicemia, higher 
counts of K. pneumoniae were found at 24 hours in the lungs of rats with KPC 
pneumonia-septicemia compared to rats with ESBL pneumonia-septicemia. By  
48 hours, differences in K. pneumoniae counts in the lungs in both models were minor. 
6
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 Figure 2. Bacterial load of K. pneumoniae in lungs and blood of rats with K. pneumoniae 
pneumonia-septicemia in the early phase of infection. Bacterial load of K. pneumoniae was 
determined for total lungs and individual lung lobes and blood (per mL) of rats with  
K. pneumoniae ESBL pneumonia-septicemia and rats with K. pneumoniae KPC pneumonia-
septicemia at 24 hours and 48 hours after initiation of infection. TL, total lungs; LL, left lobe; 
RCrL, right cranial lobe; RML, right middle lobe; RCaL, right caudal lobe; RIL, right intermediate 
lobules. Groups of 6 rats per time point. Bacterial load is expressed as log CFU (median ± 
range). 
 
After 24 hours, bacteremia was present in 4/6 (66%) of rats with ESBL pneumonia-
septicemia and in 4/6 (66%) of rats with KPC pneumonia-septicemia. Changes in liver 
and kidney function in terms of ALAT, ASAT, creatinine, and BUN were never found 
(data not shown). Histopathological examination of the infected lungs at 24 hours after 
initiation of infection revealed distinctive alveolar pathology, as shown for KPC 
pneumonia-septicemia (Supplementary Figure S1). Similar histopathological 
characteristics were observed in rats with ESBL pneumonia-septicemia (data not 
shown).  
The disease progression over time in terms of rat survival rate (Figure 3A) was similar 
for either infecting K. pneumoniae strain (p=0.4662). In both cases, the body 
temperatures (Figure 3B) initially showed some fluctuation, but decreased over time to 
below the lower limit (36.1 °C) of normal values. Rat body weight decreased over time 
(Figure 3C). A control experiment revealed that the technique of intubation and 
inoculation itself did not influence body temperature or body weight. 
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Figure 3. Disease progression in rats with K. pneumoniae pneumonia-septicemia. Groups of 
11 rats were used for each experiment. A) Rat survival (Kaplan-Meier curves) of rats reaching 
humane endpoints. B) Box plots of pooled body temperatures showing the range of the data; 
the dashed line at 34 °C represents the humane endpoint. C) Body weight loss from the onset 
of the infection (mean ± standard deviation). 
 
Therapeutic efficacy of meropenem in rats with ESBL pneumonia-
septicemia 
Treatment was started at 24 hours after infection, when bacterial numbers in the lung 
had increased 100-fold and most rats had developed early bacteremia. Increasing doses 
of meropenem were investigated ranging from 6.25 – 25 mg/kg/day administered  
12-hourly until a MED of meropenem was reached at which all rats survived. 
Meropenem showed a dose-dependent therapeutic activity, and effected survival of all 
rats at 25 mg/kg/day — the MED (Figure 4). Rat body temperatures initially showed 
some fluctuation, but stabilized around normal values after 3 days and from that time 
onward showed the normal circadian rhythm. Body weight values initially decreased but 
remained stable after 3 days. The lungs of the surviving rats sacrificed at termination of 
the experiment were sterile.  
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 Figure 4. Therapeutic efficacy of meropenem (MEM) in rats with ESBL pneumonia-septicemia. 
Groups of 11 rats were treated 12-hourly for 10 days with Placebo (physiological saline) or  
25 mg/kg/day meropenem, started at 24 hours after initiation of infection. A) Rat survival 
(Kaplan-Meier curves) of rats reaching humane endpoints. B) Box plots of pooled body 
temperatures showing the range of the data; the dashed line at 34 °C represents the humane 
endpoint. C) Body weight loss from the onset of infection (mean ± standard deviation). 
 
Pharmacokinetics of meropenem in rats with ESBL pneumonia-septicemia 
Meropenem plasma concentrations were determined to investigate the steady-state 
pharmacokinetic profile of meropenem at MED in rats with ESBL pneumonia-
septicemia. The plasma concentration-time curve indicated a one-compartment 
deposition (Figure 5). The corresponding estimated pharmacokinetic parameters are 
displayed in Table 2. The ƒT>MIC for K. pneumoniae ESBL was  
5.18 hours, which was 43.17% of the twice-daily dosing interval. For K. pneumoniae KPC, 
the ƒCmax (13.37 mg/L) did not reach the respective meropenem MIC (16 mg/L), 
resulting in a ƒT>MIC of 0 hours. 
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Figure 5. Plasma concentrations of total (bound and unbound) meropenem (MEM) in rats with 
ESBL pneumonia-septicemia. Rats were treated 12-hourly with 3 consecutive doses of  
25 mg/kg/day meropenem, started at 24 hours after initiation of infection. The concentration-
time curve predicted by a one-compartment model of extravascular administration was 
imposed over the observed concentrations at each time point in 3 rats (mean ± standard error). 
 
Table 2. Pharmacokinetic parameters of meropenem in rats with ESBL pneumonia-septicemia 
Pharmacokinetic 
parameters 
V/F CL/F t1/2 ƒCmax 
ƒT>MIC 
0.063 mg/L 16 mg/L 
Units L/kg L/kg/h h mg/L h % h % 
Estimate 1.03 1.17 0.61 13.37 5.18 43.17 0.00 0.00 
SEM 0.07 0.06 0.03 1.43 0.24 2.00 0.00 0.00 
Plasma concentrations of meropenem in rats with ESBL pneumonia-septicemia treated  
12-hourly with 3 consecutive doses of 25 mg/kg meropenem, started at 24 hours after initiation 
of infection. The ƒT>MIC was calculated based on unbound meropenem concentrations using 
the MIC of K. pneumoniae ESBL (0.063 mg/L) and the MIC of K. pneumoniae KPC (16 mg/L) 
and is shown in hours (h) as well as percentage of the 12-hour dosing interval (%). SEM, 
standard error of the mean; V, volume of distribution; F, bioavailability; CL, clearance; t1/2, 
elimination half-life time; ƒCmax, highest unbound drug concentration reached in blood plasma; 
ƒT>MIC, cumulative percentage of a 12-hour period that the unbound fraction of drug exceeds 
the MIC. 
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Therapeutic efficacy of meropenem and tigecycline in rats with KPC 
pneumonia-septicemia 
Rats with KPC pneumonia-septicemia were treated with 25 mg/kg/day meropenem 
12-hourly for 10 days, which correlates to a ƒT>MIC of 0 hours. This treatment 
resulted in survival of only 1/12 rats with KPC pneumonia-septicemia (Figure 6), which 
was not significantly different compared to the placebo-treated rats (p=0.5728). The 
failure of meropenem was also reflected in the body temperatures and the body weight 
values. 
Next, the therapeutic response to tigecycline treatment of 25 mg/kg/day 12-hourly for 
10 days was investigated in rats with KPC pneumonia-septicemia. This dosage was the 
MED of tigecycline found in a previous unilateral pneumonia-septicemia rat model 
caused by an identical K. pneumoniae ESBL strain11. The 25 mg/kg/day tigecycline 
dosage resulted in survival of all rats with bilateral KPC pneumonia-septicemia. Body 
temperatures remained stable, but body weights decreased slowly over time (Figure 6). 
Low bacterial numbers were present in the lungs of the surviving rats, with a median of 
2.6 × 103 K. pneumoniae and an upper limit of 1.9 × 104 K. pneumoniae. None of the 
isolated bacteria showed a change in susceptibility to tigecycline. 
 
Discussion 
Antimicrobial resistance continues to spread worldwide and is often encountered in 
clinically relevant organisms such as K. pneumoniae. This bacterial species is becoming 
increasingly resistant to currently available antibiotics3,34, with many isolates only 
susceptible to a limited number of ‘last-resort’ antibiotics such as colistin and 
tigecycline. However, much debate still exists on the clinical efficacy of tigecycline in 
relation to the dose administered. Freire et al. in 2010 showed a lower therapeutic 
response for tigecycline than imipenem (using a dosing regimen of initial 100 mg 
followed by 50 mg every 12 hours in a group of ventilated patients), a study often 
referenced as showing the limited efficacy of tigecycline in this situation35. Additionally,  
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Figure 6. Therapeutic efficacy of meropenem (MEM) or tigecycline (TGC) in rats with KPC 
pneumonia-septicemia. Groups of 11 rats were treated 12-hourly for 10 days with Placebo 
(physiological saline) or 25 mg/kg/day meropenem or 25 mg/kg/day tigecycline, started at  
24 hours after initiation of infection. A) Rat survival (Kaplan-Meier curves) of rats reaching 
humane endpoints. B) Box plots of pooled body temperatures showing the range of the data; 
the dashed line at 34 °C represents the humane endpoint. C) Body weight loss from the onset 
of infection (mean ± standard deviation). 
 
the administration of tigecycline treatment has been associated with an increased death 
rate5, and a number of case reports have indicated serious complications in patients as 
a consequence of tigecycline treatment36-40. On the other hand, a meta-analysis by 
Falagas et al. in 2014, concluded that high-dose tigecycline regimens may be effective 
for the treatment of severe bacterial infections9 and a meta-analysis by Gong et al. 
6
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concluded that high-dose tigecycline regimens did not elevate the risk of toxic side 
effects41. Further, pharmacokinetic and pharmacodynamic studies have indicated that 
higher dosages of tigecycline can be administered to humans, resulting in improved 
therapeutic efficacy6,42,43. This has been corroborated by more recent studies which 
have shown that administration of high-dose tigecycline regimens are tolerated and 
result in improved therapeutic efficacy in infected patients compared to conventional 
tigecycline dosing43-47. Cunha et al., reported clinical efficacy using once-daily high-dose 
tigecycline monotherapy in the treatment of multidrug-resistant Gram-negative bacilli 
and published recommendations for high-dose regimens7,42. These studies are also 
supported by the in vitro modeling studies of Tsala et al., suggesting that higher doses of 
tigecycline are required to achieve therapeutic efficacy48 and by a Monte Carlo 
simulation analysis of standard and high-dose tigecycline against carbapenemase-
producing K. pneumoniae, showing that the cumulative fractional response rate of >90% 
was only achievable with the high-dose tigecycline regimen49. Taken together, these 
studies suggest that current clinical guidelines on the antibiotic prescribing of tigecycline 
may need to be revised upwards in order to reach a clinically effective dose. In this 
respect, EUCAST has recently published a new “Guidance Document on Tigecycline 
Dosing by the EUCAST”, recommending the use of high-dosage tigecycline treatment 
in seriously ill patients infected with multidrug-resistant bacteria8. 
Complicating this debate is the fact that tigecycline is frequently applied in the treatment 
of infections caused by multidrug-resistant bacteria as part of combination therapy 
rather than monotherapy10. Based on these limitations, and on accompanying 
discussions relating to the efficacy of tigecycline administration, a study was established 
into the efficacy of high-dose tigecycline monotherapy using a newly established rat 
model of fatal acute pneumonia-septicemia caused by ESBL- or KPC-producing  
K. pneumoniae with meropenem as a comparator drug. This model is representative of a 
particularly severe multidrug-resistant infection in human patients50-52 and allows for 
research comparing the therapeutic efficacy of individual antibiotics at similar 
conditions of severity, duration of infection, and host defense, which is not possible 
with most comparative clinical efficacy studies on tigecycline treatment9,10. 
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 Treatment with tigecycline at 25 mg/kg/day 12-hourly for 10 days resulted in 100% 
survival of rats with KPC pneumonia-septicemia and normalization of body 
temperature. In our previous study using the K. pneumoniae ESBL unilateral pneumonia-
septicemia model, this tigecycline dosage was the successful MED, generating 100% 
survival of rats and normalization of body temperature. In the same study, the efficacy 
of tigecycline was found to be dose-dependent and was correlated to the ratio of the 
area under the plasma concentration-time curve (AUC) to the MIC (AUC/MIC). The 
AUC during a 24 hour period (AUC0-24h) for this tigecycline dosage in rats with was 
similar to the AUC0-24h of high-dose tigecycline treatments in human patients (a loading 
dose of 300 mg tigecycline followed by 150 mg tigecycline every 12 hours)53. For 
pneumonia-septicemia caused by K. pneumoniae ESBL with a tigecycline MIC of 1 mg/L, 
the AUC/MIC was 34.29 mg·h/L at a tigecycline dosage of 25 mg/kg/day which was 
the MED of tigecycline for survival of all rats. As the tigecycline MIC of K. pneumoniae 
KPC is 2 mg/L, the extrapolated AUC/MIC ratio for KPC pneumonia-septicemia at a 
tigecycline dosage of 25 mg/kg/day is calculated to be 17.15 mg·h/L. Despite this 
MED having a lower AUC/MIC ratio in rats with bilateral KPC pneumonia-septicemia, 
the tigecycline treatment at 25 mg/kg/day 12-hourly for 10 days remained successful. 
Unlike the meropenem treatment, this treatment did not result in normalization of body 
weight, which might be explained by either the persistence of low bacterial numbers in 
the lungs of the rats at the end of treatment, or by potential gastro-intestinal side effects 
of tigecycline. 
Treatment with meropenem in rats with ESBL pneumonia-septicemia showed a clear 
dose-response relationship. At the MED of 25 mg/kg/day, meropenem resulted in 
100% rat survival, in stabilization of body weights, in body temperatures returning to 
the circadian rhythm, and effected bacterial elimination from the lung tissue at the end 
of treatment. Meropenem concentrations in rat plasma remained above the MIC of  
K. pneumoniae ESBL for >5 hours, achieving the bactericidal target of carbapenem 
regimens in human patients, which is a ƒT>MIC of approximately 40% of the dosing 
interval54. In terms of total dosage, meropenem at 25 mg/kg/day 12-hourly for 10 days  
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in rats is similar to the current clinical treatment of ESBL pneumonia-septicemia, 
although in patients, an 8-hourly meropenem schedule is more common55. 
The MED of meropenem in rats with ESBL pneumonia-septicemia was not successful 
in rats with KPC pneumonia-septicemia which is in line with the difference in 
susceptibility of K. pneumoniae ESBL and K. pneumoniae KPC. This difference in 
susceptibility resulted in different ƒT>MIC values for the two strains, with unbound 
meropenem concentrations in rat plasma remaining above the MIC of K. pneumoniae 
ESBL for >5 hours, whereas the ƒCmax (<14 mg/L) did not reach the meropenem MIC 
of K. pneumoniae KPC (16 mg/L), resulting in a ƒT>MIC of 0 hours. The respective 
therapeutic success or failure of this meropenem dose in both infection models can be 
explained as a consequence of the time-dependent bactericidal activity of meropenem, 
which was shown in the in vitro TKK data in the present study, as well as in other in vivo 
pharmacokinetic/pharmacodynamic studies56. 
The pneumonia-septicemia model established in the present study is representative of 
a particularly severe human infection with K. pneumoniae bacteria resulting in rapid 
mortality when left untreated50-52. Further, although the tigecycline MIC of K. pneumoniae 
ESBL (1 mg/L) and K. pneumoniae KPC (2 mg/L) are considered resistant, these MICs 
remain within the wild-type distribution of tigecycline MICs for K. pneumoniae26,28. In 
view of these factors, the successful treatment of this animal model necessitated the use 
of a high-dose tigecycline regimen, as the AUC of the tigecycline monotherapy MED 
administered to rats with ESBL pneumonia-septicemia exceeds the AUC of the 
tigecycline dosage which is conventionally administered to infected patients (50 mg 
tigecycline every 12 hours)57, demonstrating the effectiveness of high-dosage tigecycline 
regimens in the treatment of severe multidrug-resistant bacterial infections. The scope 
of the current research was limited to investigating the efficacy of a high-dosage 
tigecycline regimen in a model of pneumonia-septicemia caused by two isogenic 
multidrug-resistant K. pneumoniae strains. Future research can improve on the 
generalizability of these results by investigating high-dosage tigecycline regimens in the 
treatment of infection models caused by other K. pneumoniae strains or different Gram-
negative bacterial species. Another interesting avenue for further research with the 
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 current pneumonia-septicemia model would be the investigation of high-dose 
meropenem regimens58 or high-dose meropenem and high-dose tigecycline 
combination regimens59. 
 
Conclusions 
The data obtained in the current study provide evidence that high-dosage tigecycline 
monotherapy is effective in a rat model representative of human pneumonia-septicemia 
caused by multidrug-resistant K. pneumoniae. Based on the therapeutic tigecycline dose 
observed in this publication, the limited susceptibility to tigecycline of both strains, and 
current clinical guidelines, the in vivo data reported in the present study further supports 
recent literature on the applicability of high-dosage tigecycline as a treatment of ‘last 
resort’ in patients with severe multidrug-resistant K. pneumoniae infections. The present 
work involves a clinically relevant animal model for multidrug-resistant K. pneumoniae 
infections that facilitates the future investigation of antibiotics and novel therapeutic 
approaches to pneumonia-septicemia.  
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 Supplementary Table S1. Genotypic characterization of K. pneumoniae strains 
Strain 
ATCC 
43816™ 
EMC 
2003 
EMC 
2014 
ATCC 
13883™ 
ATCC 
700603™ 
ATCC 
BAA1705™ 
Antibiotic 
profile 
WT Parent ESBL KPC WT ESBL KPC 
Sequence 
type 
493 493 493 3 489 258 
CTX-M 
1 negative negative negative negative negative negative 
2 negative negative negative negative negative negative 
8 negative negative negative negative negative negative 
9 negative negative negative negative negative negative 
25 negative negative negative negative negative negative 
TEM negative negative positive negative negative positive 
SHV positive positive positive positive positive positive 
OXA 
1 negative negative negative negative negative negative 
48 negative negative negative negative negative negative 
KPC negative negative positive negative negative positive 
NDM-1 negative negative negative negative negative negative 
Sequence types were determined by HiMLST and the presence of plasmid-mediated resistance 
genes was determined using PCR assays for the K. pneumoniae strains used in this study and 
relevant K. pneumoniae ATCC reference strains. K. pneumoniae ESBL and K. pneumoniae KPC 
both contained an SHV-5 gene, and the K. pneumoniae KPC strain had gained an additional 
KPC gene. Both K. pneumoniae strains belonged to the same sequence type (ST 493) compared 
to the WT parent strain, but were genetically different compared to the three ATCC reference 
strains, which each belonged to a different sequence type indicating the genetic diversity 
among these strains.  
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Supplementary Table S2. Phenotypic characterization of K. pneumoniae strains 
Strain 
ATCC 
43816™ 
EMC 
2003 
EMC 
2014 
ATCC 
13883™ 
ATCC 
700603™ 
ATCC 
BAA1705™ 
Antibiotic profile WT Parent ESBL KPC WT ESBL KPC 
Ampicillin 16 ≥32 ≥32 ≥32 ≥32 ≥32 
Amoxicillin/ 
Clavulanic Acid 
≤2 4 ≥32 ≤2 16 ≥32 
Piperacillin/ 
Tazobactam 
≤4 ≤4 ≥128 ≤2 32 ≥128 
Cefuroxime 2 16 ≥64 4 ≥64 ≥64 
Cefuroxime Axetil 2 16 ≥64 4 ≥64 ≥64 
Cefoxitin ≤4 ≤4 ≤4 ≤4 ≥64 ≥64 
Cefotaxime ≤1 2 8 ≤1 8 8 
Ceftazidime ≤1 ≥64 ≥64 ≤1 32 16 
Cefepime ≤1 ≤1 2 ≤1 ≤1 2 
Imipenem ≤0.25 ≤0.25 ≥16 0.5 ≤0.25 ≥16 
Meropenem ≤0.25 ≤0.25 ≥16 ≤0.25 ≤0.25 ≥16 
Gentamicin ≤1 ≥16 ≥16 ≤1 ≥16 4 
Tobramycin ≤1 ≥16 ≥16 ≤1 8 ≥16 
Ciprofloxacin ≤0.25 ≤0.25 ≤0.25 ≤0.25 0.5 ≥4 
Norfloxacin ≤0.5 ≤0.5 ≤0.5 ≤0.5 2 ≥16 
Trimethoprim ≤0.5 ≤0.5 ≤0.5 ≤0.5 2 ≥16 
Trimethoprim/ 
sulfamethoxazole 
≤1 ≤1 ≤1 ≤1 ≤1 ≥16 
Colistin ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 
MICs (mg/L) were determined using the automated VITEK®2 antimicrobial identification 
system for the K. pneumoniae strains used in this study and relevant K. pneumoniae ATCC 
reference strains. Trimethoprim/sulfamethoxazole was expressed as the trimethoprim 
concentration. Interpretation of antimicrobial susceptibility was defined by the VITEK® 
antimicrobial identification system as susceptible, intermediate (italic), or resistant (bold) 
based on EUCAST 2014 guidelines. K. pneumoniae ESBL EMC2003 and K. pneumoniae KPC 
EMC2014 had few major differences in susceptibility profile compared to ATCC reference 
strains.
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Supplementary Figure S1. Representative lung histopathology in lung tissue from rats with 
K. pneumoniae KPC pneumonia/septicaemia at 24 hours after initiation of infection. (A-C) 
Sections stained with HE at different magnifications. (D) Section stained with Gram stain. An 
outer hemorrhagic zone of the lesion was observed (in areas next to uninfected tissue) in which 
the alveoli were filled with mucoid exudates dominated by edema fluid and a light cellular 
infiltrate. More extensive areas of pneumonia were observed towards the center of the lesion 
i.e. in the zone of early consolidation. In these areas alveoli were packed with predominantly 
polymorphonuclear leukocytes and alveolar walls were necrotic. Numerous encapsulated Gram-
negative bacilli were freely present in the exudates within the hemorrhagic zone of the lesions. 
KPC, K. pneumoniae carbapenemase producing.  
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Abstract 
Introduction: Antimicrobial peptides (AMPs) have seen limited clinical use as antimicrobial 
agents, largely due to issues relating to toxicity, short biological half-life, and lack of efficacy 
against Gram-negative bacteria. However, the development of novel AMP-nanomedicines, i.e. 
AMPs entrapped in nanoparticles, has the potential to ameliorate these clinical problems. The 
authors investigated two novel nanomedicines based on AA139, an AMP currently in 
development for the treatment of multidrug-resistant Gram-negative infections.  
Methods: AA139 was entrapped in polymeric nanoparticles (PNP) or lipid-core micelles (MCL). 
The antimicrobial activity of AA139-PNP and AA139-MCL was determined in vitro. The 
biodistribution and limiting doses of AA139-nanomedicines were determined in uninfected rats 
via endotracheal aerosolization. The early bacterial killing activity of the AA139-nanomedicines 
in infected lungs was assessed in a rat model of pneumonia-septicemia caused by an 
extended-spectrum β-lactamase-producing Klebsiella pneumoniae. In this model, the 
therapeutic efficacy was determined by once-daily (q24h) administration over 10 days.  
Results: Both AA139-nanomedicines showed equivalent in vitro antimicrobial activities (similar 
to free AA139) and in uninfected rats they exhibited longer residence times in the lungs 
compared to free AA139 (~20% longer for AA139-PNP and ~80% longer for AA139-MCL), 
as well as reduced toxicity enabling a higher limiting dose. In rats with pneumonia-septicemia, 
both AA139-nanomedicines showed significantly improved therapeutic efficacy in terms of an 
extended rat survival time, although survival of all rats was not achieved.  
Conclusion: These results demonstrate potential advantages that can be achieved using AMP-
nanoformulations. AA139-PNP and AA139-MCL may be promising novel therapeutic agents for 
the treatment of patients suffering from multidrug-resistant Gram-negative pneumonia-
septicemia. 
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Introduction 
Pneumonia is responsible for over 230,000 deaths and €10 billion in economic costs 
across the European Union (EU) every year1,2, with Gram-negative bacteria being the 
primary causative pathogens in ~70% of healthcare-associated pneumonia cases3. 
Therefore, the availability of effective antimicrobial drugs is crucial if clinicians are to 
adequately treat patients suffering from Gram-negative bacterial pneumonia4. 
Unfortunately, the current crisis of growing antimicrobial resistance and fewer 
antimicrobials reaching the market has resulted in a lack of new antimicrobials that are 
effective against multidrug-resistant Gram-negative bacteria5,6. In response to this 
growing healthcare crisis, researchers have focused on the development and 
improvement of known but underutilized antibiotic classes to generate new approaches 
for treating bacterial pneumonia. 
One class of antibiotics under investigation is the antimicrobial peptides (AMPs), a 
broad family of antibiotics that are produced in nature by organisms as a natural defense 
against microbes7. Although AMPs have been known since the 1950’s, this family of 
antibiotics has seen only limited use for the treatment of pneumonia, largely due to a 
number of hurdles that have limited their clinical use, including toxic side-effects8, short 
biological half-life due to degradation by proteases8,9, and limited efficacy against Gram-
negative bacteria10.  
Some of these issues may be offset by the concurrent development of new AMPs and 
new delivery systems for these antimicrobials. For example, entrapment of AMPs into 
nanoparticles to produce nanomedicines may generate several solutions to the hurdles 
traditionally associated with the clinical utility of AMPs in the treatment of multidrug-
resistant infections11,12. Notably, nanomedicine formulations could potentially reduce 
toxic side-effects and extend the biological half-life of AMPs13. Further, the direct 
delivery of antibiotics to the site of infection represents an additional therapeutic 
improvement14, which could facilitate increased antibiotic activity at the actual site of 
infection15,16 and lead to reduced systemic toxicity and ‘collateral damage’ to 
patients17,18.  
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 As such, the direct delivery of AMP nanomedicines to the lungs is a promising research 
strategy at a time when traditional antibiotics and treatment for respiratory tract 
infections are becoming ineffective19,20. In this respect, the 7th Framework Programme 
of the EU provided funding to the PneumoNP research consortium, with the goal of 
developing and investigating novel AMP nanomedicines in the treatment of 
pneumonia21. 
One of the AMPs investigated in the PneumoNP project was AA139, an AMP originally 
isolated from the marine lugworm Arenicola marina as ‘Arenicin-3’ and subsequently 
further developed to decrease the original AMP’s plasma protein binding properties, 
cytotoxicity, and hemolytic activity22,23. AA139 is a cationic AMP with a 21-residue 
amphipathic hairpin structure that appears to have a dual mode of action involving 
direct binding of the AMP to membrane phospholipids and interruption of 
phospholipid transportation pathways, resulting in membrane dysregulation and 
bacterial cell death22,24. AA139 has previously demonstrated potent in vitro and in vivo 
activity against multidrug-resistant Gram-negative bacteria25,26 and is not readily 
absorbed into systemic circulation from the lungs following inhalation in mice27.  
With respect to the development of nanomedicines, PneumoNP utilized several 
different nanomedicine formulations including polymeric nanoparticles (PNP) and 
lipid-core micelles (MCL). PNP are hydrophilic dextran-based single-chain polymer 
nanoparticles to which cationic drugs like AA139 can be attached by electrostatic 
interaction for increased drug delivery28. MCL are self-assembling colloidal 
nanoparticles with a hydrophilic surface and a hydrophobic core in which drugs like 
AA139 can be entrapped for drug delivery29. Both PNP30 and MCL31 are suitable for 
nanomedicine formulation due to their favorable biocompatibility, non-toxicity, 
biodistribution, and ease of modification. PNP and MCL are promising nanocarriers 
for pulmonary drug delivery, as the relatively small size of PNP (1–20 nm) may allow 
for improved penetration of the respiratory mucus32, and MCL have been shown to 
facilitate sustained drug release in the lungs33. 
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In the present study, two novel AA139 nanomedicines were developed using either 
PNP or MCL: AA139-PNP, in which AA139 has been attached to PNP by electrostatic 
interactions; and AA139-MCL, in which AA139 has been enclosed in the hydrophobic 
core of MCL. Their antimicrobial activity was assessed first via in vitro concentration- 
and time-dependent bactericidal activity studies against extended-spectrum β-lactamase 
(ESBL)-producing Klebsiella pneumoniae. In vivo studies were then performed involving 
the administration of the nanomedicines by endotracheal aerosolization as a means of 
direct delivery to the lungs, the primary site of infection in pneumonia. First, the 
biodistribution and residence time in the lungs of the nanomedicines was determined 
and the maximum tolerated dose (MTD) was assessed in uninfected rats. Next, the early 
bacterial killing activity of the nanomedicines was assessed in a rat model of pneumonia-
septicemia caused by ESBL-producing K. pneumoniae. Finally, the therapeutic efficacy of 
the nanomedicines was determined in the pneumonia-septicemia rat model by once-
daily (q24h) administration over 10 days. 
 
Materials and methods 
Peptide, nanocarriers, chemical agents, and solvents 
AA139 in Ringer’s acetate solution was obtained from Adenium Biotech ApS 
(Copenhagen, Denmark). PNP were produced at CIDETEC (Donostia-San Sebastián, 
Spain). MCL were produced at Utrecht University (Utrecht, the Netherlands). 
Polyethylene glycosylated distearyl phosphatidyl ethanolamine (DSPE-PEG2000)  
Na-salt was purchased from Lipoid GmbH, Ludwigshafen, Germany. Ultrapure water 
(18MΩcm) was generated using a Milli-Q® system (MilliporeSigma, Bedford, MA, 
USA). Dextran, glycidyl methacrylate (GMA), dimethyl sulfoxide (DMSO),  
3-mercaptopropionic acid (3-MPA) and 2,2’-(ethylenedioxy)diethanethiol were of 
analytical grade and purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). 
Phosphate-buffered saline (PBS) was purchased from Scharlab SL (Barcelona, Spain). 
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 Preparation of AA139 nanomedicines 
AA139 was entrapped in the two different nanoparticles PNP or MCL to prepare two 
distinct AA139 nanomedicines: PNP were used to prepare polymeric nanoparticulate 
AA139 nanomedicines (AA139-PNP) and MCL were used to prepare lipid-core 
micellar AA139 nanomedicines (AA139-MCL). 
Preparation of AA139-PNP: Dextran-based PNPs functionalized with 3-MPA were 
obtained as previously described in the literature28. To prepare AA139-PNP, loading of 
AA139 to PNP was carried out by non-covalent interaction with an AA139-to-PNP 
mass ratio of 10%. In brief, 100 mg AA139 was incubated with 1 g PNP in 25 mL of 
saline solution at pH = 7.2 for 15 hours at room temperature. This was the maximum 
amount of AA139 that could be used, as proportions of AA139 greater than 10% 
resulted in aggregation as larger particles sizes were observed by dynamic light scattering 
(DLS). The crude complex was then purified by membrane ultrafiltration using 
Vivaspin® 500 10 kDa molecular weight cutoff (MWCO) polyethersulphone (PES) 
centrifugal concentrators (GE Healthcare, Chicago, USA) and aqueous saline solution 
at pH = 7.2 to eliminate any unbound AA139. The maximum loading, established as 
the maximum concentration of peptide at which no peptide was collected in the filtrate, 
was 0.1 mg AA139/1 mg PNP. The AA139-PNP particle dispersions (corresponding 
to 5 mg/mL AA139 and 50 mg/mL PNP) in normal saline solution (NSS) of 0.9 wt. % 
NaCl had a mean size of 20 nm as determined by DLS and were negatively charged. 
High-performance liquid chromatography (HPLC) studies demonstrated that the 
nanomedicines were stable for at least 1 year when frozen at -20°C. Size measurement 
of AA139-PNP after freeze-thaw conditions demonstrated that the diameter of the 
nanomedicines was not affected by these storage conditions. Further dilution of this 
pristine dispersion of AA139-PNP in NSS for use in in vitro and in vivo experiments did 
not show any sign of instability.  
Preparation of AA139-MCL: Entrapment of AA139 in MCL was carried out during the 
formation of MCL, which were prepared by using a thin lipid film hydration method.  
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In brief, a thin lipid film of DSPE-PEG2000 was prepared by dissolving the lipid in 
MeOH in a glass round-bottom flask and evaporation of the organic solvent under 
reduced pressure. Residual solvent was removed under a nitrogen flow. The lipid film 
was hydrated at 30 °C in PBS containing the AA139 peptide at a 1:3 molar ratio of the 
peptide to DSPE-PEG2000. This was the maximum amount of AA139 that could be 
used, as higher proportions of AA139 resulted in aggregation as determined by DLS. 
The eluted product was collected in 100 µL fractions. AA139-MCL have a size of  
15.4 (±1.5) nm according to DLS measurement and a near neutral zeta-potential of  
-2.1 (±2.2) mV as was measured from MCL prepared in 10 mM HEPES buffered saline 
(HBS) buffer. The loading was between 10–13 mg/mL AA139 in 11–14 mM DSPE-
PEG2000 with a loading efficiency of 100% (±4%). Further dilution of this pristine 
dispersion of AA139-MCL in NSS for use in in vitro and in vivo experiments did not 
show any sign of instability.  
The preparation of unloaded PNP and MCL for control experiments was identical to 
the preparation process of their respective AA139-nanomedicines. The concentration 
of unloaded PNP and MCL was adjusted with NSS after the preparation process to 
ensure that the administered concentration of unloaded PNP and MCL was identical to 
the administered concentration of nanoparticles in the nanomedicine formulations. 
All nanomedicine preparations were transported to partner locations in insulated 
thermal boxes with cooling elements frozen at -20 °C to ensure that sample 
temperatures did not exceed -5 °C. A selection of samples were sent back to the original 
partner faculties (CIDETEC or Utrecht University) for re-analysis to confirm stability 
under these transportation conditions. 
Bacterial strains 
The ESBL-positive strain K. pneumoniae ESBL EMC2003 (referred to in this publication 
as K. pneumoniae ESBL) used in this study has previously been characterized in terms of 
genotype and antimicrobial susceptibility profile and was used to establish pneumonia-
septicemia in rats34. The stability of the plasmid-containing K. pneumoniae ESBL strain 
was confirmed through five consecutive passages in Mueller Hinton II (MH-II) broth 
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 (Becton Dickinson BV, Vianen, The Netherlands). The virulence of the bacterial strain 
was maintained by rat lung passage every 12 months. 
Concentration- and time-dependent antimicrobial activity of AA139, 
AA139-PNP, and AA139-MCL in vitro 
The antimicrobial activity of AA139, AA139-PNP, and AA139-MCL was compared 
using the time-kill kinetics (TKK) assay as previously described35. Three two-fold 
increasing antibiotic concentrations were used, representing: 1) the lowest 
concentration at which AA139 showed bacterial growth inhibition; 2) the minimum 
inhibitory concentration (MIC) of AA139; and 3) the lowest concentration at which 
AA139 led to complete bacterial killing after 24 hours of antibiotic exposure. These 
AA139 concentrations were respectively: 2 mg/L, 4 mg/L, 8 mg/L. AA139-PNP 
(corresponding to 20 mg/L, 40 mg/L, 80 mg/L of PNP) and AA139-MCL 
(corresponding to 2.2 µM, 4.5 µM, 9 µM of MCL) were tested at the same AA139 
concentrations based on the AA139 content of the nanomedicines. Samples were 
serially 10-fold diluted and sub-cultured on MH-II agar plates (Becton Dickinson BV) 
for CFU counts after 24 hours at 37 °C.  
Animals 
Female Sprague Dawley rats bred at Janvier Labs (Le Genest-Saint-Isle, France) were 
used for the in vivo imaging studies (age, 6-8 weeks). Specified pathogen-free (SPF) male 
strain RP/AEur/RijHsd albino rats bred at the Laboratory Animals Center of Erasmus 
University Medical Center Rotterdam (Erasmus MC) were used for the in vivo 
tolerability and infection studies. Rats (age, 10-18 weeks; body weight, 250-350 g) were 
housed individually in ventilated cages with food and water ad libitum. Rats were 
randomly allocated to experimental groups once they reached the appropriate age and 
body weight. Group sizes were based on estimates of the hazard ratio. Euthanasia was 
applied by CO2 exposure when humane endpoints were reached or at termination of 
experiments.  
Infected rats were monitored 12-hourly for 11 days to assess the disease progression 
and signs of acute toxicity as well as pre-defined humane endpoints by changes in body 
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temperature and body weight, and by external symptoms of disease including 
ungroomed appearance, pallor, nose bleeding, lack of reactivity, inactivity, instability, or 
abnormal breathing of rats. Rat survival was based on rats reaching humane endpoints, 
at which point euthanasia was applied by CO2 exposure. The rat survival parameter thus 
reflects rats reaching humane endpoints. After dissection, bacteria isolated from lung 
and blood were identified by matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) mass spectrometry (Bruker Daltonics, Bremen, Germany) to rule out 
co-infection as a pre-established exclusion criterium.  
Ethics 
Animals were maintained and handled in accordance with the Guidelines for 
Accommodation and Care of Animals (European Convention for the Protection of 
Vertebrate Animals Used for Experimental and Other Scientific Purposes). All animal 
procedures were performed in accordance with either the Dutch Animal 
Experimentation Act (BWBR0003081) or the Spanish policy for animal protection 
(RD53/2013), both of which meet the requirements of the European Union Animal 
Directive (2010/63/EU). Experimental procedures were approved by either the Ethical 
Committee of the Asociación Centro de Investigación Cooperativa en Biomateriales 
(CIC biomaGUNE) or by the Institutional Animal Care and Use Committee of the 
Erasmus MC. The current study was designed to abide by the three Rs principles of 
animal research (replace, reduce, refine) wherever possible36 and was written to 
conform to the animal research: reporting of in vivo experiments (ARRIVE) guidelines 
for reporting animal research37. 
Endotracheal aerosolization of AA139, AA139-PNP, and AA139-MCL in 
rats 
Rats were anesthetized with 3–5% isoflurane (IsoFlo®, Abbott Laboratories, Lake 
Bluff, IL, USA) in pure O2 for 5 minutes to ensure deep sedation. Animals were placed 
on a rodent workstand (Hallowell EMC, Pittsfield, MA, USA) in supine position 
inclined at a 45° angle. Endotracheal aerosolization was performed using a 
MicroSprayer®-Syringe Assembly for Rat (Penn-Century, Inc., Wyndmoor, PA, USA). 
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 A small animal laryngoscope (Penn-Century, Inc.) was used for visualization of the 
epiglottis, ensuring correct positioning of the tip just above the carina. A pre-defined 
volume of nanomedicine suspension was administered by endotracheal aerosolization, 
and rats remained in place for 10 seconds after administration to allow for inhalation.  
Radiolabelling of AA139, AA139-PNP, and AA139-MCL for imaging studies 
The radio-iodination of AA139 was carried out by electrophilic aromatic substitution 
on the tyrosine residues. For that purpose, 1 mg/mL AA139 solution was incubated 
with [124I]NaI (Perkin Elmer, Inc., Waltham, MA, USA) in 0.2 M sodium acetate buffer 
solution (50 µL, pH 5.5) for 2 hours at 25 °C in the presence of Iodo-beads® (Thermo 
Fisher Scientific, Waltham, MA, USA). The crude reaction mixture was purified by 
retention in a Sep-Pak® C18 Plus Light cartridge (Waters Corporation, Milford, MA, 
USA) and subsequent elution using 1 mL of 0.1% aqueous trifluoroacetic acid (TFA) 
solution/ethanol 20/80. The solvent was evaporated and the residue reconstituted with 
0.2 M sodium acetate buffer solution (300 µL, pH 5.5). Chemical and radiochemical 
purity were determined by HPLC with radioactive detection (radio-HPLC), using a 
Mediterranea™ Sea 18 (5 μm, 15 x 0.46 cm) column (Teknokroma Analítica SA, 
Barcelona, Spain) as the stationary phase and 0.1% solution of TFA in water (A) and 
0.1% solution of TFA in acetonitrile (B) as mobile phase, using the following gradient: 
initial, A-90% B-10%; 4 min, A-85% B-15%; 6 min, A-75% B-25%; 10 min, A-75%  
B-25%: 16 min, A-5% B-95%; 18 min, A-5% B-95%; 20 min, A-90% B-10%, 22 min, 
A-90% B-10%. Overall decay-corrected radiochemical yield was 62±2% and the molar 
activity was within the range of 0.5-1.5 GBq/µmol at the end of the synthesis. 
Radiochemical stability of the 124I-labelled AA139 was assessed by incubation in 
different media at 37 °C, including moderately acidic conditions (sodium acetate buffer, 
pH=5.5). At different time points, samples were withdrawn and analyzed by  
radio-HPLC using the experimental conditions described above. Radiochemical 
stability was directly calculated from chromatographic profiles. [124I]AA139 was stable 
in moderately acidic conditions similar to the infected lung environment for 48 hours 
and did not lead to detachment of 124I from AA139 (Supplementary Figure S1). 
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Labelled [124I]AA139-PNP and [124I]AA139-MCL nanomedicines were prepared as 
described above using [124I]AA139. For the preparation of [124I]AA139-MCL 
nanomedicines, Illustra™ Nap™-5 Columns pre-packaged with Sephadex™ G-25 
DNA grade (GE Healthcare, Chicago, IL, USA) were preconditioned with a sodium 
acetate buffer solution (10 mL, 0.02 M, pH=5.5) and then used for final purification by 
size exclusion chromatography, using PBS (10 mM, 0.8% NaCl, pH=7.4) as the mobile 
phase.  
The radiochemical yields of labelled [124I]AA139-PNP and [124I]AA139-MCL were 
calculated as the ratio between the amount of radioactivity present in [124I]AA139 
nanomedicines and the starting amount of [124I]AA139. When the [124I]AA139-to-PNP 
mass ratio was set to 1/10, quantitative attachment of AA139 to PNP was achieved and 
radiochemical yields close to 60% were achieved after purification of [124I]AA139-PNP. 
[124I]AA139 was efficiently attached to PNP as well as efficiently incorporated within 
MCL. Incorporation of [124I]AA139 into MCL resulted in >95% radiochemical yields 
in the initial fractions of [124I]AA139-MCL. 
Imaging studies of AA139, AA139-PNP, and AA139-MCL in uninfected rats 
Rats were administered 50 μL (ca. 1.85 MBq) of [124I]AA139, [124I]AA139-PNP, or 
[124I]AA139-MCL by endotracheal aerosolization in groups of 4 rats. One group of  
2 rats was administered with an equivalent amount of [124I]NaI in saline solution as the 
control. Immediately after endotracheal aerosolization animals were positioned in an 
eXploreVista computerized tomography (CT) and positron emission tomography 
(PET) small animal preclinical imaging system (GE Healthcare). A PET scan was 
acquired over 40 minutes, while anesthesia was maintained using 1–2% isoflurane in 
pure O2 and body temperature was maintained with a homeothermic blanket control 
unit (Bruker BioSpin GmbH, Karlsruhe, Germany) to prevent hypothermia. Animals 
were then allowed to recover from anesthesia and returned to their cages. Imaging 
sessions were repeated at 3, 6, 9, 15, and 24 hours after administration.  
After each PET acquisition, a CT scan (X-Ray energy: 40 kV, intensity: 140 µA) was 
performed for a later attenuation correction application in the image reconstruction, as 
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 well as for unambiguous localization of the radioactive signal. Random and scatter 
corrections were also applied to the reconstructed image (filtered back projection 
reconstruction algorithm), generating a 175×175×220 voxel image, with a 2 mm axial 
full width at half maximum (FWHM) spatial resolution in the center of the Field Of 
View (FOV). After reconstruction, images were analyzed using πMOD analysis 
software (version 3.4, PMOD Technologies Ltd., Zürich, Switzerland). Volumes of 
interest (VOIs) were manually delineated in the whole lungs, and the concentration of 
radioactivity in the lungs was determined for each compound and time point.  
Deposition of AA139 in lungs and blood of uninfected rats  
Deposition of AA139 in lungs and distribution to blood plasma was determined in  
6 rats which were sacrificed immediately after endotracheal aerosolization of 1 mg 
AA139 in 100 μL. The five lung lobes were collected separately, weighed, and 
homogenized in 2 mL NSS using the gentleMACS™ Octo Dissociator (Milteny Biotec 
BV, Leiden, The Netherlands). Blood plasma was obtained from whole blood collected 
via cardiac puncture in lithium-heparin tubes (Sarstedt BV, Etten-Leur, The 
Netherlands) and total rat blood plasma volume was estimated based on body weight38. 
AA139 concentrations were determined at Covance Laboratories (Harrogate, UK) 
using a liquid chromatography with tandem mass spectrometric detection (LC-MS/MS) 
bioanalytical assay.  
Limiting dose of AA139, AA139-PNP, and AA139-MCL in uninfected rats 
To determine the maximum tolerated dose (MTD) or maximum feasible dose (MFD), 
rats were administered 100 μL of AA139, AA139-PNP, or AA139-MCL by 
endotracheal aerosolization in groups of 11 rats, starting at a low dose of 0.125 mg 
AA139 based on the AA139 content of the nanomedicines (corresponding to  
1.25 mg/mL AA139; 12.5 mg/mL PNP; 0.14 mM MCL). 100 μL of normal saline 
solution (NSS) was used as control treatment. After administration, animals were placed 
on an electric heating pad to emerge from anesthesia before being placed back in cages.  
Rats were then regularly checked for signs of acute toxicity over 24 hours. After  
24 hours, rats were sacrificed and blood plasma was obtained from whole blood 
8
183
Therapeutic efficacy of novel antimicrobial peptide AA139-nanomedicines
145136 van der Weide BNW.indd   183 07-08-20   14:02
collected via cardiac puncture in lithium-heparin tubes to assess blood biomarkers for 
acute toxicity: alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), 
creatinine, and blood urea nitrogen (BUN) at the Department of Clinical Chemistry, 
Erasmus MC. When no acute toxicity was observed, the dose was increased two-fold, 
either until acute toxicity was observed (in which case the lower dose was determined 
as the MTD), or until the dose could not be further increased due to technical 
limitations, thereby reaching the MFD.  
Rat model of pneumonia-septicemia 
Bilateral K. pneumoniae ESBL pneumonia-septicemia was induced as described 
previously34. In short, suspensions of washed bacteria in the logarithmic phase of 
growth were used to prepare inocula. After intubation and cannulation of the trachea 
under anesthesia, rats were held in a vertical position. Rat lungs were inoculated with  
60 µL PBS containing 2 × 106 K. pneumoniae ESBL followed by inhalation. 
Early bacterial killing activity of AA139, AA139-PNP, and AA139-MCL in 
infected rats 
K. pneumoniae ESBL pneumonia-septicemia was induced in groups of 6 rats. At 24 hours 
after initiation of infection, rats were administered 100 μL of AA139, AA139-PNP, or 
AA139-MCL by endotracheal aerosolization administered at the same dose which was 
the MTD of free A139. Rats were administered 100 μL of unloaded PNP, unloaded 
MCL, or NSS as control treatment. Rats were sacrificed at 0 hours (before start of 
treatment) and at 2, 6 and 24 hours after start of treatment, 2 rats per timepoint per 
treatment group. Lungs were homogenized in 5 mL NSS using the gentleMACS™ Octo 
Dissociator (Milteny Biotec BV). Lung homogenates were diluted and sub-cultured on 
MH-II agar plates for CFU count after 20 hours incubation of plates at 37 °C. Blood 
plasma was obtained for determination of blood biomarkers of acute toxicity as 
described above.  
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 Therapeutic efficacy of AA139, AA139-PNP, and AA139-MCL in infected 
rats  
K. pneumoniae ESBL pneumonia-septicemia was induced in groups of 12 rats. At  
24 hours after initiation of infection, rats were administered 100 μL of AA139,  
AA139-PNP, or AA139-MCL once-daily (q24h) by endotracheal aerosolization. The 
treatments were all administered at their respective limiting dose, as well as at the MTD 
of free AA139. Rats were administered 100 μL of unloaded PNP, unloaded MCL, or 
NSS as control treatments. The disease progression was monitored twice-daily (q12h) 
for 10 days. Rats having reached humane endpoints were euthanized and dissected to 
check for the presence of K. pneumoniae ESBL in lungs and blood. 
Statistics 
Statistical significance of bacterial growth inhibition was determined by interpolating 
four-parameter sigmoidal growth curves and performing extra-sum-of-squares F-tests 
for the slope in Prism 5.01 (Graphpad Inc., San Diego, CA, USA). Kaplan-Meier rat 
survival curves were generated and statistical differences in rat survival rates were 
calculated using the log rank test in Prism 5.01. 
 
Results 
Concentration- and time-dependent antimicrobial activity of AA139, 
AA139-PNP, and AA139-MCL in vitro 
TKK assays were used to determine the antimicrobial activity of free AA139, AA139-
PNP, and AA139-MCL against K. pneumoniae ESBL over 24 hours. The bacterial 
populations rapidly increased in the absence of antibiotics within 24 hours of incubation 
(Figure 1). Free AA139 showed bactericidal activity resulting in bacterial growth 
inhibition at 2 mg/L AA139, a 100-fold reduction in bacterial numbers within 2 hours 
at 4 mg/L AA139, and near-complete bacterial killing after 24 hours at 8 mg/L AA139. 
AA139-PNP and AA139-MCL both showed similar bactericidal activity compared to 
free AA139, but the bacterial growth inhibition observed at 2 mg/L AA139 (p = 0.0461) 
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was not observed for 2 mg/L AA139-PNP and 2 mg/L AA139-MCL. Unlike free 
AA139 and AA139-MCL, AA139-PNP did not lead to complete bacterial killing after 
24 hours at 8 mg/L AA139-PNP. Unlike free AA139 and AA139-PNP, AA139-MCL 
did not result in a 100-fold reduction in bacterial numbers within 2 hours at 4 mg/L 
AA139-MCL, but at 8 mg/L AA139-MCL. The rebound after 24 hours observed for 4 
mg/L AA139-PNP and 4 mg/L AA139-MCL is likely the result of degradation of 
AA13925,39. Unloaded PNP and unloaded MCL did not show any antimicrobial activity. 
Biodistribution of AA139, AA139-PNP, and AA139-MCL in uninfected rats 
PET-CT image sequences were obtained for [124I]NaI (control), [124I]AA139, 
[124I]AA139-PNP, and [124I]AA139-MCL (Figure 2) in groups of 4 rats. The images 
reveal that the biodistribution patterns of [124I]AA139, [124I]AA139-PNP and 
[124I]AA139-MCL significantly differ from the control. When [124I]NaI was 
administered, it was rapidly cleared from the lungs and almost no signal was observed 
in this organ after three hours. On the contrary, a significant fraction of [124I]AA139 
and both [124I]AA139 nanomedicines were still visible within the lungs at the same time 
point. Of note, the images reveal that the residence time of [124I]AA139-PNP and 
[124I]AA139-MCL is longer than residence time of free [124I]AA139, since for the first 
two a clear signal within the lungs is still visible at 9, 15 and 24 hours after 
administration. The elimination pathways of the different species suggest excretion via 
urine and the gastrointestinal tract. 
The deposition of free AA139 among the five lung lobes and distribution to blood 
plasma in uninfected rats immediately after endotracheal aerosolization was determined 
by LC-MS/MS bioanalysis (Supplementary Figure S2). Total deposition in the lungs (ca. 
~88% of delivered dose) was high but showed considerable variation between the lung 
lobes, with most AA139 found in the relatively large left lobe and least AA139 found 
in the small right middle lobe. Total distribution to blood plasma (ca. ~2% of delivered 
dose) was low. These findings matched our in vivo imaging results, as well as the findings 
from an earlier study in which the deposition of 2-deoxy-2-[18F]fluoro-D-glucose (a 
clinically used radiotracer) using the same administration method was studied40. 
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Figure 1. Concentration- and time-dependent antimicrobial activity of AA139, AA139-PNP or 
AA139-MCL against K. pneumoniae ESBL. Bacterial cultures of K. pneumoniae ESBL were 
exposed to two-fold increasing concentrations of free AA139, AA139-PNP, or AA139-MCL for  
24 hours at 37 °C under shaking conditions. Shown are the median ± range of triplicate 
experiments. The dashed grey line indicates the lower limit of quantification being log 0.7. 
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 Figure 2. PET-CT coronal images showing biodistribution of radiolabelled compounds after 
endotracheal aerosolization in uninfected rats. Shown are PET-CT images obtained at different 
timepoints of A) [124I]NaI (control), B) [124I]AA139, C) [124I]AA139-PNP and D) [124I]AA139-
MCL. PET images have been overlaid with CT images of the same animals for accurate location 
of the radioactive signal. 
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Figure 3. Time-dependent concentration of radioactivity in rat lungs after endotracheal 
aerosolization of radiolabelled compounds. Shown are the mean ± standard deviation of four 
experiments as well as mono-exponential curves fitted to the experimental data. 
 
 
Residence time of AA139, AA139-PNP, and AA139-MCL in lungs of 
uninfected rats 
Quantification of the radioactivity in the lungs confirmed the trends observed in these 
in vivo sequences. To determine the biological half-life (t1/2) of the radiolabelled 
compounds in the rat lungs, the concentration of radioactivity in the lungs at different 
time-points were fitted to a mono-exponential decay equation (Figure 3). The residence 
time in lungs of free [124I]AA139 (t1/2 = 1.71 h) was longer by 21.6% when administered 
as [124I]AA139-PNP (t1/2 = 2.08 h) and longer by 82.4% when administered as 
[124I]AA139-MCL (t1/2 = 3.12 h). The residence time of the control [124I]NaI in lungs 
was very short (t1/2 = 0.09 h). 
Limiting dose of AA139, AA139-PNP and AA139-MCL in uninfected rats  
Rats were administered two-fold increasing doses of free AA139, AA139-PNP, AA139-
MCL, or NSS by endotracheal aerosolization in groups of 11 rats. As shown in  
Table 1, administration of NSS did not lead to any signs of acute toxicity or discomfort.  
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Table 1. Limiting dose of AA139, AA139-PNP, or AA139-MCL 
Treatment Limiting dose Dose-limiting toxicity 
AA139 MTD = 
0.25 mg/rat 
~1 mg/kg 
Acute toxicity (abnormal breathing) 
observed at 0.5 mg/rat 
AA139-PNP MFD = 
0.5 mg/rat 
~2 mg/kg 
Maximum feasible dose 
due to technical limitations 
AA139-MCL MTD = 
0.5 mg/rat 
~2 mg/kg 
Acute toxicity (abnormal breathing) 
observed at 1 mg/rat 
NSS   Well tolerated at this volume 
Treatment was administered to groups of 11 rats via endotracheal aerosolization of 100 μL 
suspension. Rats were regularly checked for signs of acute toxicity over 24 hours. When no 
acute toxicity was observed, the dose was increased two-fold, until acute toxicity was observed 
or until the dose could not be further increased due to technical limitations. 
 
 
Free AA139 was not tolerated when administered at doses above the MTD of 0.25 
mg/rat (~1 mg/kg) which induced acute toxicity in terms of abnormal breathing. 
AA139-PNP could be safely administered at the MFD of 0.5 mg/rat (~2 mg/kg), which 
was the highest possible dose that could be given due to technical limitations.  
AA139-MCL could be safely administered at the MTD of 0.5 mg/rat (~2 mg/kg), but 
induced acute toxicity in terms of abnormal breathing at higher doses. Analysis of blood 
biomarkers showed no indications of acute toxicity at limiting doses (Supplementary 
Figure S3). 
Early bacterial killing activity of AA139, AA139-PNP, and AA139-MCL in 
infected rats 
At 24 hours after initiation of infection, rats in groups of 6 were treated with a single 
dose of free AA139, AA139-PNP, or AA139-MCL at the MTD of free AA139  
(0.25 mg/rat; ~1 mg/kg) by endotracheal aerosolization. Rats were sacrificed at 2, 6, 
and 24 hours after administration to determine bacterial counts in the rat lungs, and 
blood biomarkers (Figure 4). In rats treated with NSS as placebo, bacterial numbers 
increased almost 100-fold within 24 hours. Following treatment with free AA139, 
bacterial counts exhibited a robust decrease by 6 hours after administration, but had 
rebounded at 24 hours to bacterial counts similar to placebo. Administration of 
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Figure 4. Early bacterial killing activity of AA139, AA139-PNP or AA139-MCL in rats with ESBL 
pneumonia-septicemia. At 24 hours after initiation of infection, rats were treated with a single 
dose of free AA139, AA139-PNP, or AA139-MCL at 0.25 mg (ca. ~1 mg/kg). Rats were sacrificed 
at 2, 6, and 24 hours after administration and dissected. Shown are the mean ± range of 2 
rats per timepoint per treatment group.  
 
 
AA139-PNP resulted in a rapid decrease of bacterial counts within 2 hours after 
administration, but began to rebound at 6 hours post-dose, generating similar bacterial 
counts to placebo by 24 hours bacterial decrease which persisted for at least 24 hours. 
Rats treated with unloaded PNP or unloaded MCL had bacterial counts similar to 
placebo, showing no bacterial decrease during treatment. Analysis of blood biomarkers 
showed no indications of acute toxicity of any treatment (Supplementary Figure S4). 
Early in vivo bacterial killing activity experiments were performed to screen those 
potential nanomedicine candidates that had showed promising in vitro bactericidal 
activity. However, only a limited number of rats were used in these screening 
experiments36, and consequently, statistical evaluation of these results could not be 
performed. 
Therapeutic efficacy of AA139, AA139-PNP and AA139-MCL, in infected 
rats 
At 24 hours after initiation of infection, rats in groups of 12 were treated with free 
AA139, AA139-PNP, or AA139-MCL once-daily (q24h) for 10 days. Placebo-treated 
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rats reached humane endpoints within 7 days after start of treatment (Figure 5). The  
treatment outcomes were statistically evaluated and compared; all p-values can be found 
in Table 2. Infected rats were monitored 12-hourly for the entire duration of the 
experiment. No signs of acute toxicity were observed following administration of 
compounds at the limiting dose once-daily (q24h) for 10 days. Rats treated with free 
AA139 at MTD (0.25 mg/rat; ~1 mg/kg), unloaded PNP, or unloaded MCL did not 
show an improvement in survival compared to placebo-treated rats. Rats treated with 
AA139-PNP at MFD (0.5 mg/rat; ~2 mg/kg) showed significantly improved survival 
compared to rats treated with free AA139 at MTD, unloaded PNP, or placebo. Rats 
treated with AA139-PNP at ½MFD did not show significantly improved survival. Rats 
treated with AA139-MCL at MTD (0.5 mg/rat; ~2 mg/kg) or at ½MTD showed 
significantly improved survival compared to rats treated with free AA139 at MTD, 
unloaded MCL, or placebo. No significant differences in therapeutic efficacy were 
found between AA139-PNP and AA139-MCL.   
 
 
 
Table 2. Statistical evaluation of rat survival after treatment with AA139, AA139-PNP, or 
AA139-MCL 
p-values 
Log-rank test 
Mantel-Cox 
Placebo 
(NSS) 
Unloaded AA139 
PNP MCL Free PNP MCL 
0.25mg 0.25mg 0.5mg 0.25mg 0.5mg 
Placebo (NSS)         
Unloaded-PNP 0.9329        
Unloaded-MCL 0.9689 0.9778       
AA139 0.25mg 0.9772 0.9879 0.9747      
AA139
-PNP 
0.25mg 0.0911 0.1218 0.1680 0.1208     
0.5mg 0.0131 0.0156 0.0161 0.0079 0.5966    
AA139
-MCL 
0.25mg 0.0043 0.0074 0.0061 0.0069 0.1140 0.7208   
0.5mg 0.0055 0.0068 0.0085 0.0056 0.0997 0.5966 0.7635  
Statistical evaluation using the Log-rank (Mantel-Cox) test of rat survival after once-daily 
(q24h) administration of free AA139, AA139-PNP, or AA139-MCL over 10 days. Significant  
p-values (p < 0.05) are indicated in bold.  
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Figure 5. Therapeutic efficacy of AA139, AA139-PNP, or AA139-MCL in rats with ESBL 
pneumonia-septicemia. At 24 hours after initiation of infection, groups of 12 rats were treated 
once-daily (q24h) for 10 days with free AA139, AA139-PNP or AA139-MCL. Shown are the 
survival curves (Kaplan-Meier) representing rats reaching humane endpoints.  
 
Discussion 
The clinical utility of many AMPs is currently limited by several implementation 
barriers, such as toxic side-effects8 and short biological half-lives due to susceptibility 
to proteases8,9. However, these implementation barriers could potentially be off-set by 
the development of nanomedicine formulations based on AMPs13,19. Additionally, the 
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direct delivery of antibiotic-nanomedicines to the lungs may provide therapeutic 
advantages when compared to conventional administration methods19,20. To investigate 
this hypothesis, the novel AMP AA139 was successfully entrapped in two nanocarriers 
(PNP or MCL) to generate two novel nanomedicines (AA139-PNP and AA139-MCL). 
The in vitro antimicrobial activity of both nanomedicines was found to be comparable 
to free AA139 at multiple concentrations, suggesting that AA139 retained its 
bactericidal activity despite formulation in PNP or MCL nanocarriers, a promising 
characteristic for further in vivo studies. Further studies into the mechanisms of 
entrapment and subsequent release of AA139 from the nanomedicines were barred as 
we did not succeed in the successful labelling of AA139 for NMR studies.  
In uninfected rats, biodistribution studies showed that the residence time in the lungs 
of both AA139-PNP and AA139-MCL was longer than that observed with free AA139. 
Specifically, AA139-PNP exhibited ca. ~20% longer residence time in the lung as 
compared to free AA139. The residence time of AA139-MCL in the rat lung was 
observed to be even longer (at ca. ~80%) when compared to free AA139. As discussed 
by Kumari et al., many types of PNP-based drug delivery systems exhibit controlled 
release mechanisms, although this depends on the particular type of PNP utilized41. 
Further, Gill et al. previously reported that entrapping drugs in MCLs facilitates 
sustained drug release in the lung33. Regarding the limiting dose, both nanomedicines 
could be safely administered at twice the dose of free AA139. Although not a 
particularly high increase, this finding does demonstrate that nanomedicine 
formulations can result in reduced toxic side effects, consequently allowing the 
administration of higher doses of AMPs during treatment. Other investigators have 
previously discussed the reduction of toxic side effects as benefits of drug 
nanoformulation, which has been reported for both PNP42 and MCL31.  
The early bacterial killing activity of the nanomedicines by single-dose administration 
was investigated in rats with fatal pneumonia-septicemia caused by multidrug-resistant 
K. pneumoniae. AA139-PNP showed a rapid but short-lasting bacterial killing effect 
whereas AA139-MCL showed a slow but sustained bacterial killing effect, reflecting the 
difference in biological half-lives between AA139-PNP and AA139-MCL as observed 
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 in our biodistribution studies. Taken together, similar doses (0.25 mg/rat; ~1 mg/kg) 
of free AA139, AA139-PNP and AA139-MCL showed comparable bacterial killing 
activity over the first 6 hours post-dose; although bactericidal activity persisted through 
24 hours only for AA139-MCL, while bacterial counts following the other two 
treatments had rebounded to placebo levels by 24 hours post-dose. As these studies 
were used for early assessment of in vivo bacterial killing activity in the development 
pipeline, only a limited number of rats were used to reduce and refine the use of 
experimental animals36. As a consequence, evaluation of the early bacterial killing results 
with statistical significance calculations could not be performed. However, these 
experiments have been included to: 1) provide a preliminary look at the effect of 
AA139-nanomedicines on the bacterial load in the lungs over time, 2) to further support 
conclusions that can be drawn from the TKK assays and biodistribution studies, 3) to 
showcase how the early development pipeline of novel nanomedicines is structured, 
and 4) because the dissemination of animal experimental results should be a 
professional standard for ethical animal research43.  
Further studies assessed the therapeutic efficacy of the nanomedicines by once-daily 
(q24h) administration for 10 days at the limiting dose of both nanomedicines  
(0.5 mg/rat; ~2 mg/kg), or at the MTD of free AA139 (0.25 mg/rat; ~1 mg/kg). Both 
nanomedicines exhibited a statistically significant improvement in therapeutic efficacy 
when dosed at their limiting dose compared to free AA139 dosed at its MTD. While 
not particularly high, the two-fold increase in limiting dose was sufficient to 
demonstrate a potential advantage of nanomedicine formulations in minimizing 
potential toxic side-effects which may be associated with particular AMPs when treating 
patients. In addition, AA139-MCL showed significantly improved therapeutic efficacy 
at ½MTD as well, suggesting that the superior residence time of AA139-MCL in the 
lung resulted in further improved therapeutic efficacy in a daily dosing schedule. The 
lung residence time as well as the early bacterial killing activity of AA139-nanomedicines 
in the lung indicate that more frequent administration could have resulted in improved 
therapeutic efficacy. In our first pilot therapeutic efficacy experiment twice-daily (q12h) 
administration of AA139-nanomedicines was used, however this schedule was found 
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to show acute toxicity (abnormal breathing of rats) after several days which lead to 
termination the pilot experiment. The once-daily (q24h) dosing schedule was well 
tolerated and was therefore chosen to perform the therapeutic efficacy studies. 
Future pharmacokinetic studies of the two AA139-nanomedicines may reveal more 
appropriate dosing schedules which could lead to improvement of their therapeutic 
efficacy. The present study shows that although both nanomedicines resulted in 
significantly improved therapeutic efficacy in terms of increased rat survival time 
compared to free AA139, survival of all infected rats was not achieved. In relation to 
this, it should be noted that the pneumonia-septicemia rat model used in this study is 
representative of multidrug-resistant bacterial infections that are associated with very 
high mortality rates in patients and are particularly challenging to treat successfully34. 
Further, there is published evidence that rats may be more sensitive to the innate 
immune activation known to be caused by AMPs, including histamine release44-46. This 
makes the rat a good model for evaluating potential AMP toxicity decreases using 
nanomedicine formulation, as the tolerability of AMPs in rats is generally low. Of note, 
single and repeated AA139 aerosol administrations of up to 20 mg/kg/day have been 
well-tolerated in uninfected mice27.  
A practical limitation in the experimental set-up was the maximum volume of 
compounds (100 μL) that could be administered to the rats by endotracheal 
aerosolization in order to avoid reflux of compound after administration. This meant 
that only restricted doses could be administered to the rats, in this way preventing the 
demonstration of a more optimal therapeutic effect. In addition, the animals must be 
under anesthesia for the administration which results in a low respiratory rate and 
therefore a low efficiency of drug delivery, restricting the dose that can be administered. 
In patients, inhalation of antibiotics would be the preferred route of administration, as 
inhalation allows higher doses of antibiotic to be delivered to the lungs over a longer 
period of time47. In an attempt to improve aerogenic treatment in rats, we previously 
tested two aerosol inhalation systems for their capacity to administer the described 
nanomedicines to uninfected rats40. Although an improved uniform distribution of 
compound in the lungs was achieved, the results also indicated that only <0.1% of 
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 compound was deposited in the lungs, compared to ~85% deposition using 
endotracheal aerosolization40. Based on these results, a decision was made to utilize the 
more efficient endotracheal aerosolization in our efficacy studies in rats.  
Free AA139 has been shown to be potent in in vivo efficacy in studies using different 
infection models, including a murine pneumonia model26,27. In the present study, both 
AA139-nanomedicines showed significantly improved therapeutic efficacy in terms of 
an extended rat survival time. While these results are promising, survival of all infected 
rats was not obtained. Various factors could explain the lack of survival of infected rats 
receiving free AA139 or nanomedicine, including: 1) a suboptimal administration 
frequency, 2) the severity of the present infection model in rats, 3) the general sensitivity 
of rats to AMP toxicity, or 4) the limitations of endotracheal aerosolization as an 
administration method. Due to these factors, a maximum therapeutic effect (in terms 
of survival of all infected rats) could unfortunately not be achieved. Importantly, it is 
clear that the choice of animal model and study protocol are of significant importance 
for the success of preclinical studies involving AMPs and should be taken into 
consideration during the drug development process. In addition, future studies on 
AA139-nanomedicines should further refine these antimicrobial candidates for the 
treatment of bacterial infections to show more clinically significant improvements over 
free AA139 in different experimental set-ups. 
 
Conclusions 
The present study demonstrates that AMP nanomedicines may reduce some of the 
main barriers to the clinical use of underutilized AMP antibiotics, primarily by 
ameliorating potential toxic side-effects and prolonging the biological half-life of AMP 
at the site of infection, while maintaining the AMP antimicrobial activity. Our results 
support the further evaluation of AA139-based nanomedicines as potential ‘second-
generation’ novel therapeutic agents for the treatment of multidrug-resistant Gram-
negative pulmonary infections.  
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Supplementary Figure S1. Stability of radiolabelled AA139. [124I]AA139 was incubated in 
moderately acidic conditions (sodium acetate buffer at pH = 5.5) and the percentage of 
unchanged [124I]AA139 was determined by radio-HPLC. Experiments were performed in 
triplicate (mean ± standard deviation). 
 
 
Supplementary Figure S2. AA139 deposition in lungs and distribution to blood plasma of 
uninfected rats immediately after endotracheal aerosolization. 1 mg AA139 was administered 
to 6 rats which were immediately sacrificed after dosing. AA139 was measured in lung lobes 
and blood plasma by LC-MS/MS bioanalytical assay. Shown are the mean ± standard deviation 
of total AA139 in rat lung lobes and total blood plasma volume (estimation based on body 
weight). LL, left lobe; RCrL, right cranial lobe; RML, right middle lobe; RCaL, right caudal lobe; 
RIL, right intermediate lobe. 
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 Supplementary Figure S3. Biomarkers of acute toxicity in blood plasma of uninfected rats 
treated with a single dose of free AA139, AA139-PNP, or AA139-MCL. Each compound was 
administered at its limiting dose in 100 μL by endotracheal aerosolization. Groups of 2 rats 
were sacrificed at 24 hours after administration.   
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Supplementary Figure S4. Biomarkers of acute toxicity in blood plasma of rats with  
ESBL-producing K. pneumoniae pneumonia-septicemia treated with a single dose of free 
AA139, AA139-PNP, or AA139-MCL. Each compound was administered at 0.25 mg in 100 μL by 
endotracheal aerosolization. Groups of 2 rats were sacrificed at 2 hours, 6 hours and 24 hours 
after administration, which was 24 hours after initiation of infection.  
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Summarizing discussion 
Gram-negative pneumonia and antimicrobial resistance 
Pneumonia is responsible for over 230,000 deaths and €10 billion in economic costs 
across the European Union (EU) every year1,2, with Gram-negative bacteria being the 
primary causative pathogens in ~70% of healthcare-associated pneumonia cases3. This 
group of bacteria is at the forefront of the current antibiotic crisis4,5, capable of rapidly 
developing and disseminating resistance against novel antibiotics6. Further, the general 
lack of development of new antibiotic classes7,8 means that novel therapeutic 
approaches must be investigated to combat this emerging healthcare crisis9.  
Novel therapeutic approaches 
Among these novel approaches are the development of underutilized classes of 
antibiotics such as antimicrobial peptides (AMPs)10,11; advanced drug delivery systems 
such as nanomedicine formulation12, and more efficient and safe delivery of antibiotics 
to the site of infection13. Chapter 2 is a review of the current state of antibiotic-
nanomedicines research aimed at the treatment of antibiotic-resistant respiratory tract 
infections, including multidrug-resistant Gram-negative pneumonia. It provides an 
overview of the current state of research, the development of different nanocarriers, 
and the potential value and clinical status of inhalable antibiotic-nanomedicines. 
Research focused on combining these three therapeutic approaches is described in 
Chapters 4 – 8, helping establish an extensive pre-clinical developmental pipeline for 
novel antibiotic-nanomedicines. The key feature of this pipeline is the development and 
testing of novel nanomedicine combinations comprising novel AMPs with various 
nanocarriers, including investigations into their antimicrobial activity and therapeutic 
efficacy for the treatment of multidrug-resistant Gram-negative pneumonia (Figure 1). 
This research was supported via an EU FP7 grant (PneumoNP). 
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Figure 1. Diagram of the research in the PneumoNP pre-clinical development pipeline to 
develop novel AMP-nanomedicine candidates which is included in this thesis. 
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Novel antimicrobial peptides 
One promising class of novel antibiotics currently undergoing increased investigation 
is the antimicrobial peptides (AMPs), a broad family of antibiotics that are produced in 
nature by organisms as a natural defense against microbes14. Although AMPs have been 
known since the 1950’s, this family of antibiotics has seen only limited use for the 
treatment of pneumonia, largely due to a number of hurdles that have limited their 
clinical use, including toxic side-effects15, short biological half-life due to degradation 
by proteases15,16 and limited efficacy against Gram-negative bacteria17. However, novel 
AMPs are continually being discovered and developed17-19, and new delivery systems 
are being investigated in order to overcome these challenges. For example, entrapment 
of AMPs into nanoparticles to produce nanomedicines may generate several solutions 
to the hurdles traditionally associated with the clinical utility of AMPs in the treatment 
of multidrug-resistant infections20,21. Notably, nanomedicine formulations could 
potentially reduce toxic side-effects and extend the biological half-life of AMPs12. 
Further, the direct delivery of antibiotics to the site of infection represents an additional 
therapeutic improvement13, which could facilitate increased antibiotic activity at the 
actual site of infection22,23 and lead to reduced systemic toxicity and ‘collateral damage’ 
to patients24,25.  
In Chapter 4 and Chapter 5, the in vitro antimicrobial activity of two novel AMPs 
(AA139 and SET-M33) against Gram-negative Klebsiella pneumoniae and Pseudomonas 
aeruginosa bacteria was investigated. In Chapter 4, we examined the antimicrobial 
activity of AA139 and SET-M33 against a collection of clinically relevant K. pneumoniae 
isolates recovered from a variety of different clinical samples from individual patients. 
This collection was characterized genotypically and phenotypically to confirm that it 
represented a variety of unrelated clinical isolates that could be encountered in the clinic, 
and represented a variety of 5 distinct antibiotic resistance profiles, from susceptible to 
extensively multidrug-resistant phenotypes. The antimicrobial activity of both AMPs 
remained similar despite the various antibiotic resistance profiles present in this  
K. pneumoniae collection, including for colistin-susceptible and colistin-resistant  
 
210
Chapter 99
145136 van der Weide BNW.indd   210 07-08-20   14:02
 phenotypes. Indeed, neither AA139 nor SET-M33 was affected by resistance to colistin 
(an AMP currently used in the clinic as an antibiotic of ‘last resort’). This is an important 
finding in view of the emergence and spread of colistin-resistant bacteria26,27, as well as 
the ‘self-promoted uptake’ mechanism shared by colistin and the cationic AMPs AA139 
and SET-M33. In this mechanism, the antibiotics first bind and inhibit LPS in the 
bacterial outer membrane, which is then followed by insertion of the antibiotic into the 
cell envelope, resulting in outer membrane permeabilization, disruption of the 
cytoplasmic membrane, and bacterial cell death28.  
The concentration- and time-dependent antimicrobial activity of AA139 and SET-M33 
in comparison to colistin was investigated in a panel of extensively antibiotic-resistant 
K. pneumoniae isolates, including an isolate carrying plasmidal colistin resistance. Both 
AA139 and SET-M33 showed a concentration-dependent bactericidal effect 
irrespective of the susceptibility of the isolates to colistin, although a limited decrease 
in activity was observed in the colistin-resistant isolates. At the end of 24 hours of 
exposure to AA139 or SET-M33, only small changes in susceptibility of the  
K. pneumoniae isolates to the AMPs were observed, and only after exposure to their 
respective minimum inhibitory concentrations (MICs). In contrast, exposure of the 
same K. pneumoniae isolates to colistin resulted in large changes in colistin susceptibility 
in both colistin-susceptible and colistin-resistant isolates. The ease with which colistin 
is able to select resistance in these strains is likely to be the result of rather high mutation 
rates for colistin resistance29 or pre-existing colistin-resistant sub-populations in 
otherwise colistin-susceptible bacterial populations (colistin heteroresistance)30. This is 
a worrying observation, as it means that colistin-resistance is easily selected upon long-
term exposure to the antibiotic and therefore could easily be spread in bacterial 
populations treated with colistin. Our results show that AA139 and SET-M33 will not 
readily select for resistance, which is important in view of the potential longevity of 
these novel AMPs for clinical use. Notably, this observation remained true for colistin-
resistant strains as well, showing that AMPs will remain viable candidates for treatment 
even in the case of colistin-resistant strains. 
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In conclusion, the findings in Chapter 4 showed that both AA139 and SET-M33 may 
be suitable alternatives to colistin and viable candidates for the treatment of multidrug-
resistant K. pneumoniae infections, including infections associated with colistin-resistant 
bacteria. Both novel AMPs retain their antimicrobial activity regardless of antibiotic-
resistance profile or colistin-resistance, and do not readily generate AMP-resistance in 
bacterial isolates upon exposure. An important inclusion in this study was the MCR-
producing K. pneumoniae strain. Since its first discovery in 201526, various variants of 
plasmidal colistin-resistance have been found across the world31, meaning that it is likely 
that MCR-producing strains will become more prevalent in the coming decades32, and 
due to the partially shared ‘self-promoted uptake’ mechanism it is important to verify 
that the AMPs remain effective against isolates carrying these plasmids.  
Chapter 5 is an in-depth investigation of the in vitro bactericidal activity of SET-M33, 
as insights into its mechanism of bacterial killing could inform rational development to 
optimize the clinical utility of SET-M33. For these studies, extensively antibiotic-
resistant but colistin-susceptible clinical isolates of K. pneumoniae and P. aeruginosa were 
selected. Both strains were also used to generate isogenic colistin-resistant mutants. 
SET-M33 showed concentration-dependent bactericidal activity against isogenic 
colistin-susceptible and colistin-resistant isolates of K. pneumoniae and P. aeruginosa. 
Changes in susceptibility of the bacterial strains after 24 hours of exposure to SET-M33 
were only minor. Electron microscopic studies clearly revealed the cellular damage to 
the cell envelope of bacteria exposed to SET-M33. These studies also demonstrated 
that while SET-M33 is internalized within 5 minutes by bacteria33, this rapid 
internalization does not lead to an immediate bacterial killing effect as seen for some 
other cationic AMPs34.  
Next, a linear analogue peptide of SET-M33 was synthesized (Q-33) for supramolecular 
structure investigations of SET-M33 which could not be performed with the original 
AMP due to its tetrabranched structure. Q-33 showed a similar ability as SET-M33 to 
adopt a helix conformation, confirming it as a reliable model for structural 
investigations of SET-M33. Similar to other cationic peptides35,36, Q-33 was shown to 
adopt an α-helix structure partially buried in the membrane in a bacterial membrane-
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 mimicking environment. In contrast, it has been shown that colistin adopts a structure 
with random coiling and β-sheet features in lipid membrane models37, further 
supporting the hypothesis that there are differences in the ‘self-promoted uptake’ 
mechanism between SET-M33 and colistin.  
One commonly reported issue with cationic AMPs which share similar structural 
characteristics to SET-M33 is their tendency for self-aggregation and undesired peptide 
interactions with blood proteins38. Further investigations showed that SET-M33 
exhibited no self-aggregation, no cytotoxicity against human bronchial epithelial cells 
and only limited hemolytic activity against red blood cells. These findings indicate that 
SET-M33 does not have the disadvantageous biological characteristics reported for 
structurally similar AMPs, which is supported by previous studies where the in vivo 
administration of SET-M33 was well-tolerated39.  
In conclusion, the data obtained in Chapter 5 further corroborate the findings 
presented in Chapter 4 that SET-M33 remains a viable candidate for the treatment of 
multidrug-resistant Gram-negative pneumonia, even after prior exposure to colistin 
(potentially resulting in colistin resistance of the causative pathogen).  
Animal disease model 
Prior to continuing with in vivo studies, a suitable animal model of disease was 
developed, characterized and validated in rats as described in Chapter 6. In rats, we 
established a novel model of acute lobar pneumonia leading to fatal septicemia caused 
by an extended-spectrum β-lactamase (ESBL)-producing K. pneumoniae strain (referred 
to as K. pneumoniae ESBL) or an isogenic K. pneumoniae carbapenemase (KPC)-producing  
K. pneumoniae strain (referred to as K. pneumoniae KPC). This model is representative of 
a particularly severe multidrug-resistant infection in human patients40-42 and allows for 
research comparing the therapeutic efficacy of individual antibiotics at similar 
conditions of severity, duration of infection, and host defense, which is not possible 
with most comparative clinical efficacy studies on tigecycline treatment43,44. The course 
of infection in the disease model was characterized by a disease progression including 
complications of the pulmonary infection such as pleuritis or pericarditis, defined by 
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continuous body weight loss and fluctuating body temperatures eventually leading to 
hypothermia in the final stage, necessitating euthanasia of rats.  
The translational value of the above disease model was demonstrated in terms of the 
therapeutic response of infected rats to the antibiotics meropenem and tigecycline, 
administered in clinically relevant therapeutic schedules started when rats suffered from 
progressive pulmonary infection and had developed septicemia. Carbapenem 
antibiotics such as meropenem are the antibiotic of choice in the case of antibiotic-
resistant infections, but increasing numbers of carbapenem-resistant bacterial isolates 
such as K. pneumoniae KPC have further complicated the successful treatment of 
multidrug-resistant Gram-negative bacterial infections45. As a result, alternative drugs 
of last resort like tigecycline have therefore seen increased use in patients suffering from 
such infections, although the appropriate dosing of tigecycline has been the subject of 
debate46. We demonstrated that the in vivo response to a 12-hourly treatment of 
meropenem or tigecycline during 10 days reflected the in vitro susceptibility of the 
causative K. pneumoniae strain, with meropenem being successful in the treatment of 
pneumonia-septicemia caused by K. pneumoniae ESBL, but being unsuccessful in the 
treatment of pneumonia-septicemia caused by K. pneumoniae KPC. To confirm that 
pneumonia-septicemia caused by K. pneumoniae KPC could be effectively treated using 
appropriate antibiotic therapy, a high-dose regimen of tigecycline was successful in 
treating pneumonia-septicemia caused by K. pneumoniae KPC. The findings in our study 
in Chapter 6 support recent literature47,48 recommending the use of high-dose 
tigecycline treatment as a last resort option for the treatment of patients with severe 
infections (such as pneumonia) caused by carbapenem-resistant Gram-negative 
bacteria. 
Targeted delivery of AMP-nanomedicines 
Moving forward in the PneumoNP developmental pipeline, we followed two novel 
approaches in the in vivo efficacy studies using SET-M33 and AA139. In Chapter 7 and 
Chapter 8, we developed novel AMP-nanomedicines by entrapment of SET-M33 and 
AA139 in nanocarriers12, and we administered the nanomedicines via endotracheal 
214
Chapter 99
145136 van der Weide BNW.indd   214 07-08-20   14:02
 aerosolization to achieve more efficient and safe delivery of the nanomedicines to the 
site of infection13. The AMP-nanomedicines were developed by combining AA139 and 
SET-M33 with three distinct forms of nanocarriers: polymeric nanoparticles (PNP)49, 
liposomes (LIP)50,51, or lipid-core micelles (MCL)52.  
Multiple iterations and adjustments of the various nanomedicines were developed and 
refined based on initial in vitro antimicrobial activity screening experiments, until four 
final nanomedicines were selected for more extensive in vitro and in vivo testing. Four 
final AMP-nanomedicines were selected: SET-M33-PNP, SET-M33-LIP, AA139-PNP, 
and AA139-MCL. These four AMP-nanomedicines were compared to their respective 
AMPs in the ‘free form’ (free AMPs) and were examined by in vitro testing of bactericidal 
activity against K. pneumoniae ESBL and in vivo studies in the rat model of pneumonia-
septicemia caused by K. pneumoniae ESBL. Chapter 7 covers the examination of SET-
M33-PNP and SET-M33-LIP, and Chapter 8 covers the investigation of AA139-PNP 
and AA139-MCL. 
In Chapter 7, we observed that SET-M33-PNP showed in vitro similar rapid bactericidal 
activity leading to complete bacterial killing at the same concentrations as free  
SET-M33, whereas SET-M33-LIP exhibited a delayed bactericidal effect compared to 
free SET-M33. In uninfected rats, determination of the limiting dose showed that the 
maximum feasible dose (MFD) of both SET-M33-nanomedicines was equal to the 
maximum tolerable dose (MTD) of free SET-M33; unfortunately, the SET-M33-
nanomedicines could not be administered at higher dosages due to technical limitations 
related to SET-M33 nanoformulation and to the attainable dosage using endotracheal 
aerosolization in rats under anesthesia. In rats with K. pneumoniae pneumonia-septicemia 
after a single dose treatment, the early bacterial killing activity in the lungs of SET-M33-
PNP was similar to free SET-M33. The activity of SET-M33-LIP was slow, but 
sustained over time compared to free SET-M33. At this point, it should be noted that 
the studies described above were performed as pilot experiments, with the goal of 
providing preliminary data on the in vivo effects of the different AMP-nanomedicines 
via our PneumoNP developmental pipeline. This meant that only a limited number of 
rats were used following recommendations from our animal ethics committee53. 
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Although no firm conclusions could be drawn from these experiments, the results 
obtained were essential in the selection of AMP-nanomedicines and the design of 
further in vivo therapeutic efficacy experiments.  
Summarizing, the data obtained in Chapter 7 suggests that SET-M33-PNP retains its 
rapid bactericidal activity in vitro and in vivo against K. pneumoniae ESBL equal to free  
SET-M33 despite formulation in PNP nanocarriers, whereas SET-M33-LIP shows slow 
but sustained release of SET-M33 from the liposomes, which could have potential 
advantages compared to free SET-M33. Unfortunately, administration of higher 
dosages of SET-M33-nanomedicines could not be performed due to technical 
limitations. Further studies with a different experimental set-up could show further 
potential therapeutic advantages of SET-M33-PNP and SET-M33-LIP. 
In Chapter 8, we showed that AA139-PNP showed relatively slow bactericidal activity 
in vitro – leading to near-complete bacterial killing at the same concentrations as free 
AA139. It was concluded that AA139 retained its relatively slow bactericidal activity 
despite formulation in PNP nanocarriers, whereas AA139-MCL exhibited a delayed 
bactericidal effect compared to free AA139. In uninfected rats, both AA139-
nanomedicines were better tolerated than free AA139, demonstrating that 
nanoformulation resulted in reduced toxic side effects. Both AA139-nanomedicines 
also exhibited a longer residence time in the lungs compared to free AA139 in 
biodistribution studies. With respect to the early bacterial killing activity in the lungs of 
rats with pneumonia-septicemia after single dose administration, the killing activity of 
AA139-PNP appeared to be more rapid compared to free AA139, however, the activity 
of both AA139-PNP and free AA139 was of short duration. The killing activity of 
AA139-MCL initially appeared less compared to free AA139, however resulted in 
sustained bacterial killing activity over time. Our conclusion, drawn with caution, was 
that both AMP-nanomedicines showed a longer residence time in the lungs and 
decreased toxic side effects, but that nanoformulation of AA139 in PNP appears to 
facilitate rapid bactericidal activity, while nanoformulation of AA139 in MCL appears 
to show delayed release of AA139, both of which could have potential therapeutic 
advantages. In a final series of therapeutic efficacy studies, rats with pneumonia-
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 septicemia treated with AA139-PNP or AA139-MCL once-daily over a 10-day 
treatment period showed statistically significant improved therapeutic efficacy 
compared to free AA139. 
Summarizing, the data obtained in Chapter 8 suggest that PNP formulation of AA139 
facilitates faster killing of K. pneumoniae ESBL in the lung compared to free AA139, 
however of short duration. MCL nanoformulation of AA139 resulted in slower 
bacterial killing in the lung, however, of longer duration. Both AA139-nanomedicines 
could be safely administered at double the dosage of free AA139, indicating that 
nanoformulation improves the tolerability of AA139 allowing higher dosages to be 
administered without toxic side effects20. This is in contrast to the limiting dose of both 
SET-M33-PNP and SET-M33-LIP which was equivalent to the MTD of free  
SET-M33. Nanoformulation of AA139 also resulted in increased residence time in the 
lungs. Finally, the improved therapeutic efficacy obtained resulting from PNP- or MCL-
nanoformulation of AA139 demonstrates their potential as novel nanomedicine 
candidates against multidrug-resistant Gram-negative pneumonia. 
Conclusions 
Overall, the results presented in this thesis demonstrate the positive effects of the 
entrapment of novel promising AMP antibiotics within nanocarriers for treating 
multidrug-resistant Gram-negative pneumonia. The findings also support the concept 
that aerosol-delivered nanomedicine formulations can be useful in the design of a new 
generation of antibiotic-based medicines for the treatment of multidrug-resistant 
pneumonia, including the treatment of infections that are resistant to antibiotics of ‘last 
resort’ e.g. colistin. The future use of our nanomedicine developmental and assessment 
pipeline is a promising pre-clinical research tool at a time when traditional antibiotics 
are failing and the treatment of antibiotic-resistant respiratory tract infections are of 
global importance. We are still far from having a novel treatment approach ready for 
clinical trials, but we have generated knowledge on the road to better treatment. Future 
studies with a different experimental set-up may show the further potential therapeutic 
advantages of AMP-nanomedicines administered via the aerogenic route.  
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Future perspectives 
The studies described in this thesis were performed as part of the PneumoNP 
nanomedicine developmental pipeline and are directed at the increasing global threat of 
antibiotic-resistant respiratory tract infections54. Essentially, in order to prevent a 
dreaded ‘post-antibiotic era’, novel therapeutic strategies (such as novel nanomedicines) 
must be efficiently developed and assessed if they are to be effectively employed in the 
treatment of such devastating infections. The in vitro and in vivo studies described aim 
for therapeutic improvement by combining three new approaches: 
1. Novel antibiotic compounds  
The two novel AMPs AA13918,55 and SET-M3319 developed by PneumoNP partners 
and members of an underutilized antibiotic class of AMPs appear to be promising 
antibiotic candidates to combat multidrug-resistant Gram-negative bacteria. They 
showed rapid bactericidal activity irrespective of the antibiotic resistance profile of 
bacteria, including colistin-resistant bacteria. In addition, exposure to AA139 and  
SET-M33 did not readily generate resistant mutants. This is in contrast to colistin, an 
AMP that is currently used as a last-resort antibiotic in the clinic which easily provokes 
resistance29,30. Finally, it was observed that SET-M33 adopts a partially buried α-helix 
structure in the bacterial membrane, but unlike other AMPs which adopt this structure, 
we demonstrated that SET-M33 does not have disadvantageous biological 
characteristics such as cytotoxicity, hemolysis, and self-aggregation.  
Taken together, our studies showed that cationic AMPs like AA139 and SET-M33 are 
promising candidate antibiotics for the treatment of multidrug-resistant Gram-negative 
bacterial infections, including infections associated with colistin resistance. The 
discovery of new antibiotics is only the first step in a long process towards marketability, 
with many potential hurdles lying in the path of drug commercialization in the antibiotic 
space56. One clear example of this problem is the antibiotic AA139 (as we learned in 
November 2019), when PneumoNP partner Adenium Biotech ApS went into voluntary 
liquidation. It appears that AA139 ran into difficulties in the late pre-clinical phase. The 
experience communicated from our partner Adenium Biotech ApS was that it is 
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 essential to take advantage of any new initiatives and funding opportunities available in 
the field. SET-M33 on the other hand is currently at the end of its preclinical 
development phase and ready to enter clinical trials for the treatment of lung infections 
in cystic fibrosis (CF) patients. SET-M33 is also being investigated for the treatment of 
urinary tract infections and bacterial septicemia. 
In light of the currently unfolding antibiotic resistance crisis, studies on cationic AMPs 
should include investigations into their efficacy against pathogens with various forms 
of multidrug resistance. In this respect, colistin resistance is a particularly important 
subject for investigation, as some cationic AMPs have shown colistin cross-resistance 
due to similarities in the mechanism57-59. The precise mechanisms by which colistin and 
other cationic AMPs exert their antimicrobial killing activity and how resistance is 
generated towards these antibiotics is a complex and poorly understood matter60, and 
continued mechanistic investigations will be essential in understanding if exposure to 
AMPs is likely to generate resistance and if there is the potential for colistin  
cross-resistance.  
2. Nanomedicine formulation of antibiotics 
Although AMPs are potent antibiotics, their clinical use is limited due to toxic side 
effects15 and short biological half-life resulting from degradation by proteases15,16. 
Nanomedicine formulations could potentially reduce toxic side effects and extend the 
biological half-life of the antibiotics12. The nanoformulation of AA139 and SET-M33 
was successfully achieved using three distinct forms of nanocarriers: polymeric 
nanoparticles (PNP)49, liposomes (LIP)50,51, or lipid-core micelles (MCL)52.  
The AMP-nanomedicines were stable and antibiotic leakage was never observed during 
storage. The bacterial killing activity of AA139 and SET-M33 after nanoformulation 
was retained in vitro and in vivo, with PNP appearing to facilitate rapid bactericidal 
activity, whereas LIP and MCL appeared to facilitate sustained bactericidal activity. 
Regarding toxic side effects, the nanomedicine formulation of AA139 in PNP61 and 
MCL62 resulted in decreased toxicity, allowing for the administration of higher doses. 
For SET-M33-nanomedicines, these advantages could not be confirmed due to 
9
219
Summarizing discussion and future perspectives
145136 van der Weide BNW.indd   219 07-08-20   14:02
technical limitations which prevented the administration of higher doses of  
SET-nanomedicines. For this reason, AA139-nanomedicines were selected for 
continued in vivo investigations. Regarding biodistribution, the residence time of AA139 
in the lungs was prolonged by nanoformulation, particularly for AA139-MCL. 
Therapeutic efficacy studies using once-daily administration of AA139-nanomedicines 
over 10 days to treat fatal multidrug-resistant K. pneumoniae pneumonia-septicemia in 
rats resulted in significantly increased rat survival compared to free AA139. AA139-
PNP showed improved therapeutic efficacy when administered at a higher dose than 
the MTD of free AA139 which could be attributed to the decreased toxic side effects 
thanks to nanoformulation. AA139-MCL showed improved therapeutic efficacy at an 
equal dose to the MTD of free AA139, which could be explained by the significantly 
prolonged residence time and sustained bacterial killing activity in the lung. 
From our in vitro and in vivo studies, it is clear that the characteristics of the nanocarrier 
strongly influence the therapeutic effects of nanoformulation. The versatility of 
nanocarriers among which the size, the charge, the fluidity/rigidity, and the surface 
characteristics offers many options for different applications of distinct antibiotic-
nanomedicines20, which may allow novel or underutilized antibiotics that would 
otherwise go unexploited to be optimized for clinical use. This means that for future 
development of antibiotic-nanomedicines, the characteristics of the nanocarrier must 
be carefully considered in view of the class of antibiotic, the type of pathogen, and the 
type of infection in order to achieve optimal therapeutic improvement. For example, 
the therapeutic efficacy of antibiotics with time-dependent antimicrobial activity can be 
improved by delayed antibiotic release from nanocarriers63, antibiotics targeted at 
intracellular pathogens can benefit from intracellular delivery by nanocarriers64, and 
controlled-release nanocarriers can improve the use of topical application of 
antibiotics65. 
3. Direct delivery of antibiotic-nanomedicines 
More efficient and safe delivery of the antibiotic-nanomedicines to the actual site of 
infection could facilitate increased local antibiotic activity22,23, while reducing systemic 
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 toxicity and ‘collateral damage’ to the healthy microbiome in patients24,25. To investigate 
direct delivery to the lungs, we developed and validated a rat disease model of 
pneumonia leading to septicemia caused by multidrug-resistant K. pneumoniae. This 
model was fatal if left untreated and representative of a severe multidrug-resistant 
Gram-negative pneumonia in human patients. Endotracheal aerosolization was the 
most efficient and quantitative method of antibiotic administration for this animal 
model to achieve direct delivery of AMP-nanomedicines to the lung, the primary site 
of infection.  
The nanocarriers used to generate AMP-nanomedicines were chosen for their 
promising characteristics for pulmonary drug delivery: PNP may allow for improved 
drug penetration of the respiratory mucus66, inhaled LIP is well tolerated and has the 
potential to reduce systemic drug toxicity67-70, and MCL has been shown to facilitate 
sustained drug release in the lungs71. For SET-M33-nanomedicines, the advantages of 
nanoformulation were not evident due to the low concentration of SET-M33 in the 
nanomedicines combined with the limited volume which could be administered by 
endotracheal aerosolization. For AA139-nanomedicines, we demonstrated the 
therapeutic improvement of nanoformulation compared to the free AMP, especially in 
terms of the achieved decrease in toxicity and the prolonged residence time in the lung, 
which are important improvements over conventional systemic administration of free 
AA139.  
Important to mention here is that several factors prevented us from achieving a 
maximum therapeutic effect using the AMP-nanomedicines in our rat model of 
infection. The reason for this is the choice of aerogenic administration in small animals 
which presents some significant barriers to achieving the maximum delivery of 
compound. First, the animals must be under anesthesia for the administration, which 
results in a low respiratory rate and therefore a low efficiency of drug delivery, 
restricting the dose that can be administered72. Second, only a limited volume of drug 
can be administered in order to avoid reflux after administration, which in the case of 
antibiotic-nanomedicines with an upper limit on the antibiotic concentration in the 
nanomedicines restricts the dose that can be administered. In human patients, 
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inhalation of antibiotics would of course be the preferred route of aerogenic 
administration73. In an attempt to improve aerogenic treatment in rats, two aerosol 
inhalation systems were tested for their capacity to administer the nanomedicines to 
uninfected rats72. Unfortunately, neither of these systems resulted in an improved 
deposition over endotracheal aerosolization.  
It is clear that the choice of animal model, infection type, administration method, 
experimental set-up and the envisioned therapeutic improvements need to be important 
considerations in future studies. For the future development of AMP-nanomedicines, 
it will be pertinent to demonstrate the maximum therapeutic effect which could be 
accomplished by investigating routes of administration that allow for relatively large 
volumes to be administered so that higher doses can be applied, and by using an animal 
model which is less susceptible to AMP toxicity than rats74-76.  
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Glossary of acronyms and abbreviations 
ALAT Alanine transaminase 
AMK Amikacin 
AMP Antimicrobial peptide 
ARRIVE Animal research: reporting of in vivo experiments 
ASAT Aspartate aminotransferase 
ATCC American Type Culture Collection 
AUC Area under the plasma concentration-time curve 
AUC0-24h Area under the plasma concentration-time curve during a  
24 hour period 
AUC/MIC Ratio of the area under the plasma concentration-time curve 
to the minimum inhibitory concentration 
BUN Blood urea nitrogen 
CAZ Ceftazidime 
CD Circular dichroism 
CIP Ciprofloxacin 
CF Cystic fibrosis 
CFU Colony-forming units 
CL Clearance 
CREAT Creatinine 
CST Colistin 
CT Computerized tomography 
CTX-M Cefotaxime-M β-lactamase 
DLS Dynamic light scattering 
DMPC:Chol 1,2-dimyristoyl-sn-glycero-3-phosphocholine-cholesterol 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DPPC:Chol Dipalmitoylphosphatidylcholine-cholesterol 
DSPC:Chol 1,2-distearoyl-sn-glycero-3-phosphocholine-cholesterol 
DSPE-PEG2000 Polyethylene glycosylated distearyl phosphatidyl 
ethanolamine 
ECDC European Centre for Disease Prevention and Control 
ECOFF Epidemiological cut-off value 
ECTS European Credit Transfer and Accumulation System 
EDTA Ethylenediaminetetraacetic acid 
EEA European Economic Area 
EMA European Medicines Agency 
EPC Egg phosphatidylcholine 
EPG Egg phosphatidylglycerol 
230
Chapter 1010
145136 van der Weide BNW.indd   230 07-08-20   14:02
  
Erasmus MC Erasmus University Medical Center Rotterdam 
ESBL Extended-spectrum β-lactamase 
ESBL pneumonia Acute lobar pneumonia leading to fatal septicemia in rats 
-septicemia caused by Klebsiella pneumoniae strain ESBL EMC2003 
EU European Union 
EUCAST European Committee on Antimicrobial Susceptibility 
Testing 
E. coli Escherichia coli 
F Bioavailability 
FDA United States Food and Drug Administration 
FID Free induction decay 
FOV Field of view 
FPLC Fast protein liquid chromatography 
FWHM Full width at half maximum 
Gd(III)DTPA-BMA Gadolinium-(III)-diethylenetriaminepentaacetic acid-
bisamide 
GMA Glycidyl methacrylate 
HBS 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid buffered 
saline 
HE Hematoxylin-eosin 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HiMLST High-throughput multilocus sequence typing 
HPLC High-performance liquid chromatography 
HPLC-MS High-performance liquid chromatography mass spectrometry 
IPTT Implantable programmable temperature transponder 
ISO International Organization for Standardization 
KPC Klebsiella pneumoniae carbapenemase 
KPC pneumonia Acute lobar pneumonia leading to fatal septicemia in rats 
-septicemia caused by Klebsiella pneumoniae strain ESBL EMC2003 
K. pneumoniae Klebsiella pneumoniae 
K. pneumoniae ESBL Extended-spectrum β-lactamase-producing Klebsiella 
pneumoniae strain ESBL EMC2003 
K. pneumoniae KPC Klebsiella pneumoniae carbapenemase producing Klebsiella 
pneumoniae strain KPC EMC2014 
LC-MS/MS Liquid chromatography with tandem mass spectrometric 
detection 
LD100 Absolute lethal dose 
LPS Lipopolysaccharide 
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 LUV Large unilamellar vesicle 
MAC Mycobacterium avium complex 
MALDI Matrix-assisted laser desorption/ionization 
MALDI-TOF Matrix-assisted laser desorption/ionization time-of-flight 
MCR Mobilized colistin resistance 
MED Minimum effective dose 
MEM Meropenem 
MFD Maximum feasible dose 
MGE Mobile genetic elements 
MH-II Mueller Hinton II 
MIC Minimum inhibitory concentration 
MIC90 Minimum inhibitory concentration required to inhibit 90% 
of tested isolates 
MLST Multilocus sequence typing 
MS Mass spectrometry 
MTD Maximum tolerated dose 
MWCO Molecular weight cutoff 
M. tuberculosis Mycobacterium tuberculosis 
NDA New Drug Application 
NDM New Delhi metallo-β-lactamase 
NMR Nuclear magnetic resonance 
NOE Nuclear Overhauser effect 
NOESY Nuclear Overhauser effect spectroscopy 
NOR Norfloxacin 
NP Nanoparticle 
NSS Normal saline solution 
NTM Nontuberculous mycobacteria 
OXA Oxacillinase β-lactamase 
PB Phosphate buffer 
PBCA Poly(butylcyanoacrylate) 
PBS Phosphate-buffered saline 
PC:Chol Phosphatidylcholine-cholesterol 
PCR Polymerase chain reaction 
PDI Polydispersity index 
PEG Polyethylene glycol 
PES Polyethersulphone 
PET Positron emission tomography 
PFGE Pulsed-field gel electrophoresis 
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PLG Poly(DL-lactide-co-glycolide) 
PLGA Poly(lactic-co-glycolic acid) 
PVA Polyvinyl alcohol 
P. aeruginosa Pseudomonas aeruginosa 
QRDR Quinolone-resistance determining region 
Radio-HPLC High-performance liquid chromatography with radioactive 
detection 
RTI Respiratory tract infection 
R&D Research and development 
SDS Sodium dodecyl sulfate 
SDS-d25 Fully deuterated sodium dodecyl sulfate 
SEM Scanning electron microscopy 
SHV Sulfhydryl reagent variable β-lactamase 
SPF Specified pathogen-free 
ST Sequence type 
SXT Trimethoprim/sulfamethoxazole 
TEM Temoniera β-lactamase (Chapters 4 & 6) 
TEM Transmission electron microscopy (Chapter 5) 
TFA Trifluoroacetic acid 
TGC Tigecycline 
TKK Time-kill kinetics 
TNF-α Tumor necrosis factor α 
TOB Tobramycin 
TOCSY Total correlation spectroscopy 
t1/2 Half-life time 
UN United Nations 
UPLC Ultra-performance liquid chromatography 
UV Ultraviolet 
V Volume of distribution 
VOI Volume of interest 
WHO World Health Organization 
WT Wildtype 
3-MPA 3-mercaptopropionic acid 
ƒCmax Highest unbound drug concentration reached in blood 
plasma 
ƒT>MIC Cumulative percentage of a 12-hour period that the unbound 
fraction of drug exceeds the minimum inhibitory 
concentration 
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 Longinfecties zijn jaarlijks verantwoordelijk voor meer dan 230.000 sterfgevallen en  
10 miljard euro aan economische kosten over de gehele Europese Unie. In bijna 
driekwart van de gevallen van longinfecties in de gezondheidszorg zijn Gram-negatieve 
bacteriën de primaire ziekteverwekkers. Zulke Gram-negatieve bacteriën zijn tevens 
koplopers in de huidige antibioticacrisis en snel in staat om resistentie tegen nieuwe 
antibiotica te ontwikkelen en verspreiden. Dit heeft in combinatie met een gebrek aan 
nieuwe antibiotica gezorgd voor een opkomende crisis in de gezondheidszorg. Om deze 
crisis het hoofd te kunnen bieden is er wereldwijd aandacht voor het ontdekken en 
ontwikkelen van o.a. nieuwe klassen van antibiotica, verbeterde handhaving van 
infectiepreventieve maatregelen en snellere diagnostiek. Maar minstens zo belangrijk in 
het voorkómen van een ‘post-antibiotisch tijdperk’ is de ontwikkeling van nieuwe 
therapeutische benaderingen, waaronder: de optimalisatie van onderbenutte 
antibioticaklassen, zoals de antimicrobiële peptiden (AMPs); de ontwikkeling van 
geavanceerde systemen voor antibioticatoediening, zoals het insluiten van antibiotica in 
zeer kleine nanodeeltjes (nanoformulering); en een meer gerichte en veilige afgifte van 
antibiotica aan de infectiehaard, zoals directe toediening naar de longen via inademing 
in de behandeling van longinfecties.  
In het kader van de hierboven beschreven klinische problematiek zijn de drie hierboven 
genoemde therapeutische benaderingen gecombineerd in het door de EU gefinancierde 
‘PneumoNP’ onderzoeksproject (EU-FP7 onderzoeksbeurs). Het PneumoNP project 
heeft tot doel om nieuwe inhaleerbare antibiotica-nanogeneesmiddelen te ontwikkelen 
voor de behandeling van longinfecties veroorzaakt door antibioticaresistente Klebsiella 
pneumoniae – een Gram-negatieve bacterie. Het gebruik van nanogeneesmiddelen zou 
therapeutische voordelen kunnen hebben die enkele van de nadelen geassocieerd met 
de klinische toepassing van AMPs kunnen overwinnen, met name toxische 
bijwerkingen en een korte biologische halfwaardetijd. In het PneumoNP project waren 
de inhaleerbare antibiotica-nanogeneesmiddelen gebaseerd op twee nieuwe antibiotica; 
de ‘cationische AMPs’ SET-M33 en AA139, welke werden ingesloten in verschillende 
nanodeeltjes; polymere nanodeeltjes (PNP), liposomen (LIP), of micellen (MCL). De 
nanodeeltjes PNP, LIP en MCL werden voor nanoformulering gekozen vanwege hun 
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 gunstige biocompatibiliteit, lage toxiciteit, potentiëel goede biodistributie, en 
mogelijkheden ter aanpassing gebaseerd op toedieningsroute. Vervolgens werden in een 
unieke PneumoNP onderzoekspijplijn waaraan elf Europese onderzoeksgroepen 
deelnamen meerdere nanogeneesmiddelen ontwikkeld. In samenwerking met deze 
onderzoekspartners hebben wij de twee nieuwe AMPs en een aantal geselecteerde 
AMP-nanogeneesmiddelen getest in vitro op hun vermogen om antibiotica-resistente 
bacteriën afkomstig van patiënten te doden. Vervolgens onderzochten wij de meest 
veelbelovende kandidaten in een proefdiermodel op hun effectiviteit in de behandeling 
van een ernstige long-/bloedinfectie veroorzaakt door een multidrug-resistente 
bacterie, een type infectie met een hoge mortaliteit bij patiënten in het ziekenhuis. Alle 
dierexperimenten hadden de goedkeuring binnen de Europese richtlijn voor 
dierproeven. 
Deel I van dit proefschrift bevat de inleidende hoofdstukken. Hoofdstuk 1 beschrijft 
de aard van multidrug-resistente Gram-negatieve bacteriën, de problematiek in de 
behandeling van infecties veroorzaakt door deze bacteriën, en verschillende nieuwe 
therapeutische benaderingen. Daarbij wordt de nadruk gelegd op AMPs en directe 
toediening aan de infectiehaard. Hoofdstuk 2 is een overzichtsartikel met de huidige 
staat van antibiotica-nanogeneesmiddelonderzoek gericht op de behandeling van 
antibiotica-resistente luchtweginfecties. Hierin wordt uitgebreid ingegaan op de huidige 
onderzoekslijnen in dit veld, de ontwikkeling van verschillende nanodeeltjes en de 
potentiële waarde en klinische status van inhaleerbare antibiotica-nanogeneesmiddelen. 
Hoofdstuk 3 bespreekt het doel van het PneumoNP project en benoemt kort de 
onderzoeksactiviteiten door andere projectpartners die niet beschreven worden in dit 
proefschrift.  
De hierna volgende hoofdstukken beschrijven het onderzoek uitgevoerd binnen de 
afdeling Medische Microbiologie & Infectieziekten (MMIZ) van het Erasmus 
Universitair Medisch Centrum Rotterdam (Erasmus MC) als onderdeel van een 
preklinische ontwikkelingspijplijn betreffende het bereiden en testen van nieuwe AMP 
nanogeneesmiddelen.  
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De Hoofdstukken 4 – 5 van Deel II behandelen het in vitro onderzoek naar de 
antimicrobiële activiteit van de nieuwe AMPs SET-M33 en AA139 tegen Gram-
negatieve K. pneumoniae and Pseudomonas aeruginosa bacteriën. Zowel SET-M33 als AA139 
hebben meerdere werkingswijzen en lijken o.a. de ‘zelfgestimuleerde opname’ te delen 
met andere cationische AMPs zoals colistine – dat in de kliniek één van de laatste 
toevluchtsantibiotica tegen antibiotica-resistente Gram-negatieve bacteriën is. 
Hoofdstuk 4 beschrijft de antimicrobiële activiteit van SET-M33 en AA139 met 
colistine als vergelijkingsantibioticum tegen een collectie van genotypisch verschillende 
K. pneumoniae isolaten afkomstig van 50 individuele patiënten en diverse klinische 
monsters. Deze collectie isolaten vertegenwoordigt vijf verschillende antibiotica-
resistentieprofielen, van gevoelige tot multidrug-resistente fenotypen, en bevat ook 
colistine-resistente isolaten. Daarnaast worden de resultaten besproken van de 
concentratie- en tijdsafhankelijke antimicrobiële activiteit van SET-M33 en AA139 in 
vergelijking met colistine onderzocht in een selectie van multidrug-resistente  
K. pneumoniae isolaten, waaronder een isolaat met plasmidale colistine resistentie. 
Aangetoond werd dat SET-M33 en AA139 beiden een snelwerkende bacteriedodende 
werking hebben ongeacht het antibiotica-resistentieprofiel of de colistine-resistentie 
van de Gram-negatieve bacterie, en dat blootstelling aan SET-M33 en AA139 niet snel 
leidt tot de ontwikkeling van resistente mutanten, terwijl we dit wel zien na blootstelling 
aan colistine. Hieruit kunnen wij concluderen dat zowel SET-M33 als AA139 geschikte 
alternatieven zijn voor colistine en daardoor veelbelovend voor de behandeling van 
multidrug-resistente K. pneumoniae infecties, inclusief infecties veroorzaakt door 
colistine-resistente bacteriën. 
Hoofdstuk 5 beschrijft een diepgaand onderzoek naar de precieze werkingswijze van 
SET-M33. Aangetoond werd de bacteriedodende activiteit van SET-M33 ten opzichte 
van isogene K. pneumoniae en P. aeruginosa isolaten die enkel verschillen in hun 
gevoeligheid voor colistine, waarbij slechts zeer geringe verandering in gevoeligheid van 
de bacteriën na 24 uur blootstelling aan SET-M33 werd gezien. Middels 
elektronenmicroscopie werd de beschadiging aan de bacteriële celenvelop door  
SET-M33 onderzocht. Studies met gebruikmaking van lipide membraanmodellen lieten 
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 zien dat SET-M33 waarschijnlijk een α-helix-structuur aanneemt en deels verscholen 
ligt in de bacteriële celmembraan, in tegenstelling tot colistine dat een geheel andere 
structuur laat zien na opname in de celmembraan. De resultaten ondersteunen de 
hypothese dat SET-M33 en colistine essentieel verschillen in opnamemechanismen 
door de bacteriële celmembraan. Verder onderzoek liet zien dat SET-M33 geen zelf-
aggregatie vertoont, noch cytotoxiciteit tegen menselijke bronchiale epitheelcellen, en 
slechts beperkte hemolytische activiteit tegen menselijke rode bloedcellen. Deze 
bevindingen tonen aan dat SET-M33 niet de nadelige biologische eigenschappen heeft 
die geassocieerd zijn met structureel soortgelijke AMPs, hetgeen wordt ondersteund 
door eerdere in vivo studies waar SET-M33 na toediening in een muisinfectiemodel goed 
getolereerd werd.  
Bij elkaar genomen laat het onderzoek uit deze twee hoofdstukken zien dat SET-M33 
en AA139 veelbelovende antibioticakandidaten zijn voor de behandeling van 
multidrug-resistente Gram-negatieve bacteriële infecties en mogelijk als alternatief voor 
colistine gebruikt kunnen worden in de kliniek. Daarmee zijn beide antibiotica geschikte 
kandidaten voor de ontwikkeling van AMP-nanogeneesmiddelen.  
De Hoofdstukken 6 – 8 van Deel III behandelen het in vivo onderzoek naar de 
therapeutische effectiviteit van de ontwikkelde AMP-nanogeneesmiddelen in 
vergelijking tot die van de AMPs in de vrije vorm (‘vrije AMPs’). Daartoe werd eerst 
een dierexperimenteel infectiemodel ontwikkeld omdat dieronderzoek een essentiële en 
vereiste schakel is tussen preklinisch in vitro onderzoek en klinisch onderzoek in 
patiënten.  
Hoofdstuk 6 beschrijft een nieuw diermodel in de rat van acute lobaire longinfectie, 
waarbij ook het bloed geïnfecteerd raakt, veroorzaakt door een multidrug-resistente 
ESBL-producerende of KPC-producerende K. pneumoniae, welke infectie zonder 
behandeling fataal verloopt. Dit diermodel beoogt in zekere mate representatief te zijn 
voor ernstige multidrug-resistente longinfecties bij patiënten die heel moeilijk te 
behandelen zijn in het ziekenhuis en niet zelden een fataal verloop hebben. Een 
diermodel van een infectieziekte maakt het mogelijk de therapeutische effectiviteit van 
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antibiotica te vergelijken onder gelijke omstandigheden van ernst en duur van infectie 
en gastheerafweer, hetgeen niet mogelijk is in de meeste vergelijkende klinische 
effectiviteitsstudies van antibiotica. De translationele waarde van het diermodel werd 
aangetoond door beide infecties — op het moment dat de dieren erg ziek waren — te 
behandelen met antibiotica toegediend in klinisch relevante schema’s. Daarbij werd een 
hoge dosering van tigecycline (een laatste toevluchtsantibioticum voor multidrug-
resistente infecties) gebruikt en vergeleken met het carbapenem-antibioticum 
meropenem. Aangetoond werd dat de K. pneumoniae ESBL long-/bloedinfectie 
succesvol kon worden behandeld met meropenem of tigecycline, en dit komt overeen 
met de in vitro gevoeligheid van de bacterie voor beide antibiotica. In de multidrug-
resistente K. pneumoniae KPC long-/bloedinfectie was meropenem niet effectief, zoals 
te verwachten gezien de resistentie van de bacterie voor meropenem. Tigecycline in een 
hoge dosering was daarentegen wel succesvol. De resultaten van dit onderzoek 
ondersteunen recente studies die het gebruik van tigecycline in hoge dosering 
aanbevelen in de behandeling van patiënten met ernstige infecties (zoals long-/bloed 
infecties) veroorzaakt door carbapenem-resistente Gram-negatieve bacteriën.  
Hoofdstuk 7 en Hoofdstuk 8 beschrijven het onderzoek naar de therapeutische 
effectiviteit van de SET-M33-nanogeneesmiddelen en AA139-nanogeneesmiddelen. 
Deze werden bereid door SET-M33 en AA139 in te sluiten in drie verschillende 
nanodeeltjes: PNP, LIP, of MCL. Meerdere nanogeneesmiddelen werden ontwikkeld 
en verfijnd op basis van in vitro screeningsexperimenten, waarin ze werden vergeleken 
met de vrije AMPs op hun in vitro antimicrobiële activiteit. Op deze wijze werden de 
beste vier nanogeneesmiddelen geselecteerd: SET-M33-PNP, SET-M33-LIP, AA139-
PNP en AA139-MCL. Deze bleken allen stabiel en lekkage van antibiotica tijdens 
opslag werd nooit waargenomen. De vier geselecteerde nanogeneesmiddelen werden 
vergeleken met de respectievelijke vrije AMPs in vitro en in vivo in het ratmodel van long-
/bloedinfectie veroorzaakt door K. pneumoniae ESBL. Hoofdstuk 7 bespreekt het 
onderzoek van SET-M33-PNP en SET-M33-LIP, en Hoofdstuk 8 bespreekt het 
onderzoek van AA139-PNP en AA139-MCL.  
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 De eerste studies betroffen de concentratie- en tijdsafhankelijke antimicrobiële activiteit 
in vitro. Daaruit bleek dat, ondanks insluiting in nanodeeltjes, de bacteriedodende 
werking van SET-M33 en AA139 grotendeels behouden bleef. Insluiting in PNP leek 
een snellere werking van het AMP te faciliteren, terwijl insluiting in LIP of MCL een 
langzamere doch langer durende werking van het AMP mogelijk maakte.  
In alle in vivo studies werden de AMP-nanogeneesmiddelen direct toegediend naar de 
longen via endotracheale insufflatie met als doel dat dit zou leiden tot versterking van 
de bacteriedodende werking in de geïnfecteerde long en vermindering van systemische 
gevolgen — zoals toxische bijwerkingen en nevenschade aan het microbioom (de 
beschermende gastheer-geassocieerde bacteriën). 
In de eerste serie in vivo experimenten verricht in niet-geïnfecteerde ratten werd na een 
éénmalige dosering van het nanogeneesmiddel de limiterende dosis bepaald, met als 
doel de vervolgstudies in de geïnfecteerde ratten volledig binnen de dier-ethische 
normen te kunnen uitvoeren. De limiterende dosis die maximaal kan worden 
toegediend zonder toxische bijwerkingen van beide SET-M33-nanogeneesmiddelen 
bleek niet hoger dan de limiterende dosis van vrij SET-M33; medebepalend hierbij 
waren helaas technische beperkingen die de toediening van hogere doseringen  
SET-M33-nanogeneesmiddelen onmogelijk maakten. AA139-PNP en AA139-MCL 
daarentegen lieten wel een hogere limiterende dosis zien; ze konden bij een dubbele 
dosering veilig worden toegediend in vergelijking tot vrij AA139.  
In een tweede serie in vivo studies werd in de geïnfecteerde ratten de ‘vroege 
bacteriedodende activiteit’ van de AMP-nanogeneesmiddelen na een enkelvoudige 
dosis bepaald. Deze resultaten ondersteunden de eerdere in vitro resultaten die 
aantoonden dat de AMPs ondanks insluiting in nanodeeltjes grotendeels de 
bacteriedodende werking behouden; en dat insluiting in PNP een snellere doch 
kortdurende werking in de long leek te faciliteren, terwijl insluiting in LIP of MCL een 
langzamere doch langer durende werking van het AMP mogelijk maakten. 
Omdat de AA139-nanogeneesmiddelen hoger gedoseerd konden worden dan vrij 
AA139 (in tegenstelling tot de SET-M33-nanogeneesmiddelen en vrij SET-M33) 
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werden de AA139-nanogeneesmiddelen geselecteerd voor de vervolgstudies naar de 
therapeutische effectiviteit in geïnfecteerde ratten na meerdere doses over langere tijd. 
Dit neemt niet weg dat SET-M33 als nanogeneesmiddel of in vrije vorm nog steeds 
zeer interessante antibioticakandidaten zijn voor verder onderzoek in een andere 
experimentele set-up.  
Zoals beschreven in Hoofdstuk 8 lieten uitgebreide biodistributiestudies met beide 
AA139-nanogeneesmiddelen in niet-geïnfecteerde ratten zien dat nanoformulering van 
AA139 resulteert in een verlengde verblijfsduur van het antibioticum in de longen. Dit 
gold met name voor AA139-MCL. Vervolgens werd de therapeutische effectiviteit van 
de AA139-nanogeneesmiddelen bepaald in geïnfecteerde ratten na een eenmaaldaagse 
dosering toegediend gedurende een periode van 10 dagen. Ook in dit langdurig 
doseringsschema konden zowel AA139-PNP als AA139-MCL veilig worden 
toegediend bij een dubbele dosering vergeleken met vrij AA139. Dit geeft opnieuw aan 
dat nanoformulering de verdraagbaarheid van AA139 verbetert hetgeen hoger doseren 
zonder toxische bijwerkingen over langere periode mogelijk maakt. Dankzij de hogere 
dosering bleek de behandeling met AA139-nanogeneesmiddelen te resulteren in een 
verhoogde therapeutische effectiviteit in termen van een significant verbeterde 
overleving van de geïnfecteerde ratten.  
Samenvattend zijn onze resultaten veelbelovend voor de verdere ontwikkeling van deze 
AMP-nanogeneesmiddelen ten behoeve van de behandeling van multidrug-resistente 
Gram-negatieve longinfecties. Toekomstig onderzoek naar nanoformulering van  
SET-M33 zou zich kunnen richten op het verkrijgen van hogere concentraties  
SET-M33 binnen aangepaste nanodeeltjes om toediening van hogere doseringen van 
het nanogeneesmiddel mogelijk te maken. Wat betreft de toepassing van AA139-
nanogeneesmiddelen is een therapeutische verbetering dankzij nanoformulering van 
AA139 in ons onderzoek aangetoond. Weliswaar werd een volledige therapeutische 
effectiviteit (complete overleving van de geïnfecteerde ratten) niet bereikt. 
Verschillende factoren binnen de dierexperimentele onderzoeksopzet dragen hieraan 
bij. Zo is er de keuze van de rat als proefdier, bij welke dieren het geneesmiddel slechts 
in een beperkt volume via endotracheale insufflatie kan worden toegediend. Ook heeft 
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 het dier onder narcose tijdens de endotracheale insufflatie een lage 
ademhalingsfrequentie met als gevolg een lage efficiëntie van inhalatie van het 
geneesmiddel. Beide beperkingen zijn er niet in geval van de toediening van 
geneesmiddelen per inhalatie bij patiënten. Om de aerogene behandeling in de ratten te 
verbeteren hebben we twee andere aerosol inhalatie systemen getest in onze dieren. 
Beide methoden bleken helaas niet te leiden tot verbetering van de door ons reeds 
toegepaste methode. 
De resultaten beschreven in dit proefschrift laten het potentieel van nieuwe cationische 
AMPs als veelbelovende antibioticakandidaten zien. Ook zijn de mogelijke 
verbeteringen van AMP-nanogeneesmiddelen ten opzichte van vrije AMPs voor de 
behandeling van multidrug-resistente Gram-negatieve longinfecties aangetoond. 
Tijdens het onderzoek is een unieke PneumoNP nanogeneesmiddelen-
onderzoekspijplijn opgezet die aangepast kan worden voor het testen van nieuwe 
toekomstige (combinaties van) antibiotica als nanogeneesmiddelen. Ten slotte 
ondersteunt het onderzoek in dit proefschrift het concept dat het gebruik van 
nanogeneesmiddelen toegediend middels inhalatie een interessante onderzoeksrichting 
is in de verbetering van de behandeling van antibiotica-resistente longinfecties. 
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 Dankwoord 
 
Zoals bij de meeste mijlpalen in het leven was dit proefschrift nooit tot stand gekomen 
zonder de hulp en steun van vele mensen in mijn persoonlijke en professionele 
omgeving. Ik wil in dit hoofdstuk graag iedereen bedanken die mij in de afgelopen jaren 
met raad of daad heeft bijgestaan, of dat nou in de vorm was van een goed gesprek in 
een gezellig café of met het uitplaten van een luttele honderdtal bacteriemonsters! Ik 
wil de volgende mensen graag in het bijzonder bedanken:  
Beste Irma, het was een eer om je laatste promovendus te mogen zijn. Ik heb veel 
bewondering voor je oog voor detail en je bereidheid om altijd in de bres te springen 
voor grondig uitgevoerd onderzoek. Ook heb ik veel waarde gehecht aan de gezonde 
balans van gezellige gesprekken en constructieve kritiek tijdens onze besprekingen. Na 
zo’n illustere carrière zal het moeilijk zijn om helemaal van het onderzoek weg te 
stappen, maar je kan nu zeker welverdiend genieten van je pensioen, de (klein)kinderen, 
en nog vele fijne weekenden te Terschelling.  
Beste John, je hebt me begeleid van een groene masterstudent tot een ervaren 
doctoraalstudent. Met name tijdens de laatste zware loodjes van het schrijven van dit 
proefschrift was jouw steun onmisbaar. Jouw nieuwsgierigheid en passie voor de 
wetenschap zijn een inspiratie, meer dan enig ander ben jij altijd in staat om een nieuw 
perspectief te bieden en heb je altijd interesse in nieuwe onderzoekslijnen. Bedankt voor 
de vele jaren van prettige en productieve samenwerking! 
Beste Annelies, ik ben je zeer dankbaar dat je bereid was om de positie van promotor 
op je te nemen in de laatste fase van mijn promotie na de verdrietige gebeurtenis van 
het vroegtijdig overlijden van Johan Mouton. Hoewel niemand gewenst had dat dit 
nodig zou zijn, heb jij deze rol uitgevoerd met de karakteristieke professionaliteit en 
persoonlijke noot waarmee je de afdeling de afgelopen jaren ook hebt begeleid.  
Geachte leden van de promotiecommissie, ik wil u allen vriendelijk danken voor de 
tijd die u heeft genomen om mijn proefschrift te lezen en kritisch te beoordelen.   
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Aan alle collega’s van de MMIZ, na een veelbewogen jaar van quarantaines en social 
distancing zal het velen verbazen om te horen dat wij microbiologen toch nog best 
sociale mensen zijn! Ik wil jullie graag allemaal bedanken voor de vele helpende handen 
en de altijd gemoedelijke werksfeer. Ook buiten kantooruren heb ik genoten van de vele 
gezellige koffiepauzes, dinertjes, borrels, afdelingsuitjes, en kerstfeesten!  
Wil, hoewel jij officieel niet één van mijn co-promotoren was, leek dat af en toe wel zo. 
Bedankt dat je deur altijd open stond voor een snelle vraag of een lange bespreking, het 
was een plezier om nieuwe onderzoeksresultaten met je door te nemen en te 
brainstormen over de voortzetting van nieuwe onderzoekslijnen. 
Marian, met jouw jarenlange ervaring in het uitvoeren van wetenschappelijk onderzoek 
was jij de drijvende motor achter de vele pittige experimenten die we uitgevoerd 
hebben. Ik heb enorm veel geleerd van jouw discipline en organisatie tijdens mijn 
promotietraject, eigenschappen waar ik zelf als eeuwig warhoofd juist mee worstel! 
Bedankt voor al je steun en geduld tijdens mijn promotieonderzoek.  
Aart, bedankt voor je inzet tijdens de laatste fase van het onderzoeksproject, jouw steun 
en ervaring waren tijdens deze periode onmisbaar. Zelfs tijdens experimenten waar we 
’s avonds laat in het weekend terug voor moesten komen kwam jij wonder boven 
wonder met een goed humeur voor de dag!    
Denise, ik wil je bedanken voor al het labwerk en je altijd aanwezige gevoel voor 
humor, het lab zou niet hetzelfde zijn geweest zonder je vele sarcastische (maar altijd 
goedbedoelde) grappen. En de heerlijke zelfgebakken traktaties die je regelmatig 
meebracht naar de koffiepauzes zal ik ook niet rap vergeten! 
Heleen, Maarten, ondanks de lange dagen die we allemaal moesten maken voor onze 
experimenten hebben we toch nog ergens de tijd gevonden voor collegiaal borrelen, 
late bordspelavonden, en zelfs flink festivalvieren. Bedankt voor de leuke tijden samen! 
Anne, Gerjo, Sanne, tijdens de eerste jaren van mijn aanstelling was ons kantooreiland 
een rots in de branding om de wilde wateren van mijn promotietraject te trotseren (tot 
zover deze vergezochte metafoor). Bedankt voor de prettige kantoorsfeer! 
A
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 Agnes, Astrid, Bas, Carmine, Jasper, Michiel, Mirjam, Rogier, Stefan, Silvie, 
Suzanne, Wendy, elke kakelverse promovendus heeft een goede voorbereiding nodig 
op wat hem of haar tijdens zijn promotietraject te wachten staat – bedankt voor jullie 
oh zo wijze levenslessen als de ervarener promovendi en postdocs van de afdeling!  
Anja, Bertrand, Chinmoy, Elise, Gerdie, Hassna, Iain, Janette, Joell, Manon, 
Rixt, Rofyan, Tanmoy, Valérie, Wilson, I really appreciate that we could always 
count on the solidarity of our fellow PhD students at the department! I had a great time 
in the office and at the lab with you (including our sillier activities, like training for the 
trappenloop) and enjoyed the opportunity to get to know all of you better after hours. 
Carla, Corné, Deborah, Elke, Mehri, Mickey, Nicole, Susan, Wendy, als 
promovendus heb ik vele lange dagen moeten doorbrengen met het uitvoeren van 
experimenten, daarom wil ik jullie graag allemaal bedanken voor de behulpzaamheid en 
de immer gezellige sfeer op het lab (en tijdens de koffiepauzes natuurlijk)! 
Chiara, thank you for all the hard work during your internship! I hope you fondly think 
back on your time in Rotterdam and wish you good luck with your own doctoral studies. 
To the partners of the PneumoNP consortium, I would like to thank you all for the 
years of productive collaboration! Our half-yearly meetings were always full of 
invigorating research discussions as well as enjoyable dinner conversations. It was a 
pleasure to work together with all of you across different scientific disciplines towards 
a single scientific goal, and I hope our paths cross in the future! 
Antoinette, Marco, Jeffrey, Raquel, Rene, Sabine, Unai, Yvonne, I would like to 
thank you in particular for our close cooperation during the PneumoNP research 
project. I really enjoyed working together with all of you on the different moving parts 
involved in the project and had a great time visiting your cities and faculties!   
Alessandro, Chiara, Magnus, thank you for the pleasant collaboration – there is a 
careful balance between the interests of private biotech companies with those of 
academic institutions, but it was one that I think we managed well during the project. 
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Aan al mijn vrienden, to all my friends, the study of microbiology isn’t just limited 
to the laboratory of course – as it turns out, a lot can be learned from having one (or 
multiple) fermented beverages in good company! Thank you for all the good times 
we’ve had together and giving me the opportunity to clear my head after long workdays.  
Elmer, Jasper, Thomas, het is geweldig dat we elkaar nog steeds met enige 
(on)regelmaat weten op te zoeken sinds de dagen dat we na school gingen spelen in het 
bos of op skateboards het dorp onveilig maakten. Jasper en ik hebben uitgerekend dat 
we inmiddels ons porseleinen jubileum al hebben behaald; we hoeven het nog maar een 
paar decennia vol te houden om op een dag ons ivoren jubileum te kunnen beklinken! 
Cynthia, Mart, Randy, Ronald, Roeland, Tim, Yannick, een belangrijk onderdeel 
van elke academische carrière is natuurlijk het studentenleven dat wij uitbundig in 
Groningen hebben gevierd! Inmiddels zijn we na ons afstuderen allemaal een stuk 
wijzer en verstandiger geworden (nou ja, relatief gezien uiteraard…) maar weten we 
gelukkig net zoals vroegâh nog steeds af en toe lekker van het padje te gaan dankzij 
tradities als de Eurovisie-bingo en het jaarlijkse kerstdiner (en natuurlijk… de Fireman)!    
Bich, Elise, Miriam, sinds we elkaar hebben leren kennen in Groningen hebben wij 
ons steeds verder verspreid maar gelukkig over de jaren nog steeds contact gehouden –
voornamelijk voor het organiseren van leuke technofeestjes! Bedankt voor de vele leuke 
herinneringen die we samen hebben gemaakt en hopelijk nog gaan maken. 
Amar, Christina, Gabriel, Hugo, Judith, Kadri, Lina, Pierre, we all learned a lot 
during our time as exchange students in Sweden – and probably most of it outside of 
the university lecture halls! Most importantly, we learned we had to stay close together 
during those harsh cold winter months, and we took that to heart and after all this time 
we still manage to meet up once every while. Jag hoppas att vi ses snart igen! 
Johannes, Sahar, Sandrine, Serdar, there is no better way to relax after a long day of 
performing experiments than founding a new student union together or playing an 
intensely competitive card game to find out who has the best bluff. Thanks for all the 
good times in Rotterdam and our railway journey to play Carcassonne in Carcassonne! 
A
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 Bram & Celine, bedankt dat Lucie en ik altijd welkom waren in jullie heerlijke huisje! 
Uiteraard is er altijd een goed excuus te verzinnen om langs te komen knuffelen met 
konijnen, katten en puppy’s… en hè, dat we jullie dan toevallig weer even zien komt 
dan ook goed uit. Het is ook leuk dat we de rest van jullie vrienden hebben leren kennen 
in de afgelopen jaren en ik kijk uit naar nog vele vieringen van verjaardagen en 
nieuwjaarsdagen samen! 
Emoji Spammers, who could wish for a better moral support system than a bunch of 
guys being dudes who never stop posting? Although I’m not really sure if you guys were 
morale boosters or simply a never-ending distraction, I wouldn’t have had it any other 
way. Thanks for all the good laughs and remember… keep yourself safe! 
Rik, Waly, bedankt voor de vele gezellige avonturen die we samen beleefd hebben, dat 
er nog vele mogen volgen! Rik, het is altijd fijn om te weten dat er in ieder geval één 
persoon is met wie ik een avond kan vullen met gesprekken over meerlaags-ironische 
memes, esthetische vaporwave, en willekeurige feitjes over geschiedenis en wetenschap. 
Waly, ik kijk er naar uit om met jou als gids Valencia en omstreken te ontdekken!  
Fellow D&D players, thank you all for allowing me to express my creative side! Few 
things are more enjoyable than having weekly drinks with a great bunch of people while 
going on fantastical adventures together. I’m glad to have gotten to know you all over 
our shared hobby and look forward to many more campaigns! 
Huisgenoten van de Coloniastraat, jullie waren tijdens het grootste deel van mijn 
promotietraject met mij en mijn rare werktijden opgezadeld, bedankt voor de gezellige 
sfeer in huis en natuurlijk de leuke huisavonden (wanneer we er tijd voor hadden)! 
Famille et amis de Lucie, vous avez été patient avec moi et mes efforts pour 
comprendre la langue et la culture française. Je tiens à vous remercier tous et toutes 
pour votre accueil si chaleureux et bien sûr votre excellente gastronomie ! 
A mis nuevos amigos y colegas de Barcelona, estoy emocionado por mi nueva vida 
y trabajo en Barcelona, y por conocerlos a todos mucho major. Estoy deseando explorar 
y disfrutar de esta hermosa ciudad y sus vermuts con vosotros. ¡Hasta luego! 
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Aan mijn familie, bedankt voor jullie onvoorwaardelijke steun. De laatste jaren hebben 
we voor elkaar klaargestaan in zowel goede als zware tijden en hebben jullie me 
gesteund om mijn dromen te bereiken – en staan ons nu vele mooie jaren voor de boeg!   
Lieve Mam, bedankt dat je me altijd hebt ondersteund om mijn ambities te kunnen 
bereiken en mijn creatievere kant hebt aangespoord, waar dit proefschrift een prachtig 
voorbeeld van is (en dan met name de kaft, natuurlijk)! Niets maakt mij blijer dan te 
zien dat je weer helemaal goed op je plek zit na een aantal uitdagende jaren. Ik hou van 
je en wens Herman en jou nog een gelukkig huwelijk samen tegemoet.  
Lieve Pap, bedankt dat je mijn interesse in de wetenschap van jongs af aan hebt 
aangewakkerd met kinderboeken en later krantenartikelen waar ik geen genoeg van kon 
krijgen. Ik waardeer enorm dat ik door weer en wind op je steun heb mogen rekenen 
en hoop dat ik hetzelfde ook voor jou kan betekenen. Ik hou van je en hoop dat Manon 
en jij nog vele jaren samen gelukkig zijn.   
Lieve Rutger, ook jij hebt geen gemakkelijke jaren achter de rug, maar tegelijkertijd 
heb je de juiste stappen vooruit gezet en ga je een hele mooie toekomst tegemoet, daar 
ben ik van overtuigd! Als broers blijven we natuurlijk altijd ervaringsdeskundigen in 
elkaar op de kast jagen, maar ik wil dat je weet dat ik van je hou en je alle geluk toewens.  
Lieve Opa & Oma, bedankt voor jullie goede zorgen voor de oudste kleinzoon. Het 
is natuurlijk vervelend als die steeds verder van je af gaat wonen, maar gelukkig zijn 
jullie nog steeds bereid om te reizen naar verre oorden om de familie op te zoeken – en 
ben ik evengoed van plan om regelmatig langs te komen in het Noorden! 
Lieve Mireille, Jan, Tijn, jullie zijn een onmisbare bron van steun en behulpzaamheid 
geweest in de afgelopen jaren, bedankt voor alles wat jullie gedaan hebben voor de 
familie. Ik kijk er naar uit om regelmatig op bezoek te kunnen komen in jullie 
vakantiehuis te Spanje (niet in het minst voor het zwembad natuurlijk)!   
Lieve familie van der Weide, bedankt voor de gezelligheid tijdens de jaarlijkse 
voorjaarsbrunches. Het is fijn om te weten dat er nu goed voor Oma van der Weide 
wordt gezorgd en iedereen goed op weg is naar een leuke toekomst!  
A
251
Dankwoord
145136 van der Weide BNW.indd   251 07-08-20   14:02
 Beste paranimfen, Aart & Rutger, bedankt voor jullie steun tijdens mijn promotie. 
Aart, naast je vele bijdragen aan het onderzoeksproject heb ik je ook buiten werk leren 
kennen als een goede vriend die altijd wel zin heeft in een laatste borrel, ook al zit het 
qua tijd niet altijd mee! Rutger, als mijn broer heb ik niemand liever aan mijn zijde 
tijdens de verdediging van mijn proefschrift – hoewel onze gezamenlijke videogame-
talenten ditmaal niet zo bruikbaar zullen zijn! Ik ben heel dankbaar dat jullie beiden mij 
zullen bijstaan in mijn verdediging. 
Chère Lucie, je suis tellement heureuse de tous les moments que nous avons partagés 
pendant mes études. Merci pour tous les rires pendant les bons moments, et merci 
d'avoir été mon roc solide pendant les moments difficiles – je n'aurais pas pu le faire 
sans ton amour et ton soutien. Je me réjouis de toutes les aventures que nous allons 
vivre ensemble dans les nombreuses années à venir. 
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the University of Groningen, the Netherlands, where he majored in Molecular Life 
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of a multi-national consortium in the European Union FP7-funded project 
‘PneumoNP’, with the goal to develop a novel theragnostic approach using 
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pneumonia. His main role was as lead researcher for the in vitro and in vivo investigations 
into the antimicrobial activity and therapeutic efficacy of the antimicrobial peptides and 
nanomedicines. After writing this thesis, Hessel started a fellowship at Ysios Capital in 
Barcelona, Spain on venture capital in the field of biotechnology and drug development.  
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Scientific meetings Year 
Workload 
(ECTS) 
    
  
Research meetings & Journal clubs 
Department of Medical Microbiology & Infectious Diseases 
Erasmus MC, Rotterdam, the Netherlands 
2014 - 2018 2.0 
    
  
Progress meetings & Review meetings 
PneumoNP Consortium 
Various locations and organizations 
2014 - 2017 3.0 
 
Teaching Year 
Workload 
(ECTS) 
    
  
Supervision of 2nd year medical students  
“VO Infectieziekten” 
Erasmus MC, Rotterdam, the Netherlands 
2015 - 2018 3.0 
    
  
Supervision of 1st year research master students  
“Lab rotations Infection & Immunity” 
Erasmus MC, Rotterdam, the Netherlands 
2017 1.0 
    
  
Supervision of master student  
3-month internship of Chiara Ambrosini 
University of Siena, Siena, Italy 
2015 2.0 
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 Courses and workshops Year 
Workload 
(ECTS) 
    
  
Attendance 
2nd International Molecular Imaging Workshop 
CIC biomaGUNE, Donostia-San Sebastián, Spain 
2017 1.2 
    
  
Oral presentation 
NAREB Workshop: Nanomedicine & antibiotic resistance 
NAREB project, Madrid, Spain 
2017 1.3 
    
  
Poster presentation 
Course on Translational Research & Medicine Development 
C-COMEND, Manchester, United Kingdom 
2016 2.8 
    
  
Oral presentation 
Novel approaches to fight bacteria Workshop 
Jacobs University, Bremen, Germany 
2016 2.2 
    
  
Attendance 
Scientific integrity 
Erasmus MC, Rotterdam, the Netherlands 
2015 0.3 
    
  
Attendance 
Translational Imaging Workshop: From mouse to man 
Erasmus MC, Rotterdam, the Netherlands 
2014 1.3 
 
National and international conferences Year 
Workload 
(ECTS) 
    
  
Attendance 
28th ECCMID 
ESCMID, Madrid, Spain 
2018 1.5 
    
  
Attendance 
Scientific Spring Meeting KNVM & NVMM 
KNVM & NVMM, Papendal, the Netherlands 
2018 0.6 
    
  
Oral presentation 
Irma Bakker-Woudenberg Symposium 
Erasmus MC, Rotterdam, the Netherlands 
2018 1.3 
    
  
Oral presentation 
MMIZ Science Day 
Erasmus MC, Rotterdam, the Netherlands 
2017 1.3 
    
  
Poster presentation 
Scientific Spring Meeting KNVM & NVMM 2017 
KNVM & NVMM, Papendal, the Netherlands 
2017 1.1 
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